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Abstract
Brown adipose tissue (BAT) has become a promising target for obesity treatment and
prevention. However, effective dietary factors to promote BAT mass and function have not
been

identified.

17,18-epoxyeicosatetraenoic

acid

(17,18-EEQ)

and

19,20-

epoxydocosapentaenoic acid (19,20-EDP) are two prominent epoxy fatty acids (EpFAs)
produced from n-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), respectively. EpFAs are quickly metabolized to less active diols
by soluble epoxide hydrolase (sEH). In this dissertation, the effects of an sEH inhibitor (tTUCB) (which stabilizes EpFAs) alone or combined with n-3 EpFAs on thermogenic activity
in the BAT and brown adipocytes in treating/preventing diet-induced obesity are investigated.
Using the mini osmotic pump delivery system, the effects of t-TUCB were studied in the
obese mice. t-TCUB decreased serum triglycerides and increased perilipin protein expression
in the BAT. Next, the effects of 19,20-EDP alone or combined with t-TUCB were investigated
in diet-induced obese mice. 19,20-EDP alone or combined with t-TUCB did not improve body
weight but improved the cold tolerance in the obese mice. We further investigated the effects
of t-TUCB alone or combined with 19,20-EDP or 17,18-EEQ on BAT activation in preventing
diet-induced obesity in mice. We found that 19,20-EDP or 17,18-EEQ combined with t-TUCB
decreased the fasting glucose and serum triglycerides, in part through differentially regulating
the thermogenic and lipid metabolic protein expression and inflammatory pathways in the
iBAT of mice fed a high-fat diet. Finally, we investigated the effects of n-3 epoxides combined
with t-TUCB on brown adipogenic differentiation and thermogenic capacity in murine brown
adipocytes. We found that 19,20-EDP or 17,18-EEQ combined with t-TUCB promoted murine
brown adipogenesis and mitochondrial respiration and uncoupling in vitro, which were
accompanied by PPARγ activation and suppression of NFkB activation. Moreover, when
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combined with t-TUCB, 17,18-EEQ and 19,20-EDP differentially promote the thermogenic
function of mature brown adipocytes.
In summary, sEH inhibition alone or combined with n-3 EpFAs may be beneficial in
obesity-associated metabolic disorders through improving BAT activity by modulating
thermogenic and lipid metabolic protein expression in mice. Moreover, 17,18-EEQ is more
potent than 19,20-EDP in promoting brown adipocyte activity both in vitro and in vivo.
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Chapter I Introduction

1

A version of this chapter was originally published in:
1. Overby H*, Yang Y*, Xu X, Graham K, Hildreth K, Choi S, Wan D, Morisseau C, Zeldin
DC, Hammock BD, Wang S, Bettaieb A, Zhao L. Soluble Epoxide Hydrolase Inhibition by tTUCB Promotes Brown Adipogenesis and Reduces Serum Triglycerides in Diet-Induced
Obesity. Int J Mol Sci. 2020 Sep 24;21(19):7039. * Denotes both authors contributed equally
to this work and shared the first authorship.
2. Yang Yang, Xinyun Xu, Haoying Wu, Jun Yang, Jiangang Chen, Christophe Morisseau,
Bruce D. Hammock, Ahmed Bettaieb, and Ling Zhao. Differential Effects of 17,18-EEQ and
19,20-EDP Combined with Soluble Epoxide Hydrolase Inhibitor t-TUCB on Diet-induced
Obesity in Mice. Int. J. Mol. Sci. 2021, 22(15), 8267;
This chapter has been revised from the published article in the following ways: the material
and method, result, and discussion sections were excluded and the introduction sections of
these two articles were combined and modified to fit with this dissertation content; font were
altered to fit with this dissertation format.
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Obesity remains one of the biggest public health challenges worldwide [1]. It is associated
with various complications, such as type 2 diabetes, dyslipidemia, and cardiovascular diseases,
leading to a shorter lifespan and higher medical cost [2, 3]. Recent studies have indicated that
obesity is also associated with increased prevalence and severity of coronavirus disease 2019
(COVID-19), an infectious disease caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) [4, 5]. Brown adipose tissue (BAT) has become a promising target to treat or
prevent obesity due to its ability to increase energy expenditure through non-shivering
thermogenesis [6-9]. Cold exposure has been reported to improve glucose and lipid metabolism
in rodents and humans, associated with the cold-induced thermogenesis of BAT [10-12].
Therefore, strategies that activate BAT thermogenic and metabolic activity (i.e., BAT
activation) may confer beneficial effects in diet-induced obesity and associated metabolic
comorbidities.
N-3 polyunsaturated fatty acid (PUFA)-derived epoxy fatty acids (n-3 EpFAs) are
bioactive metabolites generated by cytochrome P-450 (CYP450) epoxygenases from n-3
PUFAs

[13,

14].

17,18-epoxyeicosatetraenoic

acid

(17,18-EEQ)

and

19,20-

epoxydocosapentaenoic acid (19,20-EDP) are the major EpFAs derived from eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA), respectively. These EpFAs modulate
angiogenesis, vascular dilation, inflammation, and cell growth and differentiation and are
implicated in tumor growth and metastasis, cardiovascular disease, diabetes, metabolic
syndromes, and pain [15-17]. Because these epoxides are unstable and quickly metabolized to
less active diols by soluble epoxide hydrolase (sEH), a cytosolic enzyme encoded by the Ephx2
gene [14], many of the beneficial effects of these EpFAs were potentiated by co-administration
of an sEH inhibitor [14, 16, 17].
Recent studies indicate that higher sEH activity was associated with obesity and metabolic
diseases in rodents [18]. Further, sEH expression in the subcutaneous white adipose tissue of
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obese adults was significantly higher than that of lean subjects [19]. Therefore, sEH ablation
or inhibition has become a promising strategy to protect against obesity and associated
metabolic disorders by stabilizing endogenous EpFAs. For example, potent sEH inhibitors
were reported to improve systemic metabolism in rodents [20-23]. Interestingly, one study
reported that an sEH inhibitor decreased the body weight in the high-fat and high-fructose
induced obese mice, accompanied by increases in heat production and UCP1 protein
expression in the interscapular BAT (iBAT) [22]. Another study found that the iBAT mass in
the fat-1 mice was significantly increased by a different sEH inhibitor [23]. Fat-1 mice had the
transgenic expression of n-3 desaturase, resulting in the accumulation of endogenous n-3
PUFA and resulting n-3 PUFA-derived EpFAs in the liver and adipose tissue[23]. It is worth
noting that in some disease models, sEH inhibitor alone did not show strong beneficial effects
unless it was combined with an EpFA [24] or enriched tissue levels of n-3 PUFAs [23].
We have previously demonstrated that a potent sEH inhibitor trans-4-{4-[3-(4trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy-benzoic acid (t-TUCB) promoted brown
adipogenesis in vitro [25]. However, whether an sEH inhibitor alone or combined with n-3
epoxides promotes brown adipogenesis, enhances iBAT activity, and improves metabolic
dysfunction in diet-induced obesity has not been investigated.
In the current dissertation, the effects of sEH inhibitor by t-TUCB and 17,18-EEQ or
19,20-EDP alone or in combination on brown adipogenesis and iBAT activation were studied
both in vitro and in vivo. We investigate (1) the effects of t-TUCB alone or combined with
19,20-EDP on obesity and associated metabolic parameters in diet-induced obese C57BL/6J
mice (Chapter III and IV); (2) the effects of t-TUCB alone or combined with 19,20-EDP or
17,18-EEQ in preventing the development of diet-induced obesity and associated metabolic
disorders in C57BL/6J mice (Chapter V); (3) the effects of 17,18-EEQ and 19,20-EDP
combined with t-TUCB on brown adipogenic differentiation and thermogenic capacity in an in
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vitro cell model (Chapter VI). The schematic diagrams of the study designs are shown in
Figure 1.1 (see in the Appendix).
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Figure 1.1. Schematic diagrams of the study designs used in the dissertation.
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2.1 Obesity prevalence and health risks: an overview
Obesity is a worldwide epidemic affecting nearly one-third population of the United
States[1, 2]. Based on the most recent data of the National Health and Nutrition Examination
Survey, obesity incidence in the adults was 42.4% in the United States in 2017-2018, showing
a significantly increasing trend over the past twenty years [3]. Obesity is the major risk factor
for multiple chronic disorders, leading to increased morbidity and mortality, responsible for 46
percent increased medical care costs in the United States [4-6].
Obesity is defined by the body mass index (BMI), which is significantly associated with
total body fat content [7]. BMI is calculated as weight (kg)/height squared (m2), and people
with higher BMI and larger waist circumference are at increased risk for type 2 diabetes,
hypertension, and cardiovascular diseases [7]. In addition, obesity is also associated with
higher risks of certain types of cancer, such as breast cancer, colorectal carcinoma, and
esophageal adenocarcinoma [8]. Moreover, obesity also affects outcomes of acute infectious
diseases, such as coronavirus disease 19 (COVID-19) [9-11]. Obese patients with COVID-19
infection had increased risks for respiratory failure, resulting in higher demand for mechanical
ventilation and higher mortality [10, 11].
Establishing effective methods to prevent and manage obesity is thereby critical for human
health and well-being. However, many challenges exist in weight loss approaches that focus
on changing personal lifestyles [4]. It is not always achievable to lose or maintain body weight
by restricting energy intake or a well-balanced diet along with regular physical activity,
especially in the aged group [4]. On the other hand, pharmacological or surgical treatments for
obesity are often associated with risks of side effects, including hypoglycemia, hypotension, or
malnutrition [4].
The causes of obesity are multifaced, including individual behavior, community and social
environment, and genetics [4, 12, 13]. However, fundamentally, obesity is characterized by
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excess fat accumulation in the body caused by imbalanced energy intake and expenditure [14,
15]. Understanding of adipose tissue holds great potential to prevent or treat obesity as adipose
tissue is critical for modulating energy homeostasis [16].
2.2 Brown adipose tissue
2.2.1 Historical Perspective
Adipose tissue (AT) has been recognized as the major depot for energy storage and an
endocrine organ that releases adipokines, such as adiponectin and leptin. White adipose tissue
(WAT) and brown adipose tissue (BAT) are classified as two primary types of AT according
to distinct morphology and function. One of the primary functions of WAT is to manage energy
homeostasis by its lipid storage function and through release of free fatty acids (FFAs), mainly
from subcutaneous WAT (sWAT), in response to hormonal signals [17]. In contrast, BAT
regulates energy homeostasis by dissipating energy as heat through non-shivering
thermogenesis (NST) in response to cold exposure or other stimuli.
BAT was first described and identified in the interscapular area of the marmot important
for hibernation in the middle of the 16th century [18]. Four centuries later, after World War II,
the physiology and biochemistry of BAT were investigated both in vitro and in vivo, which
defined BAT as a thermogenic organ critical for the regulation of body temperature in
hibernators and newborns [18, 19]. Thanks to the upsurge of studies of BAT in the 1970s and
early 1980s, the more detailed understanding of the molecular and mechanistic basis for the
thermogenic capacity of BAT was proposed and confirmed [19, 20]. In situ methods that assess
tissue activity in the experimental animals revealed that BAT is primarily responsible for nonshivering thermogenesis in cold-adapted conditions [19]. Moreover, the identification of
uncoupling protein 1 (UCP1) in the mitochondria of brown adipocytes uncovered the unique
mechanism of BAT to increase energy expenditure [20]. Further, the involvement of BAT in
diet-induced thermogenesis was proposed, suggesting the significance of BAT in multiple
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types of metabolic inefficiency, such as obesity, at least in rodents [21]. Since thermogenic
defect is recognized as an important cause for human obesity in some theories, BAT has
become a potential target for human obesity [22]. Such a hypothesis is based on the findings
that adult humans contain metabolically active BAT, similar to what had been observed in
experimental small mammals.
It has long been believed that BAT is only functional significant for newborn infants,
evidenced by the requirement of an incubator for premature infants to survive due to poorly
developed BAT [23]. The size and function of BAT are thought to drastically decrease with
age as the physiological and environmental acclimation, such as the decreased surface-tovolume ratio and constant room temperature [20]. But the possibility that adult humans could
maintain or recruit the thermogenic ability that occurred in infancy cannot be entirely excluded,
even though the early evidence was controversial [23, 24]. In 2009, several studies successfully
used scanning techniques in nuclear medicine,
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fluoro-deoxyglucose positron emission

tomography/Xray computed tomography (18FDG-PET/CT), to visualize BAT in vivo and
demonstrated that human adults present a certain amount of BAT that could be activated by
cold exposure [25-27]. In addition, these studies revealed that BAT activity was negatively
correlated with BMI and body fat percentage, age, outdoor temperature, and the season [2527]. Later, histological features and messenger ribonucleic acid (mRNA) and protein
expression profiles of the speculated BAT in human adults through PET/CT scan were
analyzed, which further confirmed the presence of functional BAT in adult humans [26, 28].
Since the rediscovery of metabolically active BAT in adult humans, BAT and its potential
regulators have become a research focus in recent 12 years with extensive animal and
epidemiological studies [29, 30]. Several pharmacological or dietary compounds have been
reported to activate BAT to improve metabolic health in combating obesity and other metabolic
disorders [31-33].
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2.2.2 Anatomic and cellular identities
In rodents, BAT primarily exists in the interscapular area during fetal life and be present
throughout life [34]. It also exists in the deep anterior cervical, subscapular, axillary, periaortic,
and perirenal areas in rodents [35] (Fig. 2.1A see in the Appendix). In human infants, iBAT
accounts for the largest depot of the total BAT, while axillary-deep cervical and perirenal area
present only a small portion of the total BAT [24] (Fig. 1.1B). Recently, with PET/CT imaging
techniques, BAT activities were detected in adult humans, mainly in the upper trunk, including
cervical, supraclavicular, axillary, paravertebral, and pericardial area [25-27] (Fig. 1.1C).
As the major cell population in BAT depots, brown adipocytes are characterized by the
distinct morphology compared to white adipocytes (Fig. 2.2) [36]. Brown adipocytes present
multilocular cytoplasmic lipids and a higher density of UCP1-positive mitochondria,
responsible for uncoupling adenosine triphosphate (ATP) synthesis from oxidative
phosphorylation [36]. Although both BAT and WAT are associated with vascular and nerve
networks, BAT is more densely vascularized and innervated than white fat depots [35]. The
rich vascularity of the BAT and the high mitochondrial density in brown adipocytes are mainly
responsible for the brown color of BAT seen even by gross inspection [35].
In recent years, discrete clusters of UCP1-expressing adipocytes were found to develop in
anatomical white fat depots presenting similar thermogenic capacity and phenotype as brown
adipocytes in response to thermogenic stimuli, such as cold and beta-adrenergic agonists [37].
Although it remains debatable whether these UCP1-positive adipocytes come from the de novo
differentiation of precursors or stem cells or the trans-differentiation of pre-existing white
adipocytes, these UCP1-positive adipocytes did not share identical genetical and functional
signatures with brown adipocytes in rodents [37]. For example, the zinc finger transcription
factor (ZIC-1), epithelial V-like antigen 1 (EVA1), LIM homeobox eight protein (LHX8),
pyruvate dehydrogenase 4 (PDK4), and epithelial stromal interaction one (EPSTI1) are highly
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expressed in brown adipocytes [38-40], whereas CD137, T-box 1 (TBX1), transmembrane
protein 26 (TMEM26), and short stature homeobox 2 (SHOX2) are highly expressed in UCP1
positive adipocytes from WAT [40-42]. Moreover, UCP1 positive adipocytes expressed a
significant lower level of UCP1 and did not show thermogenic capacity unless activated by
certain stimuli, such as cold and beta-adrenergic agonists [40]. Further, additional UCP1
independent thermogenic processes were found in mouse and human beige adipocytes under
cold or beta-adrenergic stimulation, affecting systemic energy homeostasis, such as the creatine
cycle [43, 44]. Therefore, at least clearly applicable in rodents, brown adipocytes reside in
anatomically defined BAT depots are defined as ‘classical’ brown adipocytes, whereas the
UCP1-expressing adipocytes found in WAT are named as ‘beige’ or ‘brite’ cells, based on the
distinct functional features and gene expression patterns (Fig. 2.2).
However, characterizations of the BAT at the upper trunk anatomical areas in humans
based on gene expression profiles are mixed. Several studies reported a typical beige
adipocytes expression pattern, but not a classical brown adipocyte expression pattern, in the
supraclavicular BAT in neonates, children, and adult humans [40, 45]. Moreover, another study
reported that human fetuses presented both classical brown adipocytes and beige cells in the
different anatomical regions [42]. Furthermore, the deep cervical and supraclavicular fat of
adults have been reported to contain adipocytes with identical gene expression patterns to those
of classical BAT [41, 46]. Overall, it seems that there is heterogeneity in brown fat composition
in humans, which may result from genetic differences between donors or different human
brown adipocyte precursors [47]. Since the iBAT in mice and the brown adipocytes within the
iBAT of mice are the major targets investigated in the current dissertation, the following
content focuses on classical BAT.
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2.2.3 The developmental origins and molecular controllers
A. Developmental origins of BAT
It is generally believed that, in rodents, WAT grows mainly after birth while BAT develops
during embryonic formation and presents throughout life [34]. Brown adipocytes present in
major BAT depots (the dorsal anterior region in mice) originate from precursors in the
embryonic mesoblastic somite analyzed by fate-mapping studies (Fig. 2.3). The cells in the
central dermomyotome expressing a homeobox transcription factor gene engrailed 1 (En1)
were considered to form dorsal dermis and epaxial muscle in mice, which also give rise to
interscapular brown fat [48-50]. The timing of En1 expression in these precursors during the
embryonic day is critical to their developmental fate. Cells expressing En1 at early embryonic
days 8.5 to 9.5 (E 8.5-9.5) are predominantly confined to brown adipocytes development [48].
In contrast cells expressing En1 at a later embryonic stage can give rise to all three tissues
including BAT, muscle, and dermis, presenting a multipotent capacity [48]. En1+ cells in
embryonic somite that also express myogenic factor 5 (Myf5) and paired box (Pax7), two
markers expressed in skeletal myogenic cells, were found to develop brown adipocytes or
skeletal muscle cells [49-52]. Early Pax7+ cells preferentially undergo brown fat commitment
while cells expressing Pax7 at a later stage are confined to skeletal muscle lineage [50]. The
above evidence suggests a similar developmental origin between BAT and skeletal muscle.
B. Molecular controllers of BAT development
The commitment or determination of Myf5+ and Pax7+ or En1+ precursors into either
muscle linage or brown fat linage are regulated by multiple cell-fate controllers (Fig 2.3). Bone
morphogenetic protein 7 (BMP7) is one of the critical regulators that induce the differentiation
of somatic precursors into brown preadipocytes, which is transcriptionally regulated by ewing
sarcoma breakpoint region 1 (EWSR1) and Y-box-binding protein 1 (YBX1) [53, 54]. Besides,
the embryonic precursors that preferentially express a transcription factor early B-cell factor 2
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(EBF2) by embryonic day 12 can uniquely differentiate into brown adipocytes [55]. However,
upstream regulators to activate EBF2 expression in embryonic precursors remain elusive.
PR domain containing 16 (PRDM16) is a crucial transcriptional co-regulator that promotes
brown fat linage determination and suppresses muscle commitment [49, 56-58]. Ablation of
PRDM16 in Myf5+ precursors impairs brown adipocyte development both in vitro and in vivo
[49, 56, 58] while promotes muscle differentiation [49]. PRDM16 interacts with the
transcriptional factor CCAAT/enhancer-binding protein-beta (C/EBPβ) to form the PRDM16
complex to control brown adipocyte cell fate, mediated by an enzyme named euchromatic
histone-lysine N-methyltransferase 1 (EHMT1) [57]. The specific knockout of Ehmt1 in
murine brown adipocytes in vivo led to histone demethylation at muscle-selective gene
promoters, resulting in severe loss of brown fat identities and enhanced skeletal muscle gene
expression in the BAT [57]. Moreover, the deletion of Ehmt1 in Myf5+ myoblasts abolished
the myogenic differentiation induced by PRDM16 [57]. These results indicate that EHMT1 is
indispensable for PRDM16-mediated development of brown adipocytes and suppression of
muscle lineage commitment from the common precursor cells.
Preadipocytes undergo morphological and gene expression changes before differentiated
into mature adipocytes, which refers to as the adipogenic differentiation process (Fig. 2.3) [59].
Adipogenic differentiation of white preadipocytes and brown preadipocytes shares common
molecular regulators [60]. The nuclear receptor peroxisome proliferator-activated receptor
gamma (PPARg) is one of the master transcriptional regulators for adipogenic differentiation
[61, 62]. In brown adipogenesis, PPARg activate the expression of multiple downstream brown
marker genes, including Ucp1 [63]. The agonists of PPARg, such as rosiglitazone, significantly
improve insulin sensitivity and lipid metabolism by increasing BAT differentiation and
thermogenesis [64]. Dominant-negative mutation of Pparg led to BAT dysfunction, including
decreased development and thermogenic ability, in parallel with increased white adiposity and
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insulin resistance in a mouse model [65]. PPARg’s control of the transcriptional pathways in
adipogenesis is facilitated by several co-activators [66-70]. PPARg-coactivator-1 alpha (PGC1a) co-activates PPARg through direct interactions to promote brown adipogenesis but was
dispensable by complementary action of family member PGC-1β [66, 67]. EBF2 also acts as
PPARg co-activator to promote brown adipogenesis by recruiting PPARg to its binding sites in
addition to serving as a selective marker of brown adipogenic precursors [68] (Fig 2.3).
Similarly, in addition to brown adipose lineage determination, PRDM16 also promotes the
PPARg-induced brown marker genes transcription through forming a promoter loop to interact
with mediator of RNA polymerase II transcription subunit 1 (MED1), which in turn interacts
with preinitiation complex (PIC) to start gene transcription of PPARg target genes in brown
adipocytes [69, 70] (Fig 2.3).
2.2.4 Thermogenesis in brown adipose tissue
A. Adaptive thermogenesis
Energy homeostasis is a dynamic balance between energy intake and energy expenditure.
Food intake constitutes almost entirely energy intake, while it is more complicated when
analyzing the components of energy expenditure [71]. In general, total energy expenditure
consists of three major elements: obligatory energy expenditure, energy expenditure from
physical activity, and from adaptive thermogenesis [72]. Obligatory energy expenditure is
primarily for the functional performance of cells and organs, which produces heat through
exothermic forward reactions and contributes to more than half of total energy expenditure
[72]. Energy expenditure from physical activity is variable due to personal lifestyle and socialcultural environments [72]. Adaptive thermogenesis-induced energy expenditure is thought to
be heat production in response to diet or environmental temperature [72, 73]. All three
components of total energy expenditure could be summarized as the conversion of stored
energy (such as glycogen, fat, or protein), food, and oxygen to water, carbon dioxide, work
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performance, and heat [72, 73]. Therefore, when at rest without physical activities, the energy
expenditure of an organism could be directly represented as heat production by direct
calorimetry, or indirectly measured by the amount of oxygen consumption as indirect
calorimetry [72, 73].
B. Cold-induced adaptive thermogenesis in BAT
Environmental temperature affects thermogenesis intensely [74]. Skeletal muscle
undergoes rapid contraction and relaxation to generate excessive heat in response to acute cold
exposure, referred to as cold-induced shivering thermogenesis (acute thermogenesis) [75].
Although with high efficiency for heat production, cold-induced shivering thermogenesis could
not be used in long-term cold acclimation since it is detrimental to muscle function [75]. Coldinduced NST, named in contrast to shivering thermogenesis, has evolved to help an organism
survive in long-time cold environments and is also recognized as cold-induced adaptive
thermogenesis [76].
In mammals, especially in rodents, brown fat is the major site of NST during cold exposure,
primarily because of UCP1 expression [18-20]. As we described in the previous section, brown
adipocytes in the defined BAT depots contain multilocular lipid droplets and high
mitochondrial density with UCP1 expression. Due to the presence of UCP1 in the inner
membrane of mitochondria, brown adipocytes can uncouple proton gradient from ATP
synthase to generate heat, thereby increasing energy expenditure (Figure 2.4) [20].
a. Acute cold exposure
UCP1 activity increases within seconds upon cold stimulation, to confer a rapid proton
leak to produce heat, which is modulated by the TRP-SNS-BAT axis both in rodents and
humans [73]. Specifically, cold is sensed by transient receptor potential (TRP) channels
expressed in sensor neurons on the body surface [77]. TPR then transmits temperature changes
to the brain and activates the sympathetic nervous system (SNS) [77], leading to the release of

19

norepinephrine (NE) from the sympathetic nerve endings that innervate the BAT [20].
Released NE interacts with all three types of adrenergic receptors, including alpha1-, alpha2-,
and beta-adrenergic receptors; however, only beta-adrenergic receptor (b-AR) is critical in
stimulating BAT thermogenesis [20]. β-AR is a G protein-coupled membrane receptor, which
couples with Gs subtype protein in brown adipocytes [78, 79]. Once being activated by NE,
the alpha subunit of Gs protein (GsaS) coupled with β-AR is released to activate the adenylyl
cyclase (AC) activity, leading to increases in intracellular cyclic adenosine monophosphate
(cAMP) levels, which consequently activates protein kinase A (PKA) to enhance lipolysis of
intracellular lipid droplets [80, 81]. The PKA-stimulated intracellular lipolysis depends on
proteins involved in mobilization and catabolism of triglycerides, including perilipin (PLIN),
hormone-sensitive lipase (HSL), and adipocyte triglyceride lipase (ATGL) [82]. As a lipidcoating protein, PLIN protects triglycerides from lipolytic enzymes and is deactivated and
dissociated from lipid droplets upon phosphorylated by PKA [83]. Furthermore, the
phosphorylation of serine 517 residue at murine PLIN is essential to activate ATGL [84].
ATGL hydrolyzes sn-1 fatty acids in stored TGs to produce diacylglycerols (DAGs) [85],
which are then hydrolyzed by activated HSL to generate monoacylglycerol (MAG) [86]. The
resulting monoacylglycerols are further hydrolyzed by monoacylglycerols lipase [86]. In
contrast to PLIN, phosphorylation by PKA stimulates HSL activity to translocate to lipid.
Increased FFAs resulting from the intracellular lipolysis are thought to fuel the
mitochondrial oxidative phosphorylation by providing reducing equivalents through β oxidation and stimulate UCP1 activity simultaneously [19, 20]. FFAs β-oxidation is enhanced
in brown adipocytes in response to adrenergic stimulation partially due to increased expression
of carnitine palmitoyltransferase I (CPT 1), a rate-limiting enzyme in FFAs β-oxidation [87].
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b. Prolonged cold exposure
As cold exposure persists over hours and days, the thermogenesis of BAT is enhanced not
only by stimulated UCP1 activity but also by increased UCP1 abundance and mitochondrial
biogenesis, which is critical for maintaining cellular ATP levels at a proper level in response
to enhanced mitochondrial proton leak [72]. PGC-1a primarily regulates mitochondrial
biogenesis induced by prolonged cold exposure in brown adipocytes [66, 88]. As a coldinducible transcription coactivator, PGC-1a induces the gene expression of two transcription
factors, including nuclear respiratory factor 1(NRF1) and NRF2, that regulate genes encoding
the subunits of the mitochondrial respiratory chain [88]. Moreover, PGC-1a binds to and
activates the NRF1, resulting in an upregulation of mitochondrial transcription factor A
(mtTFA), which is another transcription factor activating the mitochondrial deoxyribonucleic
acid (DNA) replication and transcription [88].
Increased UCP1 abundance induced by chronic cold exposure generally results from
upregulated UCP1 mRNA expression in both differentiation-dependent and -independent
manners [72]. On the one hand, the cold-induced NE-cAMP signaling pathway promotes the
differentiation of brown preadipocytes into mature brown adipocytes, thereby increasing total
UCP1 expression through regulating several transcription factors and coactivators such as
PPARg, PRDM16, and PGC-1a [20]. On the other hand, UCP1 expression could be directly
upregulated in mature brown adipocytes. One critical mechanism involves the cAMP-PKACREB/ATF2 pathway [89, 90]. cAMP response element-binding protein (CREB) or activating
transcription factor 2 (ATF2) (both belong to ATF/CREB subfamily) is activated by p38
mitogen-activated protein kinase (MAPK) in response to cold-induced cAMP signaling
pathway. It then binds to CRE2 located at the upstream enhancer region of the UCP1 gene,
leading to UCP1 transcriptional activation [89, 90]. Moreover, CREB also induces zinc finger
protein 516 (ZFP516), which also acts as a transcriptional activator to stimulate UCP1

21

expression [91]. Several other cold-inducible transcriptional activators for UCP1 are also
identified, including nuclear factor erythroid 2-related factor 2 (NFE2L2) [89] and thyroid
hormone receptor beta (TRβ) [92, 93]. Moreover, persistent cold exposure also modifies the
cell composition of BAT by promoting the proliferation of both brown preadipocytes and
Ucp1+ mature brown adipocytes, contributing to BAT hyperplasia [94-95]. Since cold-induced
NE-cAMP signaling pathway promotes the differentiation of brown preadipocytes into mature
brown adipocytes, cold-induced hyperplasia leads to increases in the percentage of mature
brown adipocytes and total UCP1 amount in BAT [94, 95].
Although FFAs from intracellular lipolysis are the major substrates for BAT in coldinduced NST, brown adipocytes can also uptake FFAs from circulation derived from WAT
lipolysis or triglyceride-enriched lipoprotein (TRLs) [30]. Moreover, cold exposure also
stimulates glucose uptake and utilization in an insulin-independent manner, indicating that
glucose is an additional substrate for BAT in response to NE [96]. The substrate utilization of
BAT is discussed in more detail in Section 2.3.2).
c. Diet-induced adaptive thermogenesis in BAT
Diet-induced thermogenesis (DIT) is one of the components of adaptive thermogenesis
that is critical to energy homeostasis[97]. DIT generally refers to as a long-term overfeedinginduced adaptive increase in energy expenditure [97]. Firstly reported in 1979, BAT is found
to be involved in DIT in rodents to increase energy inefficiency in response to increased energy
intake [21], which may be under similar sympathetic catecholamines regulation as in coldinduced NST [98, 99]. Moreover, UCP1 ablation abolishes the DIT in mice fed with a normal
diet or obesogenic diet at thermoneutral temperature [100, 101]. Further, ingestion of a single
meal also has been reported to enhance BAT activity in rodents [102-104]. In humans, the
evidence of diet-induced thermogenesis in BAT is controversial. The postprandial
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FDG

uptake by the BAT was lower than that after overnight fasting or cold exposure, while no
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difference in whole-body energy expenditure occurred. However, whole-body energy
expenditure after meals is higher in healthy humans with a higher amount of BAT characterized
by higher 18FDG uptake [105]. In addition to 18FDG-PET/CT, oxygen consumption and blood
flow measured by 15O[O2]-PET has also been used to analyze BAT activity in humans [106].
After meals, the oxygen consumption and blood flow in the BAT of healthy adults increased
to a similar extent as in cold stress [107]. The inconsistent results between 18FDG-PET/CT and
15

O[O2]-PET may be due to the limitation of
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FDG-PET/CT [108]. Cold-induced
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FDG

uptake is primarily increased in BAT in response to adrenergic activation. In contrast, 18FDG
uptake is elevated in multiple tissues other than BAT, such as skeletal muscle, heart, and WAT,
in response to insulin [108]. Therefore, BAT activity after meals measured by 18FDG-PET/CT
may underestimate the BAT thermogenic capacity because of the competitive inhibition of
18

FDG uptake by other insulin-sensitive tissues [108]. Collectively, these results suggest that

BAT plays a role in DIT in both rodents and humans, but the significance of BAT-mediated
DIT on energy homeostasis or systematic metabolism is still unclear [109].
2.2.5 Secretory function of brown adipose tissue
Traditionally, the beneficial effects of BAT have been attributed to its thermogenic
function. However, recent studies have revealed that BAT also plays a secretory role by
releasing multiple molecules, also known as batokines. These batokines can be categorized into
complement elements, hormones, extracellular matrix proteins, and growth factors [110].
These batokines regulate the development and thermogenic recruitment of BAT in an autocrine
manner and interact with other organs involved in systemic metabolisms, such as bone, liver,
and heart, in a paracrine manner [111].
Collectively, the thermogenic and secretory function of BAT become new targets to
combat obesity and obesity-related metabolic disorders.
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2.3 Brown adipose tissue, obesity, and its associated metabolic disorders
2.3.1 The significance of BAT in obesity
With the rediscovery of BAT in adult humans and its role in energy expenditure, BAT has
become a promising target to combat obesity [37]. The significance of BAT in obesity has been
demonstrated in both rodents and humans in the past four decades [112].
Early studies using genetically obese models established a link between BAT and obesity.
In response to cold stimulation, decreased blood flow and oxygen consumption in the iBAT
were found in the genetically obese rodent models, such as ob/ob and db/db strains, suggesting
a defective BAT thermogenesis in genetic obesity [113-116]. In addition, mature ob/ob mice
showed significantly decreased UCP1 expression and reduced sympathetic activity in the BAT
compared to their lean controls [117-119]. Moreover, adrenalectomy reduced body weight gain
and energy efficiency in ob/ob mice fed a high-carbohydrate diet, partially associated with
increased SNS-stimulated BAT thermogenesis [120]. The increased BAT thermogenesis in
adrenalectomized ob/ob mice may be associated with increased responsiveness to
corticotropin-releasing factor (CRF) by the BAT [120]. These results lead to the hypothesis
that BAT dysfunction contributes to obesity and could be a target to combat obesity. Surgically
denervating or removing BAT in mice thereby were used as experimental models to address
this hypothesis. BAT denervation in mice led to increased energy efficiency and adiposity,
indicating the important role of BAT in obesity development [121]. However, Sprague-Dawley
rats with BAT denervation failed to gain more weight than sham denervation controls under a
high-calorie diet [122, 123], which may be due to compensatory pathways that regulate the
BAT metabolism and thermogenesis in response to a chronic defect in SNS [124]. Similarly,
surgical removal of the BAT increased adiposity in rats [125, 126], but contradictory results
have been reported, possibly due to the compensatory regeneration and hypertrophy of BAT
from other depots [127, 128].
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Genetic ablation and overexpression techniques have also been used in rodents to
investigate the contribution of BAT in combating obesity. Transgenic mice with the expression
of diphtheria toxin A (DTA)-chain driven by UCP1 promoter (UCP-DTA) showed decreased
thermogenic response to cold exposure and β-AR agonist [129]. Moreover, these mice showed
primary and persistent BAT deficiency and developed extreme obesity and associated
metabolic abnormalities, including insulin resistance and hyperlipidemia [129]. Furthermore,
UCP-DTA mice were resistant to leptin [130] and more susceptible to high-fat diet-induced
obesity compared to their wild-type littermates [131]. Consistently, another transgenic mice
model with specific expression of an attenuated mutant DTA driven by UCP1 promoter (UCP176) had impaired BAT development and were extremely obese at an early age (0-2 weeks old)
[129]. Interestingly, the BAT in these mice was nearly completely regenerated at 8 weeks old,
followed by a reversal of obese phenotype, further demonstrating the therapeutic potential of
BAT in obesity [129].
In addition to BAT ablation, the UCP1 knockout mouse model has also been used to
investigate the link between BAT dysfunction and obesity. However, results from UCP1-null
mice are unexpected. Although UCP1-null mice are susceptible to high-fat diet-induced obesity
with age [132], no obesogenic effect of UCP1 ablation has been observed in younger mature
mice [133, 134]. The discrepancy found between UCP1 knockout and BAT ablation may be
due to alternative adrenergic thermogenesis developed in other thermogenic sites, such as
muscle, in UCP1-null mice [133, 134]. Indeed, when housed at a thermoneutral condition
(30 ℃), mice with ablated UCP1 developed obesity even fed with standard chow diet and were
much more vulnerable to high-fat diet-induced obesity [100]. Moreover, mice with deletion of
PKA-RIIβ subunit presented a high amount of UCP1 protein expression, which are resistant to
obesogenic stresses, including expression of obesity gene (agouti gene) and high-fat diet [135,
136]. In another gene knockout model, mice with specific ablation of cell death-inducing DNA
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fragmentation factor-a-like effector A (Cidea), a protein expressed abundantly in BAT,
showed enhanced UCP1 mRNA expression in the BAT, which might be partially responsible
for the lean phenotype and the resistance to diet-induced obesity [137].
In humans, early studies using
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FDG-PET/CT demonstrated that functional BAT is

present in adults [25, 27, 28]. Overweight or obese people showed decreased BAT activity
compared to lean individuals [27]. In addition, BAT activity positively correlates with resting
metabolic rate while negatively associates with adiposity and BMI [25]. Such findings suggest
the association between BAT and obesity in humans, but questions remain as to how BAT
significantly contributes to the whole-body energy expenditure and thus confer anti-obesity
effect in humans. BAT volume in humans measured by 18FDG PET/CT varies from a few to
hundreds of milliliters [138]. Some individuals present an amount of BAT up to 60 grams [28],
which can consume around 4 kilograms of WAT within one year if fully activated [139].
Besides, it was speculated that nearly 20% of daily energy expenditure could be contributed
from as little as 50 grams of BAT [140]. Although the 18FDG-PET/CT is the common method
to quantify total BAT mass and activity, 18FDG uptake was found to be more stable to indicate
insulin sensitivity of BAT, but not the BAT volume [139]. Thus, the contribution of BATmediated thermogenesis to whole-body energy expenditure may be largely underestimated
based on BAT estimation by 18FDG uptake [139]. In addition, BAT volume could range from
510 to 2358 ml analyzed by radiological 3D mapping technology. Based on such volume, BAT
thermogenesis could contribute up to 123 kcal energy expenditure per day even at room
temperature and up to 211 kcal per day under mild cold conditions [141]. It is worth noting
that even a small negative energy balance, as little as 50-100 kcal/day, is promising to induce
weight loss in the overweight and obesity population and confers clinical benefits [142, 143].
In this context, combined with evidence from animal models, it is appropriate to believe that
BAT holds a promising therapeutic potential in human obesity.
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2.3.2 Metabolic impact of brown adipose tissue
Obesity is associated with multiple metabolic disorders, such as insulin resistance,
hyperlipidemia, leading to increased morbidity and mortality [2]. The thermogenesis property
of BAT drives it to consume a considerable amount of substrates from circulation, including
triglycerides (TG), non-esterified fatty acids (NEFA), and glucose, which makes BAT a
metabolic sink [20]. Therefore, BAT is considered to be beneficial in obesity-associated
glucose and lipid disorders.
A. Substrates utilization by brown adipose tissue
a. Intracellular lipolysis derived FFAs
In rodents, it is believed that lipolysis of intracellular lipid droplets is drastically enhanced
in cold-induced NST to release FFAs as the fuel for mitochondrial oxidative phosphorylation
through β-oxidation and to directly activate UCP1 [20]. Intracellular lipolysis is regulated by
multiple lipolytic enzymes, including ATGL, HSL, and MAG, as well as lipid coating protein
PLIN [144]. In brown adipocytes, while both key enzymes ATGL and HSL are activated to
enhance lipolysis in response to cold-induced adrenergic stimulation [82], ATGL may be more
important in lipolytic regulation [145-149]. Inhibition of ATGL by the antagonist abolished
80% of UCP1-dependent proton leak in response to adrenergic stimulus isoproterenol (ISO),
while HSL inhibition only induced a 30% reduction of UCP1-dependent proton leak [145]. In
addition, although globally knockout of HSL (HSL-/-) led to increased BAT lipid content, body
weight and cold tolerance were not affected [146, 147]. In contrast, both global and adiposespecific ablation of ATGL in mice significantly reduced the TG hydrolysis activity in the BAT
by 85% [148], leading to severely impaired BAT thermogenesis in response to cold exposure
[148, 149]. Together, these results suggest that, at least in rodents, intracellular lipolysis is
required for UCP1-mediated thermogenesis and is primarily dependent on ATGL activity in
BAT during cold exposure.
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In humans, intracellular lipids lipolysis in BAT were indirectly investigated by imaging
techniques [150-153]. Radio-density measured by computed tomography (CT) scanning is an
index inversely correlated with lipid contents in tissue [150, 151], whereas fat fraction
measured by magnetic resonance imaging (MRI) represents lipid accumulation in tissue [152,
153]. It was found that the radio-density of BAT measured by CT scanning was increased,
while the fat fraction of BAT measured by MRI was decreased in human participates exposed
to cold, suggesting that intracellular lipolysis was increased to provide FFA for BAT
thermogenesis in humans upon cold activation [150-153]. In addition, by microdialysis
analysis, glycerol released from the BAT was increased to higher levels than the WAT when
adult humans were exposed to cold, further suggesting cold-induced lipolysis in human BAT
[154].
b. FFAs from circulation
In addition to FFAs derived from intracellular lipolysis, FFAs derived from circulating
NEFA and TRLs are also important fuels for BAT thermogenesis in rodents [82]. The direct
evidence for the utilization of circulating FFAs and TRLs by BAT in cold-induced NST has
been reported [155, 156]. There was increased uptake of

14

C-triolein-derived FFAs and

albumin-bound 14C-oleic acid by the BAT during cold exposure [155, 156], higher than that
for muscle in mice [155]. In addition, when injected with double isotope-labeled TRLs, H3cholesteryl ether and C14-triolein as markers for lipoprotein core and TG, respectively, into
mice, cold exposure induced an increased accumulation of both H3 and C14 radioactivity in the
BAT [156]. Moreover, fluorescent nanoparticle-labeled TRL (QD-TRL) were observed to
rapidly attach to endothelium and then internalized into the BAT in cold-exposed mice when
visualized through intravital microscopy, which was attenuated by inhibition of lipoprotein
lipase (LPL) activity [155]. LPL is responsible for hydrolyzing TRLs to release FFA [157].
Therefore, decreased uptake of TRLs induced by LPL inhibition suggests that BAT may take
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up both holo-TRL-particles and TRL-derived FFA [155]. Analysis of gene expression profile
of BAT after cold exposure showed significantly upregulated gene expression of cluster of
differentiation 36 (Cd36), a membrane scavenger receptor responsible for FFA and lipoprotein
uptake. CD36 upregulation is consistent with increases in TRLs internalization in BAT upon
cold stimulation [155]. CD36 knockout mice presented severely impaired cold tolerance,
slower TRLs turnover, decreased TRL uptake into the BAT, and increased plasma NEFA level,
which further demonstrate the critical role of CD36 in TRLs-FFA uptake in the BAT [155,
158]. Interestingly, a later study found that BAT primarily takes up TRL-derived FA rather
than entire TRL particles upon activation by injecting double radio-labeled TRL-mimicking
particles [159], which is inconsistent with previous observation [155]. Such inconsistency may
be due to the different size or apolipoproteins composition in TRL particles used in these two
studies [160]. Collectively, these results demonstrate that, in rodents, BAT takes up circulating
FFAs, TRL-derived FFAs, and possibly holo TRL particles upon activation, suggesting a
hypolipidemic role of BAT.
Interestingly, several studies reported that the selective uptake of TRL-derived FFA by
activated BAT in rodents might modulate subsequent cholesterol-enriched remnants clearance
by the liver through the hepatic apoE-LDLR pathway [161, 162]. When low-density lipoprotein
receptor knockout (Ldlr-/-) or apolipoprotein E knockout (Apoe-/-) mice were exposed to cold
or treated with β3-AR agonist to active BAT thermogenesis, both Ldlr-/- mice and Apoe-/- mice
presented increased heat production as expected, but no reduction of plasma cholesterol was
observed [161, 162]. Instead, cold exposure even exacerbated the hypercholesterolemia in both
Ldlr-/- mice and Apoe-/- mice [161]. In contrast, in the hyperlipidemic APOE*3-Leiden.CETP
(E3L.CETP) transgenic mice models, β3-AR agonist treatment significantly decreased plasma
cholesterol levels due to, at least in part, activated BAT thermogenesis [162]. Although
E3L.CETP mice are also hyperlipidemic; unlike Ldlr-/- mice or Apoe-/- mice, they expressed a
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human apoE3 mutant that still had a binding affinity to LDLR even though lower than normal
apoE [162]. It is believed that when circulating TRLs are hydrolyzed by LPL, the resulting
cholesterol-enriched remnants are assembled with apoE that could interact with low-density
lipoprotein receptor (LDLR) to facilitate the uptake of remnants by tissues, such as the liver
[163]. In fact, activated BAT is responsible for the clearance of nearly half triglycerides from
a meal measured by oral fat tolerance test [164]. Therefore, in this context, these results
indirectly demonstrate the uptake of TRL-derived FFAs by the BAT upon activation in rodents
may induce a reduction of plasma cholesterol level in the presence of apoE-LDLR interaction
[160].
In humans, circulating FFA uptake by BAT during cold exposure is confirmed by
radiotracer

18

fluoro-6thia-heptadecanoic acid-mediated PET/CT (18(FTHA) PET/CT) [150,

165]. However, evidence for TRL-derived FFA uptake by activated human BAT is limited.
FFA uptake by BAT was increased during cold exposure accompanied by increased LPL
expression in human BAT, indirectly suggesting a link between FFA uptake in the activated
BAT and LPL-mediated TRL hydrolysis in humans [166]. In addition, prolonged (4 weeks)
BAT activation by β3-AR agonist mirabegron significantly increased the plasma high-density
lipoprotein cholesterol (HDL-c) level in human adults [167]. When TRLs are hydrolyzed by
LPL, HDL-c may be subsequentially produced by transferring cholesterol from the resulting
cholesterol-enriched remnants to HDL particles, possibly catalyzed by phospholipid transfer
protein (PLTP) [168]. Therefore, BAT activation-associated increase in plasma HDL-c level
in humans may indirectly suggest an enhanced TRL clearance by stimulated BAT
thermogenesis [167]. Together, these results suggest a possible role of BAT activation in TRL
clearance by uptake of TRL-derived FFA in humans.
De novo fatty acid synthesis in BAT is also enhanced under cold exposure and adrenergic
stimulation, suggesting that it could be another source of FFA to fuel BAT thermogenesis [169-
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171]. But this may be more relevant with glucose utilization by BAT during active
thermogenesis [169], which is discussed below.
Collectively, FFAs derived from intracellular lipid droplets and circulating NEFA or TRLs
may be important fuels for BAT thermogenesis in rodents and humans, which may lead to
enhanced TG and cholesterol clearance. Therefore, BAT activation may be a promising
approach for regulating obesity-related hyperlipidemia.
c. Glucose
Although FFA is the primary substrate for cold-induced NST of BAT in both rodents and
humans, cold exposure also stimulates glucose uptake and utilization, indicating that glucose
is an additional substrate for BAT in cold-induced thermogenesis[96].
In rodents, the investigation of glucose utilization in BAT may be due to early findings in
the late 1970s that the hyperglycemic action of glucagon was attenuated in cold-acclimated
rats [172]. After glucagon infusion for 30 minutes, glucose concentrations in venous drainage
from the iBAT of rats at warm temperature were significantly increased. In contrast, such a
glucagon-induced increase in glucose levels in venous blood near iBAT was markedly reduced
by cold-acclimation [172]. In addition, later studies found that glucagon induced an increase
in heat production, core body temperature, and BAT temperature in both warm- and coldacclimated rodents, and such increases in thermogenesis were potentiated by cold acclimation
while attenuated by warm acclimation [173, 174]. All these results suggest that glucose uptake
may facilitate BAT thermogenesis during cold exposure.
Directly evidence of glucose utilization in rodents has been reported in the late 1980s and
early 1990s through 2-deoxy-[3H]glucose method [175-177]. 2-deoxyglucose can only be
phosphorylated by hexokinase and then trapped in the tissue, glucose utilization rate can then
be measured by the amount of 2-deoxyglucose 6-phosphate [178]. The glucose utilization by
BAT was significantly increased in cold-acclimated rats at fed state[175-177]. Moreover, after
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rats have fasted for 18 hours at room temperature, glucose uptake significantly decreased in
heart and skeletal muscles but not in BAT [176]. Further, cold exposure significantly induced
an increase in glucose uptake by peripheral tissues in fasted rats, especially in BAT, with a 95fold increase, suggesting that the glucose uptake induced by cold in tissues may be independent
of the action of insulin [176]. Such insulin-independent glucose uptake by BAT upon cold
stimulation was further demonstrated by a recent study [179]. The specific inhibitor of
phosphoinositide 3-kinase alpha (PI3Ka), a critical enzyme involved in insulin signaling
pathways, did not affect glucose uptake by the BAT and systemic glucose clearance upon βAR activation in mice [179].
The increased glucose uptake by BAT under cold exposure may be regulated by the
glucose transporter system, which is dependent on SNS stimulation [175] [177, 180, 181]. By
quantifying glucose transporters through [3H]cytochalasin B-binding assays, it was found that
the total number of glucose transporters was increased in the BAT in cold-acclimated mice,
accompanied by increased glucose transporters on plasma membranes and decreased
microsomal glucose transporters in the BAT [175, 177]. In addition, total GLUT4 expression,
the predominant glucose transporter in mature brown adipocytes [182], was significantly
increased in the BAT from cold-acclimated rodents but not in the WAT or skeletal muscle [180,
181]. Also, functional activity and amount of plasma GLUT1 in brown adipocytes treated with
adrenergic stimuli were significantly increased [182, 183]. Moreover, surgically sympathetic
denervation of BAT abolished the cold-induced increases in glucose uptake and glucose
transporter numbers [177, 181]. These results suggest that BAT takes up glucose during cold
exposure in an insulin-independent manner, which may be regulated by the SNS-dependent
modulation of de novo synthesis, redistribution, and functional activity of glucose transporters
in rodents.
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In human adults, the rediscovery of functional BAT was, in fact, based on the hypothesis
that human BAT consuming glucose similar to rodents upon activation. Through PET-CT
imaging with the 18Fluoro-deoxyglucose (18FDG) tracer, human adults were found to present
adipose tissue depots that actively take up 18FDG in response to cold, which were identified as
classical BAT or beige fat later [25-28]. Moreover, human BAT, but not WAT, also takes up
glucose during warm conditions, suggesting a higher metabolic activity of BAT independent
of the thermogenic function [184].
After glucose is taken up into BAT, it can be metabolized in multiple ways. First, a
significant portion of glucose is used to provide ATP in the cytosol, as evidenced by the
increased expression of glycolytic enzymes in the BAT of mice in response to cold [185]. In
addition, it was reported that in cold-acclimated rats, 33% of glucose taken up by BAT was
released as lactate or pyruvate, suggesting a considerable portion of glucose undergoes
cytosolic glycolysis [186]. Second, glucose can be used to synthesize FFAs in rodents. It was
found that de novo fatty acid synthesis was significantly increased after cold stimulation, which
was paralleled with increased activities and expression of enzymes involved in fatty acid
synthesis, including acetyl-coenzyme A carboxylase (ACC), fatty acid synthase (FAS),
elongase of very long-chain fatty acids (ELOVL), and fatty acid desaturase [20]. Such increase
in fatty acid synthesis was markedly potentiated after glucose administration [169] and was
paralleled with increased activation of carbohydrate response element-binding protein
(ChREBP), a glucose sensor that activates glucose transportation [187]. Pyruvate generated
from cytosolic glycolysis could be the precursors for de novo fatty acid synthesis by producing
acetyl-coenzyme A (acetyl-CoA) as evidenced by the cold- or adrenergic stimuli-induced
increase in the expression of glycolytic enzymes, mitochondrial pyruvate transporters (MPC),
pyruvate dehydrogenase (PDH), and ACC both in vivo and in vitro [185, 187, 188]. FFAs
synthesized from glucose are primarily incorporated into TG and simultaneously hydrolyzed
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as FFAs to fuel thermogenesis rather than directly used as energy substrates or activate UCP1
[189]. Third, glucose may contribute to triglyceride synthesis. In adrenergic stimulated murine
brown adipocytes, glucose-derived glyceraldehyde-3-phosphate is converted to glycerol-3phosphate and then used as substrates for TG synthesis, but only accounts for a small portion
[188]. However, evidence for the contribution of glycolysis in the cytosol and the subsequential
metabolism upon BAT activation in humans is limited. One study reported that glucose uptake
by the BAT during cold activation was around 11.5 μmol/100g tissue/min, and lactate release
by the BAT during cold exposure was around 21 μmol/100g tissue/min, accounting for about
90% glucose uptake by BAT in human adults [184]. This result suggests that glucose uptake
by BAT may primarily undergo cytosolic glycolysis pathway to generate lactate upon
activation in humans, but more detailed evidence and underlying mechanisms need further
study. Together, studies have suggested that BAT consumes glucose at a higher rate upon
activation, which could benefit systemic glucose homeostasis.
In sum, it is clear that activated BAT may increase heat production and is involved in
systemic lipid and glucose metabolism by taking up circulating FFAs and glucose. BAT,
therefore, has become a target to combat obesity and its associated metabolic disorders through
nutritional and pharmacological strategies.
2.3.3. Strategies targeting BAT to improve obesity and associated metabolic disorders
A. Cold exposure
Cold exposure (acute or chronic) is the most classical stimulus used to active BAT to
investigate its thermogenesis capacity and the precise mechanisms underlying BAT activation.
Understanding how cold activates BAT helps researchers identify endogenous regulators or
targets that could be used in BAT activation instead of the uncomfortable long-term cold
exposure, especially in humans. Studies on cold exposure as a strategy to treat or prevent
obesity and associated metabolic disorders are limited both in rodents and humans [155, 190,
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191]. In rodents, chronic cold exposure (8 weeks) has been reported to prevent high-fat dietinduced obesity and improve glucose tolerance [190, 191].

Moreover, short-term cold

exposure (24 hr) significantly increased the TRL clearance independent of insulin levels and
insulin resistance, and decreased plasma TG levels in diet-induced obese mice [155].
Furthermore, 24 hour-cold exposure improved the glucose tolerance in diet-induced obese mice
to a level comparable to that of lean control mice [155]. However, intermittent chronic cold
exposure did not reduce body weight gain in mice fed a high-fat diet but instead promoted
high-fat diet-induced obesity in mice[192, 193]. The possible reason is that intermittent cold
exposure may not be strong enough, and the resulting increased energy expenditure thereby
could be fully compensated by hyperphagia in response to chronic cold exposure [192, 193].
In humans, short-term cold acclimation (10 days) was able to increase the BAT volume and
activity, leading to increased non-shivering thermogenesis in both healthy [194] and obese
participants [195]. In addition, chronic (4-6 weeks) daily cold exposure (1-2 hours per day)
increased BAT volume, activity, metabolic rate, and energy expenditure [151, 196, 197],
paralleled with a decreased body fat mass in the healthy participants [196]. However, no current
studies reported the effects of chronic cold exposure in the obese population on body weight,
fat mass, or other systemic metabolic parameters. Moreover, severe and long-term cold
exposure is intolerable in humans, making cold exposure impractical in human trials. Therefore,
other strategies such as pharmacological compounds and food ingredients are investigated to
target BAT in obesity treatment, either by mimicking cold exposure or acting on molecular
regulators involved in BAT development.
B. Pharmacological Strategies
It is well believed that during cold-induced NST, NE released from the SNS acts on β-AR
to activate BAT thermogenesis [20]. Since β3-AR is primarily, but not exclusively expressed,
in brown adipocytes in both rodents and humans, pharmacological agonists of β3-AR have
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been developed to target BAT as therapeutics against obesity [20]. Administration of β3-AR
agonists, including BRL 26830A [198-200], BRL 35135A [201], or CL 316,243 [202-204],
was reported to enhance BAT thermogenesis and increase energy expenditure and was partially
responsible for decreased body weight gain [198, 201, 202], improved glucose tolerance [199201, 203], insulin sensitivity [201, 203, 204], and hyperlipidemia [201] in diet-induced obese
and genetically obese rodents. However, the anti-obesity effects of β 3-AR agonists are
complicated and controversial in humans. Non-selective β-AR agonist isoproterenol failed to
increase thermogenesis and lipid utilization [205] or activate BAT measured by 18FDG uptake
in humans [206]. Moreover, chronic administration of selective β3-AR agonists, such as CL
316,243 [207], ZD7114/ZD2079 [208], or L-796568 [209], failed to activate BAT, increase
energy expenditure, or change body weight and composition in the healthy [207] or obese
humans [208, 209]. Although a higher dose of L-796568 (1000mg compared to 358mg/day
used in chronic administration) acutely increased lipolysis and energy expenditure in
overweight men, it also caused significant increases in systolic blood pressure [210], which has
hindered its therapeutic potential as an anti-obesity drug in humans.
Recently, single-dose administration (200 mg) of a selective β3-AR agonist mirabegron,
an approved drug for overactive bladder treatment, has been reported to increase BAT
metabolic activity and resting metabolic rate in healthy men with a minimal increase in systolic
blood pressure compared to other β 3-AR [211-213]. Moreover, chronic administration of
mirabegron at the dose of 100 mg/day for 4 weeks significantly increased the BAT metabolic
activity, resting energy expenditure, concurrently with improved glucose tolerance, insulin
sensitivity, and increased plasma apolipoprotein A1 (apoA1) and HDL-c levels in the healthy
women [167]. However, chronic mirabegron treatment in obese, insulin-resistant humans
improved glucose homeostasis and insulin sensitivity mainly through the formation of beige
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adipose in the subcutaneous WAT depot rather than improving BAT activity [214, 215].
Therefore, whether this high-affinity β3-AR mirabegron could be an effective anti-obesity drug
in humans and its precise mechanisms need further study.
C. Bioactive compounds from foods
Due to the compliance issue or possible side effects from cold exposure and
pharmacological agents, increasing studies have focused on identifying thermogenic food
ingredients that activate BAT to improve obesity and its associated disorders [216, 217].
a. Resveratrol
Polyphenols have been reported to present many beneficial effects in metabolic syndrome
in humans [32]. Resveratrol is one of the natural polyphenols, mainly found in the root of
polygonum cuspidatum, mulberries, and grapes [218]. Resveratrol exerts anti-obesity effects
[219], at least in part, through promoting BAT development [220].
In mice fed either with a high-fat diet [221, 222] or a standard diet [223], chronic (4-15
weeks) administration of resveratrol (0.1-0.4% w/w) reduced the body weight gain [221, 222],
visceral fat mass [221, 223], and plasma glucose and total cholesterol levels [223], which were
accompanied by increases in cold-induced thermogenesis [221] and basal energy expenditure
[221, 223], possibly through upregulated mitochondrial biogenesis [221] and UCP1 expression
[221-223] in the iBAT of mice. Similarly, resveratrol treatment in high-fat diet-fed spraguedawley rats (30mg/kg/day for 8weeks) [224] or Otsuka long evans tokushima fatty (OLETF)
rats (10mg/kg/day for 27 weeks) [225] improved the insulin sensitivity [225], which was
associated with increased UCP1 expression and mitochondrial activity of the iBAT [224, 225].
The effects of resveratrol on BAT are likely through the modulation of AMP-activated protein
kinase-Sirtuin 1-PGC-1a (AMPK-SIRT1-PGC-1a) axis to increase mitochondrial activity and
biogenesis [221-224], as well as via the upregulation of the expression of PRDM16, BMP7,
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and estrogen receptor alpha (ERa) expression to promote brown fat development and
adipogenic differentiation [222, 223, 225].
Although positive effects of resveratrol on BAT to induce weight loss have been
demonstrated in rodents, the effects of resveratrol in humans are mixed. Resveratrol
administration (1-2 g/day for 4-6weeks) was reported to improve glycemic control in
individuals with impaired glucose tolerance [226] or type 2 diabetes [227] but failed to improve
glucose tolerance or insulin sensitivity in the obese but otherwise healthy humans [228]. None
of these studies reported changes in energy expenditure, metabolic rate, adiposity, or body
weight [226-228]. Another study reported that 1.5 g of trans-resveratrol ingestion for 12 weeks
reduced the body weight, fat mass, waist circumference, and insulin secretion in subjects with
metabolic syndrome, but with no changes in energy expenditure or metabolic rate [229]. It is
worth noting that resveratrol treatment (150-500 mg/day) for 30 days in the obese participants
improved mitochondrial respiration in muscle by activating AMPK-SIRT1-PGC-1a axis [230]
while decreased the size of subcutaneous white adipocytes possibly by upregulating
autophagy-induced lipid breakdown [231] and expression of brown markers (UCP1, PRDM16,
and PGC-1a) [232] concurrently with improved glycemic and lipid profiles [230, 232]. All
these results suggest that the effects of resveratrol may vary due to the different health condition
of subjects and the dose or duration of treatment. The beneficial metabolic effects of resveratrol
in obese subjects may come from the regulation of muscle and WAT activity rather than
activating BAT, which was observed in the rodent studies. Therefore, it is not conclusive
whether resveratrol is an effective anti-obesity compound in humans by increasing energy
expenditure through BAT activation.
b. Capsaicin and capsinoids
Capsaicin is a worldwide-consumed spice from chili pepper, generating hotness and
pungency sensation. Capsaicin has shown beneficial health effects, including anti-obesity
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effects, in humans [233, 234]. Capsinoids, primarily found in red peppers, inducing much less
pungency sensation than capsaicin, present similar chemical structures and confer similar
beneficial effects as capsaicin [235]. Administration of either capsaicin or capsinoids can
activate the gastrointestinal TRP potential cation channel subfamily V member 1-SNS
(TRPV1-SNS) pathway to activate thermogenesis, energy expenditure, and fat oxidation [233,
236], making them promising in activating BAT thermogenesis and thereby fighting against
obesity.
In rodents, capsaicin and/or capsinoids increased SNS activity in the BAT and increased
core body temperature and whole-body energy expenditure, paralleled with decreased body fat
mass [237-241]. These effects were attenuated by b-AR antagonists [237], parasympathetic
denervation of jejunum [238, 239], TRPV1 ablation [238, 240], or UCP1 knockout [242]. In
humans, a single dose of capsinoids increased energy expenditure only in the healthy
participates with 18FDG-PET/CT-detectable BAT, suggesting the functional BAT is critical for
capsinoid-induced beneficial effects in humans [243]. In addition, chronic capsinoid ingestion
(6-12 weeks) was able to enhance cold-induced thermogenesis in healthy humans with low
BAT activities [196] and induce a reduction of visceral fat in the obese participates [244],
possibly due to BAT activation as confirmed by
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FDG-PET/CT and near-infrared time-

resolved spectroscopy (NIRTRS) [245, 246]. The important role of TRPV1 in capsinoidinduced beneficial effect was demonstrated by the fact that fat-reducing effects of capsinoids
were diminished in the participates with TRPV1 mutation [244], consistent with the results
found in TRPV1 ablated mice [238, 240]. Importantly, either single ingestion of 30 mg [243]
or chronic administration of 6-9 mg/day [196, 244] of capsinoids did not induce severe adverse
effects in humans.
In sum, capsaicin and capsinoids may be a safe and practical strategies to combat obesity
through the TRP-SNS-BAT axis in humans.
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c. Other food ingredients targeting the TRP-BAT axis
Other than capsaicin and capsinoids, multiple food ingredients present TRPV1 activation
capacity, such as piperine found in black pepper and gingerols and 6-paradol found in the
gingers and Guinea peppers (GP). These food components may activate BAT thermogenesis
similar to those of capsaicin and capsinoids [247]. However, evidence for these food
ingredients is limited. Acute ingestion of the GP extract (40 mg) increased the cold-induced
thermogenesis only in the subjects with metabolically active BAT [248], and chronic ingestion
of the GP extract (30 mg/day for 4 weeks) in non-obese women decreased the visceral fat mass
and increased whole-body energy expenditure [249]. However, further studies are needed to
investigate whether the fat-reducing effects of the GP extract in non-obese women can be
translated to the obese population.
In addition to TRPV1, another critical member of the TRP family is TRPM8, which is
sensitive to lower temperatures. TRRPM8 stimulation holds promise to activate BAT similar
to cold exposure [216, 217]. Menthol, responsible for the cooling sensation of mint, is a
representative agonist of TRPM8, which has been demonstrated to increase thermogenesis in
a UCP1-dependent manner to prevent diet-induced obesity in mice [250]. However, such
beneficial effects of menthol need to be further investigated in human trials.
d. Long-chain fatty acid (LCFA) species
An early study reported that voluntary over-eating stimulated the SNS and brown adipose
tissue thermogenesis, suggesting a role of diet on BAT thermogenesis [251]. The degree of
BAT thermogenesis differs in response to diet with different compositions of macronutrients
[252]. Rodents fed on a high-protein diet present lower SNS-induced BAT thermogenesis than
the rodents fed on a high-carbohydrate or high-fat diet [252-256]. Moreover, a high-fat diet has
been reported to increase UCP1 content in the BAT in rodents, which was not affected by fat
content but instead associated with the unsaturation index of dietary fat [257]. In the early
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1990s, dietary polyunsaturated fatty acids (PUFAs) are considered to be the causative factor to
induce BAT thermogenesis [258]. Later, several studies reported that fish oil, rich in EPA and
DHA, decreased high-fat diet-induced body fat accumulation while increased the UCP1 mRNA
expression in the iBAT of rats to a greater extent than safflower oil (rich in linoleic acids) [259,
260]. In addition, a low dietary n-6/n-3 ratio (3.7) has been reported to improve the thermogenic
activity of the iBAT in mice in response to β3-AR agonist [261]. Consistently, a high ratio of
n-6/n-3 PUFAs found in current western diets is associated with an increased risk of
cardiovascular diseases, cancer, inflammatory diseases, and obesity in humans [262, 263]. N3 PUFAs have been a particular focus in BAT activation to combat metabolic disorders in
recent 20 years, which are discussed in the next section.
2.4 N-3 PUFA, BAT activation, and Obesity
2.4.1 Structure, nomenclature, and food sources
PUFAs are a family of fatty acids with two or more double bonds in the hydrocarbon chain,
which could be classified as either n-6 or n-3 PUFAs based on the first double bond position
relative to the methyl carbon [264, 265]. If counting the methyl carbon as the first carbon (n1) of the acyl chain, PUFAs containing a double bond starting from the third carbon atoms (n3) are defined as n-3 PUFAs, while PUFAs having a double bond beginning from the sixth
carbon atoms are classified as n-6 PUFAs [265]. PUFAs are named according to the number
of carbon atoms and the number of double bonds [265]. For example, linoleic acid (LA) and
alpha-linolenic acids (ALA) are named as 18:2 n-6 and 18:3 n-3, respectively, which are the
simplest n-6/n-3 PUFAs found only in plant sources and cannot be synthesized in animals [265].
Thereby, LA and ALA are essential FAs for humans [266]. LA and ALA could be converted
to other n-6/n-3 PUFAs, such as arachidonic acid (ARA, 20:4n-6) from LA or EPA (20:5n-3)
and DHA (22:6n-3) from ALA, by a series of elongation and desaturation [264].
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Several plant seeds-derived oil and nuts are rich in ALA, such as flaxseeds and flaxseeds
oil, rapeseed oil, and walnuts, containing more than half of the total fatty acids as ALA [267].
Other plant oil, such as corn oil, sunflower oil, and safflower oil, are critical food sources for
LA which is the main PUFA in most western diets and is consumed in a large amount 5- to 20fold greater than ALA [268]. Alternatively, other more unsaturated very-long-chain n-3 PUFAs
could be obtained from marine sources. Fish, especially fatty fish, and seafood are good dietary
sources for DHA and EPA [267]. The content of DHA and EPA in fish differs between fish
species, season, water temperature, and the diet of fish [268]. One serving of salmon or
mackerel, two typical fatty fishes, provides up to 3 grams of very-long-chain n-3 PUFAs, which
is 10 fold of one serving of lean fish meal [268]. However, it has been reported that the typical
intake of fatty fish was less than half of the intake of lean fish in North America, East Europe,
the United Kingdom, and Australasia [268].
Currently, a typical western diet with a high ratio of n-6/n-3 PUFAs is associated with
increased risk of cardiovascular diseases, cancer, inflammatory diseases, and obesity in humans
[262, 263]. Over the past 20 years, DHA- and EPA-enriched foods, such as fish oil added
spreads, yogurts or milk and meat, eggs or dairy products from the animals fed with n-3 fatty
acids, are good sources to provide up to a hundred milligrams of DHA and EPA per day to help
people increase n-3 PUFAs intake without significantly changing eating habits [266].
2.4.2 Metabolism of n-3 PUFA and its biological effects
A. ALA converted to EPA and DHA
Upon being absorbed through the small intestine, dietary n-3 PUFAs are primarily
incorporated into TG-rich chylomicrons (CMs) entering into the lymphatic system and then
blood circulation to be taken up by tissues [269]. Two major metabolic fates of ALA are βoxidation and carbon recycling for de novo synthesis of fatty acids and cholesterol in mammals,
including humans [270]. Also, it could be utilized as precursors to synthesize EPA and DHA
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following several tissue-specific desaturations and elongations in humans [271]. Similarly, LA
could also be converted to ARA by desaturation and elongation following the same enzyme
pathways as ALA [271]. ALA competitively inhibits ARA synthesis from LA, thereby
increasing the ratio of n-3/n-6 PUFAs ratio to confer beneficial effects [271].
B. EPA/DHA metabolisms
One of the important metabolic fates of dietary EPA/DHA is as substrates for cellular
oxygenase to generate oxylipins, including cyclooxygenase (COX), lipoxygenase (LOX), and
cytochrome P450 (CYP450) monooxygenases, all of which also catalyze the oxidation of ARA
[272].
The major COX and LOX products of ARA, including various thromboxanes (TXs),
leukotrienes (LTs), and prostaglandins (PGs), are potent modulators of platelet aggregation,
smooth muscle contraction, and immune cell infiltration and adherence [273]. Excess
production of ARA-derived PGs/LTs may lead to pathological processes resulting in certain
diseases such as cardiovascular diseases (CVD) [273]. In contrast, EPA-derived PGs and LTs
are far less potent in pathological processes [273]. Therefore, n-3 PUFAs could competitively
reduce the level of ARA-derived eicosanoids to promote beneficial outcomes related to CVD
[273]. Moreover, several COX- and LOX-generated oxylipins from n-3 PUFAs are antiinflammatory modulators, such as resolving E1-3 (RvE1-3) from EPA and resolving D1-6 (RvD16)

and maresin1 (MaR1) from DHA, which play protective roles in inflammatory diseases [274,

275].
The CYP450 enzymes produced metabolites include hydroxy fatty acids, dihydroxy fatty
acids, and epoxy fatty acids, whose synthesis is thought to be intensely regulated in response
to different dietary fatty acid compositions [276]. Among these derivatives, epoxides formed
by CYP450 epoxygenases from ARA, namely epoxyeicosatrienoic acids (EETs), present welldocumented beneficial effects on cardiovascular and renal diseases primarily through autocrine

43

and paracrine regulation [277]. In rodents and humans, CYP 2C and 2J subfamilies are two
major CYP epoxygenases that produce epoxides from ARA but also efficiently epoxidized
alternative substrates, such as n-3 PUFAs [276]. CYP epoxygenases metabolized EPA and
DHA with higher efficiencies than ARA in the healthy participants when supplemented with
n-3 PUFAs [278].
C. Biological effects of EPA/DHA
Intracellular free n-3 PUFAs, primarily DHA and EPA, are quickly esterified by acyl-CoA
synthetase (ACS) to fatty acyl-CoA thioesters and then incorporated into complex lipids,
including triglycerides and phospholipids [279]. N-3 PUFAs enriched phospholipids are
critical for membrane structure and function in most cells, such as rods of the retina and neurons
in the brain [268, 280, 281].
In addition, n-3 PUFAs bind to membrane surface receptors to regulate cell and tissues
behavior[282]. One well-established cell surface receptor that is activated by n-3 PUFAs is Gprotein coupled surface receptor 120 (GPR120) highly expressed in inflammatory
macrophages and adipocytes [282]. Moreover, n-3 PUFAs modulate various transcription
factors or nuclear receptors, including nuclear factor kappa-light-chain-enhancer of activated
B cells (NFkB), PPARa, PPARg, sterol regulatory element-binding proteins (SREBPs),
retinoid X receptor alpha (RXRa), liver X receptor (LXR), and hepatocyte nuclear factor-4
alpha (HNF-4a) to modulate intracellular signal transduction, thereby influencing a wide range
of cells and tissues functions [264, 279, 282].
In general, n-3 PUFAs present protective effects in cardiovascular diseases [283],
neurodegenerative diseases [284], non-alcoholic fatty liver diseases[285], and chronic
inflammatory diseases [286]. In recent years, dietary n-3 PUFAs have been reported to be
beneficial effects in obesity treatment and prevention [287].
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2.4.3 Anti-obesity effects of N-3 PUFA: the role on BAT
A. N-3 PUFA promotes BAT activity in obesity
Evidence from animal studies has shown that EPA and DHA supplementation may prevent
high-fat diet-induced body weight gain, visceral WAT accumulation, and metabolic disorders
[287-290]. Possible mechanisms underlying the fat-reducing effects of n-3 PUFAs include
appetite regulation, anti-inflammation, inhibition of white adipocyte proliferation and
adipogenesis, and regulation of gene expression involved in lipid metabolism and brain-gutWAT axis [287-290]. The effects of n-3 PUFAs supplementation on weight loss and body fat
composition in human trials are inconsistent, which may be due to the heterogeneity of study
design, demographics of participants, dose, and duration of n-3 PUFA administration [263].
Overall, based on current evidence from rodents and human studies, n-3 PUFAs hold promising
therapeutic potentials in obesity and associated metabolic disorders. Recently, n-3 PUFAs have
been reported to prevent high-fat diet-induced adiposity in parallel with an increase in energy
expenditure in rodents, suggesting the possible role of n-3 PUFAs on BAT [291].
It was firstly reported that 4-weeks of administration of a mixture of EPA and DHA
prevented the high-fat diet-induced epididymal and retroperitoneal fat accumulation in rats,
associated with an increase in total DNA content and UCP content in iBAT [292]. Such results
suggest that BAT-related thermogenesis induced by the mixture may be responsible for their
WAT-reducing effects in diet-induced obesity [292]. Consistently, later studies reported that
fish oil consumption prevented the excessive WAT accumulation induced by a high-fat diet in
rats, accompanied by an increase in total iBAT mass [293], UCP1 mRNA [259] and protein
expression [293].
Similar results were reported in mouse models. Dietary n-3 PUFA supplementation in the
forms of fish oil with different formulations [294-298] or pure DHA and/or EPA [299-303]
prevented high-fat diet-induced body weight gain and abdominal WAT accumulation possibly

45

through enhanced BAT thermogenic function as indicated by increased core body temperature
or oxygen consumption [294, 297, 298, 303], increased mitochondrial biogenesis [301], and
upregulated expression of thermogenic genes, including β3-AR, UCP1, PGC-1a, and PRDM16
[294-298, 300-303]. Moreover, dietary n-3 PUPA consumption improved glucose intolerance
[296, 298], insulin resistance [297], and hypertriglyceridemia [294, 296, 299, 303] in high-fat
diet-fed mice concurrently with upregulated mRNA expression of genes involved in glucose
uptake (GLUT4), lipids uptake (LPL and CD36), and fatty acid beta-oxidation (CPT1B) in the
iBAT [294, 296, 301]. These results suggested that the anti-obesity effects of n-3 PUFAs in
rodents may be partially achieved by improving BAT thermogenic and metabolic function.
B. Mechanisms by which n-3 PUFA promotes BAT activity
The mechanisms by which n-3 PUFA potentiates BAT function are not well-understood,
and several mechanisms have been reported. Since BAT thermogenesis is intensely regulated
by SNS, it is possible that n-3 PUFA regulate BAT thermogenesis through SNS activation.
DHA- or EPA-enriched fish oil administration prevented high-fat diet-induced obesity and
hypertriglyceridemia in mice [294]. These effects were accompanied by increased energy
expenditure, urine catecholamine levels, noradrenaline turnover rate, and β3-AR and UCP1
expression in the iBAT, suggesting an enhanced sympathetic activity in the iBAT induced by
n-3 PUFA [294]. Moreover, such SNS activation effects were abolished in TRPV1 knockout
mice, indicating that n-3 PUFAs may stimulate SNS- β 3-AR pathways through TRPV1
activation [294], similar to those of TRPV1 agonists capsaicin and capsinoids discussed in the
previous section (2.3.3. C).
In addition, adrenergic-independent pathways have been proposed recently. Mice fed a
high-fat diet enriched with DHA and EPA showed significantly upregulated UCP1 protein
expression in the iBAT compared to the controls, which was associated with upregulated
mRNA levels of GPR120 and fibroblast growth factor 21 (FGF21) in the iBAT [301]. GPR120
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is a lipid sensor that can be activated by n-3 PUFAs to induce FGF21 production in the brown
adipocytes [304], which has been identified as a novel autocrine mediator in BAT
thermogenesis [305, 306]. Moreover, phosphorylation of AMPKa was increased in the iBAT
from n-3 PUFAs treated mice [301], which may be the downstream signaling pathway induced
by FGF21 to regulate BAT thermogenesis [307]. Therefore, n-3 PUFAs may enhance BAT
thermogenesis by activating GPR120-FGF21-AMPKa pathway to improve diet-induced
obesity in mice. However, the effect of n-3 PUFAs in inducing FGF21 was inconsistent.
Although administration of fish-derived n-3 PUFA concentrates in mice prevented high-fat
diet-induced adiposity, hyperinsulinemia, and hypertriglyceridemia, neither plasma FGF21
level nor FGF21 mRNA expression in the iBAT and WAT were increased compared to the
controls [299]. These results suggest that FGF21 induction may not be the major mechanism
underlying the anti-obesity effects of n-3 PUFAs. Moreover, the importance of GPR120 in n3 PUFAs-induced beneficial effects was challenged by the study using GPR120 knockout mice
[308]. It was reported that effects of fish oil administration in GPR120 knockout mice on core
body temperature, energy expenditure, and BAT mass did not differ from those in wild-type
mice [308]. These results suggest that GPR120 activation is not required by n-3 PUFAs to
confer anti-obesity effects, and alternative mechanisms may exist [308]. Indeed, in addition to
upregulated GPR120 mRNA level, n-3 PUFAs supplementation in mice fed a high-fat diet
significantly upregulated PPARa and PPARg mRNA levels in the iBAT [295, 296, 301, 302].
PPARg is a well-documented transcription factor that regulates BAT development and function.
PPARa is another member of the PPARs family that contributes to the thermogenic activation
of BAT by modulating genes involved in lipids metabolism and mitochondrial biogenesis [309].
Together, these results suggest that n-3 PUFAs may regulate BAT function to combat obesity
through multiple distinct targets, such as GPR120, PPARa, and PPARg.
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A growing evidence suggests that n-3 PUFAs, especially DHA, can remodel mitochondrial
inner membrane structure and composition associated with increased cardiolipins [310], a
group of phospholipids synthesized by cardiolipin synthase one that is responsible for
mitochondrial biology and energetic function [311, 312]. Recently, the lipidomic analysis
found that cold adaptation significantly increased cardiolipins in the iBAT of mice [313, 314].
Moreover, cardiolipins are essential for UCP1-mediated thermogenesis in BAT by
transcriptionally modulating UCP1 expression [313] and structurally supporting UCP1 activity
[315, 316]. All these results suggest that cardiolipins may be a possible mechanism by which
n-3 PUFAs promote BAT thermogenesis to fight against obesity. However, no studies have
reported the changes of cardiolipin profiles in the BAT by n-3 PUFA supplementation in obese
models. More direct evidence is needed to support the roles of cardiolipins in BAT activation
by n-3 PUFAs.
While a majority of studies reported that n-3 PUFAs protected against diet-induced obesity
in rodents through UCP1-dependent thermogenesis by increasing energy expenditure via
upregulating UCP1 mRNA and/or protein expression in iBAT [259, 292-296, 300-302], a few
exceptions have been reported [298, 299]. Moreover, results from UCP1 deficient mice have
indicated that n-3 PUFAs may enhance energy expenditure through UCP1-independent
pathways [297, 298]. Fish oil or EPA-enriched fish oil administration protected both wild type
and UCP1 knockout mice from high-fat diet-induced obesity with increased energy
expenditure at both room temperature and thermoneutrality conditions [297, 298]. One
possible UCP1-independent mechanism by which n-3 PUFAs enhance energy expenditure may
be glycerol 3-phosphate dehydrogenase (GPD)-mediated thermogenic futile cycle [297]. It is
a mechanism that regenerates reducing equivalent by substrates converting between glycerol
3-phosphate and dihydroxyacetone phosphate catalyzed through cytosolic/mitochondrial GDP
[317]. mRNA expression of mitochondrial GPD (mGPD) was increased in the inguinal WAT
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(iWAT) of UCP1 knockout mice treated with fish oil, indicating that n-3 PUFAs may enhance
the mGDP-induced futile thermogenic metabolic cycle to increase energy expenditure [297].
In addition, EPA-enriched fish oil administration upregulated PGC-1a protein and mRNA
expression and increased mitochondrial DNA content in the iBAT of UCP1 knockout mice,
suggesting that increased mitochondrial biogenesis may be, at least in part, responsible for the
enhanced energy expenditure induced by n-3 PUFAs in UCP1 knockout mice [298].
C. Differential effects of DHA and EPA on BAT activity in obesity
Early evidence found that DHA or EPA supplementation for 4 weeks (11% energy intake
from DHA or EPA) in rats protected against high-fat diet (40% energy intake from fat) induced
abdominal WAT accumulation, possibly through activating BAT thermogenesis [292].
Whereas DHA significantly increased total DNA content and mitochondrial thermogenic
activity in the iBAT compare to the control group, EPA significantly increased total
mitochondrial and UCP content compared to the control group and DHA-treated group [292].
These results suggest that DHA or EPA administration may limit high-fat diet-induced white
fat accumulation in rats, possibly by promoting BAT thermogenesis through different
mechanisms. DHA may enhance BAT thermogenesis through hyperplasia effects, while EPA
may induce mitochondrial biogenesis to enhance UCP1-dependent thermogenesis in rats fed
with a high-fat diet.
In a mouse model, DHA or EPA administration (2% energy intake from DHA or EPA) for
5 weeks significantly decreased the lipid accumulation in the iBAT of mice fed a high-fructose
diet [318]. However, the gene expression was differentially regulated by DHA and EPA. Gene
expression of thermogenic markers, including UCP1 and PGC-1a, in the iBAT were
upregulated in both DHA- and EPA-treated groups, but UCP1 mRNA expression was more
efficiently augmented in the EPA-treated mice compared to DHA-treated mice [318]. mRNA
expression of genes involved in fatty acid utilization, such as LPL, were upregulated in the
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DHA and EPA groups, while HSL mRNA expression was only increased in the EPA-treated
group [318]. Both DHA and EPA treatment increased the PPARa mRNA expression, whereas
PPARg mRNA was only upregulated by the EPA treatment [318].
Although these studies suggest that DHA and EPA may promote BAT thermogenesis via
different mechanisms to confer beneficial effects in rodents, many of the studies on DHA or
EPA only showed upregulated thermogenic gene expression with no functional analysis of the
thermogenesis. It is note that several other studies have reported that EPA increased the oxygen
consumption in brown adipocytes [295, 300, 304, 319] and increased the energy expenditure
in mice [295, 298, 300, 302, 303] by targeting thermogenetic genes in the iBAT to protect
against obesity and associated metabolic disorders, which further confirms that the anti-obesity
effects of EPA are at least in part originated from the improved BAT thermogenesis.
In addition, inconsistent results have been reported regarding the effects of DHA on fat
mass and BAT thermogenic function. In one study, purified DHA supplementation (1% wt/wt)
for 15 weeks in the obese mice fed a high-fat diet did not affect body weight but significantly
decreased the iWAT mass and serum TG and TC levels in parallel with increased iBAT mass,
18

FDG uptake in the iBAT, and whole-body oxygen consumption, possibly due to upregulated

UCP1 expression in the iBAT [303]. These results suggest that DHA may limit WAT fat
accumulation and improve hyperlipidemia, possibly through increased energy expenditure by
activating BAT in mice. However, other studies failed to confirm the WAT-limiting and
thermogenic effects of DHA in rodents [320-322]. DHA supplementation (1% wt/wt) for 16
weeks did not reduce body weight or WAT fat mass but improved the hypercholesterolemia in
mice fed a high-fat, high-sucrose diet (45% energy intake and 14% energy intake from fat and
sucrose, respectively) [323]. Another study reported that 1% DHA administration (1% wt/wt)
for 12 weeks in insulin resistant mice prevented the high-fat diet (45% energy intake)-induced
body weight gain and fat accumulation without improving the serum TG or TC levels, while
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4% DHA treatment significantly decreased the serum TC and LDL cholesterol (LDL-c) levels
without changing body weight gain or fat mass [322]. In addition, administration of purified
DHA (1g/d/kg bw) for 4 weeks significantly decreased the plasma TG and TC levels but did
not change the body weight, WAT fat mass, iBAT cellularity (DNA content), or the ex vivo
oxygen consumption of the iBAT from rats [320]. Moreover, prolonged DHA administration
for 16 weeks even significantly decreased the iBAT oxygen consumption in the basal state and
NE-stimulated state [320]. In a most recent study, 12-month administration of a DHA-enriched
high-fat diet (6.7% energy intake from DHA, 45% energy intake from fat) in the aged obese
mice significantly improved the lipid profiles without affecting the body weight or adiposity
[321]. Moreover, the activity of BAT in response to cold, measured by

18

FDG uptake, was

drastically decreased in the aged obese mice, which was not reversed by DHA supplementation
even though a restored UCP1 protein expression and PRDM16 mRNA expression in BAT were
observed [321]. Such discrepancy in the effects of DHA treatment may result from the different
rodent species, study design, and the form and dose of DHA used in these studies.
In summary, current evidence for DHA supplementation is more profound and consistent
in its lipids lowing effects in rodents compared to the fat-reducing effects, whereas EPA may
be more protective against WAT accumulation in obesity. In addition, whether DHA and EPA
have comparable effects on modulating BAT activity need further investigation. Moreover, the
mechanisms by which DHA and EPA differentially regulate the thermogenic gene expression
and the activity of BAT remain unclear. One possible speculation is that CYP-produced
epoxides from DHA and EPA may partially contribute to their differential effects since these
epoxides are bioactive metabolites participating in multiple physiological processes [276].
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2.5 Effects of epoxy fatty acids from DHA and EPA in obesity
2.5.1 Overview: Production, Structure, and Metabolism
Inside the cell, the majority of n-3 PUFAs are incorporated into the cell membrane as
phospholipids [264]. In addition, n-3 PUFAs are also incorporated into intracellular TG, mainly
in adipose tissue [264]. Upon certain stimuli, n-3 PUFAs from TG or membrane phospholipids
were released by the action of lipolytic enzymes, which then are converted to multiple bioactive
metabolites through different enzymatic processes [264]. One of the major enzymes is CYP450
epoxygenase, which convert one of the double bonds in n-3 PUFAs to a monoepoxide group
and generate epoxy fatty acids (EpFAs) [276]. Epoxydocosapentaenoic acids (EDPs) and
epoxyeicosatetraenoic acids (EEQs) are EpFAs produced from DHA and EPA, respectively,
with different regioisomers depending on the position of the monoepoxide group [276]. EDPs
consist of 6 regioisomers, including 4,5-, 7,8-, 13,14-, 16-17, and 19,20-EDP, whereas EEQs
consist of 5 regioisomers, including 5,6-, 8,9-, 11,12-, 14,15-, and 17,18-EEQ [276]. In rodents
and humans, CYP 2C and 2J subfamilies are two major CYP epoxygenases efficiently
metabolize n-3 PUFAs [276]. They metabolize DHA to 19,20-EDP and EPA to 17,18-EEQ in
a predominate ratio [276].
N-3 PUFA-derived EpFAs (n-3 EpFAs) are reported to be involved in vasculature function,
angiogenesis, inflammation, cell growth, and pain and are beneficial in cardiovascular diseases,
pulmonary disease, neurodegenerative diseases, and cancer [276, 324-326]. However, these
EpFAs are not stable and are quickly metabolized into far less active diols by sEH, an enzyme
encoded by the EPXH2 gene in humans [326]. Potent sEH inhibitors are developed and widely
used to study the functional effects of EpFAs [326-328]. Many of the beneficial effects of
EpFAs were potentiated by co-administration of an sEH inhibitor [326-328].
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2.5.2 Effects of n-3 EpFA in obesity
It has been well-documented that n-3 PUFAs present cardioprotective and neuroprotective
effects [329], which could be partially due to the production of n-3 EpFAs as they were reported
to modulate a variety of physiological processes such as angiogenesis, vasodilation,
inflammation, and cell growth/differentiation [276, 324-326].
Recent studies indicated that higher sEH activity was associated with obesity and
metabolic diseases in rodents [330]. Moreover, sEH expression in the sWAT of obese adults
was significantly higher than that of lean subjects [331]. Thereby, sEH has been targeted to
treat or prevent obesity.
sEH knockout mice fed a high-fat diet have been reported to show decreased body weight
[332] and improved glucose tolerance and insulin sensitivity [333, 334], accompanied by
decreased inflammation in the colon or adipose tissue [332], suppressed gut bacterial leakage
and translocation [332], and enhanced insulin signaling in the liver and adipose tissue [333].
Consistently, administration of sEH inhibitors 1-(1-methanesulfonyl-piperidin-4-yl)-3-(4trifluoromethoxy-phenyl)-urea

(TUPS)

[333],

trans-4-[4-(3-adamantan-1-yl-ureido)-

cyclohexyloxy]-benzoic acid (t-AUCB) [335, 336], or t-TUCB [337] have been demonstrated
to improve fasting glucose [335], glucose tolerance [333, 336], insulin sensitivity [333], and
plasma NEFA and LDL-c levels [336] in mice fed a high-fat diet, accompanied by enhanced
insulin signaling in the adipose tissue and liver [333], improved hepatic steatosis [336], or
decreased inflammation in the kidney, liver and adipose tissue [335-337]. In rats with dietinduced metabolic syndrome, t-AUCB also improved the glucose, insulin, and lipid profiles,
decreased the systolic blood pressure, and restored the cardiovascular and hepatic structure and
function [338].
Interestingly, sEH deletion in mice reduced body weight and visceral fat mass concurrently
with significant reduced size of white adipocytes and increased mitochondrial and thermogenic

53

genes expression in the WAT, including mitofusin-1 (Mfn1), cytochrome c oxidase subunit 1
(COX1), and UCP1, suggesting browning of WAT induced by sEH ablation [339]. Moreover,
sEH inhibitor 1-(1-acetypiperidin-4-yl)-3-adamantanylurea (AR9281 or APAU) was reported
to promote weight loss and reduce visceral fat mass in obese mice fed a high-fat diet in parallel
with increased oxygen consumption and UCP1 protein abundance in the iBAT, indicating a
possible effect on activating BAT thermogenesis by sEH inhibitor [340].
Considering that bioactive EpFAs are metabolized by sEH, and many of the beneficial
effects of EpFAs were potentiated by co-administration of an sEH inhibitor [326-328], sEH
inhibition may improve obesity and its associated metabolic disorders due to, at least in part,
stabilized endogenous EpFAs. However, the downstream EpFAs responsible for the antiobesity effects of sEH inhibition have not been identified. Although the contribution of n-6
PUFA-derived EpFAs (n-6 EpFAs) cannot be ruled out, many studies have focused on the
effects of n-3 EpFAs because of the well-recognized anti-obesity effects of n-3 PUFAs
(discussed in section 2.4.3).
The transgenic mice fat-1 mice have provided a valuable model to study the effects of n3 EpFAs in obesity and associated metabolic disorders [337]. Fat-1 mice expressed an n-3
desaturase that increases endogenous n-3 PUFAs in tissues [337]. It was found that insulinsensitive tissues, including the liver and adipose tissue of fat-1 mice were enriched with n-3
EpFAs, such as 17,18-EEQ and 19,20-EDP [337]. When fed a high-fat diet, fat-1 mice gained
significantly less body weight compared to the wild-type mice with a smaller adipocyte sizes
and lower levels of inflammation and fibrosis in the epididymal WAT [337]. In addition, highfat diet-induced hepatic inflammation and steatosis were significantly reversed in fat-1 mice,
which were further reduced by the administration of sEH inhibitor t-TUCB [337]. Interestingly,
the iBAT volume in fat-1 mice treated with t-TUCB was significantly increased compared to
untreated controls, while t-TUCB treatment in wild-type mice did not affect the iBAT mass
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[337]. But this study did not further investigate thermogenic genes expression in the iBAT or
whole-body energy metabolism to qualify the BAT thermogenic activity.
Overall, these results suggest that sEH inhibition alone or combined with n-3 EpFAsgenerating diet may be beneficial in obesity by targeting insulin-sensitive tissues, such as liver,
WAT, and possibly BAT [337]. However, to our knowledge, no studies on the effects of
specific n-3 EpFAs (EDPs/EEQs) on BAT in obesity treatment and prevention have been
reported. Therefore, studies investigating the effects of EDPs/EEQs on BAT in obesity and the
underlying mechanisms are warranted.

55

References
1.

Jaacks, L.M., et al., The obesity transition: stages of the global epidemic. Lancet
Diabetes Endocrinol, 2019. 7(3): p. 231-240.

2.

Flier, J.S., Obesity wars: molecular progress confronts an expanding epidemic. Cell,
2004. 116(2): p. 337-50.

3.

Hales, C.M., et al., Prevalence of Obesity and Severe Obesity Among Adults: United
States, 2017-2018. NCHS Data Brief, 2020(360): p. 1-8.

4.

Guidelines (2013) for managing overweight and obesity in adults. Preface to the
Expert Panel Report (comprehensive version which includes systematic evidence
review, evidence statements, and recommendations). Obesity (Silver Spring), 2014.
22 Suppl 2: p. S40.

5.

Finkelstein, E.A., et al., Annual medical spending attributable to obesity: payer-and
service-specific estimates. Health Aff (Millwood), 2009. 28(5): p. w822-31.

6.

Tremmel, M., et al., Economic Burden of Obesity: A Systematic Literature Review. Int
J Environ Res Public Health, 2017. 14(4).

7.

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight
and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res,
1998. 6 Suppl 2: p. 51s-209s.

8.

Lauby-Secretan, B., et al., Body Fatness and Cancer--Viewpoint of the IARC Working
Group. N Engl J Med, 2016. 375(8): p. 794-8.

9.

Yadav, R., S. Aggarwal, and A. Singh, SARS-CoV-2-host dynamics: Increased risk of
adverse outcomes of COVID-19 in obesity. Diabetes Metab Syndr, 2020. 14(5): p.
1355-1360.

10.

Steinberg, E., E. Wright, and B. Kushner, In Young Adults with COVID-19, Obesity Is
Associated with Adverse Outcomes. West J Emerg Med, 2020. 21(4): p. 752-755.

56

11.

Sanchis-Gomar, F., et al., Obesity and Outcomes in COVID-19: When an Epidemic
and Pandemic Collide. Mayo Clin Proc, 2020. 95(7): p. 1445-1453.

12.

Qasim, A., et al., On the origin of obesity: identifying the biological, environmental
and cultural drivers of genetic risk among human populations. Obes Rev, 2018.
19(2): p. 121-149.

13.

Castillo, J.J., R.A. Orlando, and W.S. Garver, Gene-nutrient interactions and
susceptibility to human obesity. Genes Nutr, 2017. 12: p. 29.

14.

Friedman, J.M., Obesity: Causes and control of excess body fat. Nature, 2009.
459(7245): p. 340-2.

15.

Spiegelman, B.M. and J.S. Flier, Obesity and the regulation of energy balance. Cell,
2001. 104(4): p. 531-43.

16.

Jequier, E. and L. Tappy, Regulation of body weight in humans. Physiol Rev, 1999.
79(2): p. 451-80.

17.

Hammarstedt, A., et al., Impaired Adipogenesis and Dysfunctional Adipose Tissue in
Human Hypertrophic Obesity. Physiol Rev, 2018. 98(4): p. 1911-1941.

18.

Smith, R.E. and B.A. Horwitz, Brown fat and thermogenesis. Physiol Rev, 1969.
49(2): p. 330-425.

19.

Nicholls, D.G. and R.M. Locke, Thermogenic mechanisms in brown fat. Physiol Rev,
1984. 64(1): p. 1-64.

20.

Cannon, B. and J. Nedergaard, Brown adipose tissue: function and physiological
significance. Physiol Rev, 2004. 84(1): p. 277-359.

21.

Rothwell, N.J. and M.J. Stock, A role for brown adipose tissue in diet-induced
thermogenesis. Nature, 1979. 281(5726): p. 31-5.

22.

James, W.P. and P. Trayhurn, Thermogenesis and obesity. Br Med Bull, 1981. 37(1):
p. 43-8.

57

23.

Blaza, S., Brown adipose tissue in man: a review. J R Soc Med, 1983. 76(3): p. 213-6.

24.

Lean, M.E., Brown adipose tissue in humans. Proc Nutr Soc, 1989. 48(2): p. 243-56.

25.

Cypess, A.M., et al., Identification and importance of brown adipose tissue in adult
humans. N Engl J Med, 2009. 360(15): p. 1509-17.

26.

Saito, M., et al., High incidence of metabolically active brown adipose tissue in
healthy adult humans: effects of cold exposure and adiposity. Diabetes, 2009. 58(7):
p. 1526-31.

27.

van Marken Lichtenbelt, W.D., et al., Cold-activated brown adipose tissue in healthy
men. N Engl J Med, 2009. 360(15): p. 1500-8.

28.

Virtanen, K.A., et al., Functional brown adipose tissue in healthy adults. N Engl J
Med, 2009. 360(15): p. 1518-25.

29.

Wang, W. and P. Seale, Control of brown and beige fat development. Nat Rev Mol
Cell Biol, 2016. 17(11): p. 691-702.

30.

Cohen, P. and S. Kajimura, The cellular and functional complexity of thermogenic fat.
Nat Rev Mol Cell Biol, 2021. 22(6): p. 393-409.

31.

Whittle, A., J. Relat-Pardo, and A. Vidal-Puig, Pharmacological strategies for
targeting BAT thermogenesis. Trends in Pharmacological Sciences, 2013. 34(6): p.
347-355.

32.

Amiot, M.J., C. Riva, and A. Vinet, Effects of dietary polyphenols on metabolic
syndrome features in humans: a systematic review. Obes Rev, 2016. 17(7): p. 573-86.

33.

El Hadi, H., et al., Food Ingredients Involved in White-to-Brown Adipose Tissue
Conversion and in Calorie Burning. Frontiers in physiology, 2019. 9: p. 1954-1954.

34.

Cereijo, R., M. Giralt, and F. Villarroya, Thermogenic brown and beige/brite
adipogenesis in humans. Ann Med, 2015. 47(2): p. 169-77.

58

35.

Cinti, S., The adipose organ. Prostaglandins Leukot Essent Fatty Acids, 2005. 73(1):
p. 9-15.

36.

Cinti, S., Between brown and white: novel aspects of adipocyte differentiation. Ann
Med, 2011. 43(2): p. 104-15.

37.

Harms, M. and P. Seale, Brown and beige fat: development, function and therapeutic
potential. Nat Med, 2013. 19(10): p. 1252-63.

38.

Timmons, J.A., et al., Myogenic gene expression signature establishes that brown and
white adipocytes originate from distinct cell lineages. Proc Natl Acad Sci U S A,
2007. 104(11): p. 4401-6.

39.

Petrovic, N., et al., Chronic peroxisome proliferator-activated receptor gamma
(PPARgamma) activation of epididymally derived white adipocyte cultures reveals a
population of thermogenically competent, UCP1-containing adipocytes molecularly
distinct from classic brown adipocytes. J Biol Chem, 2010. 285(10): p. 7153-64.

40.

Wu, J., et al., Beige adipocytes are a distinct type of thermogenic fat cell in mouse
and human. Cell, 2012. 150(2): p. 366-76.

41.

Jespersen, N.Z., et al., A classical brown adipose tissue mRNA signature partly
overlaps with brite in the supraclavicular region of adult humans. Cell Metab, 2013.
17(5): p. 798-805.

42.

Lidell, M.E., et al., Evidence for two types of brown adipose tissue in humans. Nat
Med, 2013. 19(5): p. 631-4.

43.

Guerra, C., et al., Emergence of brown adipocytes in white fat in mice is under genetic
control - Effects on body weight and adiposity. Journal of Clinical Investigation,
1998. 102(2): p. 412-420.

44.

Kazak, L., et al., A creatine-driven substrate cycle enhances energy expenditure and
thermogenesis in beige fat. Cell, 2015. 163(3): p. 643-55.

59

45.

Sharp, L.Z., et al., Human BAT possesses molecular signatures that resemble
beige/brite cells. PLoS One, 2012. 7(11): p. e49452.

46.

Cypess, A.M., et al., Anatomical localization, gene expression profiling and
functional characterization of adult human neck brown fat. Nat Med, 2013. 19(5): p.
635-9.

47.

Nedergaard, J. and B. Cannon, How brown is brown fat? It depends where you look.
Nature Medicine, 2013. 19(5): p. 540-541.

48.

Atit, R., et al., Beta-catenin activation is necessary and sufficient to specify the dorsal
dermal fate in the mouse. Dev Biol, 2006. 296(1): p. 164-76.

49.

Seale, P., et al., PRDM16 controls a brown fat/skeletal muscle switch. Nature, 2008.
454(7207): p. 961-7.

50.

Lepper, C. and C.M. Fan, Inducible lineage tracing of Pax7-descendant cells reveals
embryonic origin of adult satellite cells. Genesis, 2010. 48(7): p. 424-36.

51.

Schulz, T.J., et al., Identification of inducible brown adipocyte progenitors residing in
skeletal muscle and white fat. Proc Natl Acad Sci U S A, 2011. 108(1): p. 143-8.

52.

Sanchez-Gurmaches, J., et al., PTEN loss in the Myf5 lineage redistributes body fat
and reveals subsets of white adipocytes that arise from Myf5 precursors. Cell Metab,
2012. 16(3): p. 348-62.

53.

Tseng, Y.H., et al., New role of bone morphogenetic protein 7 in brown adipogenesis
and energy expenditure. Nature, 2008. 454(7207): p. 1000-4.

54.

Park, J.H., et al., A Multifunctional Protein, EWS, Is Essential for Early Brown Fat
Lineage Determination. Developmental Cell, 2013. 26(4): p. 393-404.

55.

Wang, W.S., et al., Ebf2 is a selective marker of brown and beige adipogenic
precursor cells. Proceedings of the National Academy of Sciences of the United
States of America, 2014. 111(40): p. 14466-14471.

60

56.

Seale, P., et al., Transcriptional control of brown fat determination by PRDM16. Cell
Metab, 2007. 6(1): p. 38-54.

57.

Ohno, H., et al., EHMT1 controls brown adipose cell fate and thermogenesis through
the PRDM16 complex. Nature, 2013. 504(7478): p. 163-167.

58.

Harms, M.J., et al., Prdm16 Is Required for the Maintenance of Brown Adipocyte
Identity and Function in Adult Mice. Cell Metabolism, 2014. 19(4): p. 593-604.

59.

Koutnikova, H. and J. Auwerx, Regulation of adipocyte differentiation. Annals of
Medicine, 2001. 33(8): p. 556-561.

60.

Farmer, S.R., Transcriptional control of adipocyte formation. Cell Metab, 2006. 4(4):
p. 263-73.

61.

Barak, Y., et al., PPAR gamma is required for placental, cardiac, and adipose tissue
development. Molecular Cell, 1999. 4(4): p. 585-595.

62.

Lehrke, M. and M.A. Lazar, The many faces of PPARgamma. Cell, 2005. 123(6): p.
993-9.

63.

Nedergaard, J., et al., PPARgamma in the control of brown adipocyte differentiation.
Biochim Biophys Acta, 2005. 1740(2): p. 293-304.

64.

Petrovic, N., et al., Thermogenically competent nonadrenergic recruitment in brown
preadipocytes by a PPARgamma agonist. Am J Physiol Endocrinol Metab, 2008.
295(2): p. E287-96.

65.

Gray, S.L., et al., Decreased brown adipocyte recruitment and thermogenic capacity
in mice with impaired peroxisome proliferator-activated receptor (P465L
PPARgamma) function. Endocrinology, 2006. 147(12): p. 5708-14.

66.

Puigserver, P., et al., A cold-inducible coactivator of nuclear receptors linked to
adaptive thermogenesis. Cell, 1998. 92(6): p. 829-39.

61

67.

Uldry, M., et al., Complementary action of the PGC-1 coactivators in mitochondrial
biogenesis and brown fat differentiation. Cell Metab, 2006. 3(5): p. 333-41.

68.

Rajakumari, S., et al., EBF2 determines and maintains brown adipocyte identity. Cell
metabolism, 2013. 17(4): p. 562-574.

69.

Harms, M.J., et al., PRDM16 binds MED1 and controls chromatin architecture to
determine a brown fat transcriptional program. Genes & development, 2015. 29(3):
p. 298-307.

70.

Iida, S., et al., PRDM16 enhances nuclear receptor-dependent transcription of the
brown fat-specific Ucp1 gene through interactions with Mediator subunit MED1.
Genes Dev, 2015. 29(3): p. 308-21.

71.

Rosen, E.D. and B.M. Spiegelman, Adipocytes as regulators of energy balance and
glucose homeostasis. Nature, 2006. 444(7121): p. 847-853.

72.

Lowell, B.B. and B.M. Spiegelman, Towards a molecular understanding of adaptive
thermogenesis. Nature, 2000. 404(6778): p. 652-660.

73.

Rosenbaum, M. and R.L. Leibel, Adaptive thermogenesis in humans. International
journal of obesity (2005), 2010. 34 Suppl 1(0 1): p. S47-S55.

74.

Major, G.C., et al., Clinical significance of adaptive thermogenesis. International
Journal of Obesity, 2007. 31(2): p. 204-212.

75.

Periasamy, M., J.L. Herrera, and F.C.G. Reis, Skeletal Muscle Thermogenesis and Its
Role in Whole Body Energy Metabolism. Diabetes & metabolism journal, 2017. 41(5):
p. 327-336.

76.

Davis, T.R.A., et al., Regulation of shivering and nonshivering heat production
during acclimation of rats. American Journal of Physiology-Legacy Content, 1960.
198(3): p. 471-475.

62

77.

Dhaka, A., V. Viswanath, and A. Patapoutian, Trp ion channels and temperature
sensation. Annu Rev Neurosci, 2006. 29: p. 135-61.

78.

Granneman, J.G., Norepinephrine infusions increase adenylate cyclase
responsiveness in brown adipose tissue. J Pharmacol Exp Ther, 1988. 245(3): p.
1075-80.

79.

Marette, A. and L.J. Bukowiecki, Noradrenaline stimulates glucose transport in rat
brown adipocytes by activating thermogenesis. Evidence that fatty acid activation of
mitochondrial respiration enhances glucose transport. The Biochemical journal,
1991. 277 ( Pt 1)(Pt 1): p. 119-124.

80.

Prusiner, S.B., et al., Oxidative Metabolism in Cells Isolated from Brown Adipose
Tissue. European Journal of Biochemistry, 1968. 7(1): p. 51-57.

81.

Bukowiecki, L.J., et al., Metabolic relationships between lipolysis and respiration in
rat brown adipocytes. The role of long chain fatty acids as regulators of
mitochondrial respiration and feedback inhibitors of lipolysis. J Biol Chem, 1981.
256(24): p. 12840-8.

82.

Townsend, K.L. and Y.-H. Tseng, Brown fat fuel utilization and thermogenesis.
Trends in Endocrinology & Metabolism, 2014. 25(4): p. 168-177.

83.

Souza, S.C., et al., Perilipin regulates the thermogenic actions of norepinephrine in
brown adipose tissue. J Lipid Res, 2007. 48(6): p. 1273-9.

84.

Miyoshi, H., et al., Control of adipose triglyceride lipase action by serine 517 of
perilipin A globally regulates protein kinase A-stimulated lipolysis in adipocytes. J
Biol Chem, 2007. 282(2): p. 996-1002.

85.

Zimmermann, R., et al., Fat mobilization in adipose tissue is promoted by adipose
triglyceride lipase. Science, 2004. 306(5700): p. 1383-6.

63

86.

Bezaire, V. and D. Langin, Regulation of adipose tissue lipolysis revisited. Proc Nutr
Soc, 2009. 68(4): p. 350-60.

87.

Mottillo, E.P., et al., Lipolytic products activate peroxisome proliferator-activated
receptor (PPAR) α and δ in brown adipocytes to match fatty acid oxidation with
supply. J Biol Chem, 2012. 287(30): p. 25038-48.

88.

Wu, Z., et al., Mechanisms controlling mitochondrial biogenesis and respiration
through the thermogenic coactivator PGC-1. Cell, 1999. 98(1): p. 115-24.

89.

Rim, J.S. and L.P. Kozak, Regulatory motifs for CREB-binding protein and Nfe2l2
transcription factors in the upstream enhancer of the mitochondrial uncoupling
protein 1 gene. J Biol Chem, 2002. 277(37): p. 34589-600.

90.

Thonberg, H., et al., A novel pathway for adrenergic stimulation of cAMP-responseelement-binding protein (CREB) phosphorylation: mediation via alpha1adrenoceptors and protein kinase C activation. Biochem J, 2002. 364(Pt 1): p. 73-9.

91.

Dempersmier, J., et al., Cold-inducible Zfp516 activates UCP1 transcription to
promote browning of white fat and development of brown fat. Mol Cell, 2015. 57(2):
p. 235-46.

92.

Martinez de Mena, R., T.S. Scanlan, and M.J. Obregon, The T3 receptor beta1
isoform regulates UCP1 and D2 deiodinase in rat brown adipocytes. Endocrinology,
2010. 151(10): p. 5074-83.

93.

Ribeiro, M.O., et al., Expression of uncoupling protein 1 in mouse brown adipose
tissue is thyroid hormone receptor-beta isoform specific and required for adaptive
thermogenesis. Endocrinology, 2010. 151(1): p. 432-40.

94.

Bukowiecki, L., et al., Brown adipose tissue hyperplasia: a fundamental mechanism
of adaptation to cold and hyperphagia. Am J Physiol, 1982. 242(6): p. E353-9.

64

95.

Bukowiecki, L.J., A. Géloën, and A.J. Collet, Proliferation and differentiation of
brown adipocytes from interstitial cells during cold acclimation. Am J Physiol, 1986.
250(6 Pt 1): p. C880-7.

96.

Inokuma, K., et al., Uncoupling protein 1 is necessary for norepinephrine-induced
glucose utilization in brown adipose tissue. Diabetes, 2005. 54(5): p. 1385-91.

97.

Westerterp, K.R., Diet induced thermogenesis. Nutr Metab (Lond), 2004. 1(1): p. 5.

98.

Young, J.B., et al., Effect of diet and cold exposure on norepinephrine turnover in
brown adipose tissue of the rat. J Clin Invest, 1982. 69(5): p. 1061-71.

99.

Yoshida, T., et al., Diet, lighting, and food intake affect norepinephrine turnover in
dietary obesity. Am J Physiol, 1987. 252(2 Pt 2): p. R402-8.

100.

Feldmann, H.M., et al., UCP1 ablation induces obesity and abolishes diet-induced
thermogenesis in mice exempt from thermal stress by living at thermoneutrality. Cell
Metab, 2009. 9(2): p. 203-9.

101.

von Essen, G., et al., Adaptive facultative diet-induced thermogenesis in wild-type but
not in UCP1-ablated mice. Am J Physiol Endocrinol Metab, 2017. 313(5): p. E515e527.

102.

Glick, Z., R.J. Teague, and G.A. Bray, Brown adipose tissue: thermic response
increased by a single low protein, high carbohydrate meal. Science, 1981. 213(4512):
p. 1125-7.

103.

Lupien, J.R., et al., Guanosine diphosphate binding to brown adipose tissue
mitochondria is increased after single meal. Am J Physiol, 1985. 249(6 Pt 2): p.
R694-8.

104.

Saito, M., Y. Minokoshi, and T. Shimazu, Metabolic and sympathetic nerve activities
of brown adipose tissue in tube-fed rats. Am J Physiol, 1989. 257(3 Pt 1): p. E374-8.

65

105.

Hibi, M., et al., Brown adipose tissue is involved in diet-induced thermogenesis and
whole-body fat utilization in healthy humans. Int J Obes (Lond), 2016. 40(11): p.
1655-1661.

106.

Muzik, O., et al., 15O PET measurement of blood flow and oxygen consumption in
cold-activated human brown fat. J Nucl Med, 2013. 54(4): p. 523-31.

107.

M, U.D., et al., Postprandial Oxidative Metabolism of Human Brown Fat Indicates
Thermogenesis. Cell Metab, 2018. 28(2): p. 207-216.e3.

108.

Orava, J., et al., Different metabolic responses of human brown adipose tissue to
activation by cold and insulin. Cell Metab, 2011. 14(2): p. 272-9.

109.

Kozak, L.P., Brown fat and the myth of diet-induced thermogenesis. Cell Metab,
2010. 11(4): p. 263-7.

110.

Deshmukh, A.S., et al., Proteomics-Based Comparative Mapping of the Secretomes of
Human Brown and White Adipocytes Reveals EPDR1 as a Novel Batokine. Cell
Metab, 2019. 30(5): p. 963-975 e7.

111.

Villarroya, F., et al., Brown adipose tissue as a secretory organ. Nature Reviews
Endocrinology, 2017. 13(1): p. 26-35.

112.

Betz, M.J. and S. Enerbäck, Targeting thermogenesis in brown fat and muscle to treat
obesity and metabolic disease. Nature Reviews Endocrinology, 2018. 14(2): p. 77-87.

113.

Boissonneault, G.A., et al., Oxygen consumption and body fat content of young lean
and obese (OB/OB) mice. Proc Soc Exp Biol Med, 1978. 157(3): p. 402-6.

114.

Trayhurn, P. and W.P. James, Thermoregulation and non-shivering thermogenesis in
the genetically obese (ob/ob) mouse. Pflugers Arch, 1978. 373(2): p. 189-93.

115.

Thurlby, P.L. and P. Trayhurn, Regional blood flow in genetically obese (ob/ob) mice.
Pflügers Archiv, 1980. 385(3): p. 193-201.

66

116.

Trayhurn, P. and L. Fuller, The development of obesity in genetically diabetic-obese
(db/db) mice pair-fed with lean siblings. Diabetologia, 1980. 19(2): p. 148-153.

117.

Knehans, A.W. and D.R. Romsos, Reduced norepinephrine turnover in brown
adipose tissue of ob/ob mice. Am J Physiol, 1982. 242(4): p. E253-61.

118.

Zaror-Behrens, G. and J. Himms-Hagen, Cold-stimulated sympathetic activity in
brown adipose tissue of obese (ob/ob) mice. American Journal of PhysiologyEndocrinology and Metabolism, 1983. 244(4): p. E361-E366.

119.

Ashwell, M., et al., Measurement by radioimmunoassay of the mitochondrial
uncoupling protein from brown adipose tissue of obese (ob/ob) mice and Zucker
(fa/fa) rats at different ages. FEBS Lett, 1985. 179(2): p. 233-7.

120.

Kim, H.K. and D.R. Romsos, Adrenalectomy increases brown adipose tissue
metabolism in ob/ob mice housed at 35 degrees C. Am J Physiol, 1990. 259(3 Pt 1):
p. E362-9.

121.

Dulloo, A.G. and D.S. Miller, Energy balance following sympathetic denervation of
brown adipose tissue. Can J Physiol Pharmacol, 1984. 62(2): p. 235-40.

122.

Levin, B.E., et al., Dietary obesity and neonatal sympathectomy. I. Effects on body
composition and brown adipose. Am J Physiol, 1984. 247(6 Pt 2): p. R979-87.

123.

Cox, J.E. and J.F. Lorden, Dietary obesity: brown fat denervation fails to alter
development or recovery. Am J Physiol, 1986. 250(6 Pt 2): p. R1108-16.

124.

Levin, B.E. and A.C. Sullivan, Dietary obesity and neonatal sympathectomy. II.
Thermoregulation and brown adipose metabolism. Am J Physiol, 1984. 247(6 Pt 2):
p. R988-94.

125.

Stern, J.S., et al., Scapular brown fat removal enhances development of adiposity in
cold-exposed obese Zucker rats. Am J Physiol, 1984. 247(5 Pt 2): p. R918-26.

67

126.

Moore, B.J., et al., Brown adipose tissue lipectomy leads to increased fat deposition
in Osborne-Mendel rats. Am J Physiol, 1985. 248(2 Pt 2): p. R231-5.

127.

Rothwell, N.J. and M.J. Stock, Surgical removal of brown fat results in rapid and
complete compensation by other depots. Am J Physiol, 1989. 257(2 Pt 2): p. R253-8.

128.

Stephens, D.N., S.C. Nash, and C. Proffitt, Dietary obesity in adult and weanling rats
following removal of interscapular brown adipose tissue. Pflugers Arch, 1981.
392(1): p. 7-12.

129.

Lowell, B.B., et al., Development of obesity in transgenic mice after genetic ablation
of brown adipose tissue. Nature, 1993. 366(6457): p. 740-742.

130.

Mantzoros, C.S., et al., Severe leptin resistance in brown fat-deficient uncoupling
protein promoter-driven diphtheria toxin A mice despite suppression of hypothalamic
neuropeptide Y and circulating corticosterone concentrations. Diabetes, 1998. 47(2):
p. 230-8.

131.

Hamann, A., J.S. Flier, and B.B. Lowell, Decreased brown fat markedly enhances
susceptibility to diet-induced obesity, diabetes, and hyperlipidemia. Endocrinology,
1996. 137(1): p. 21-9.

132.

Kontani, Y., et al., UCP1 deficiency increases susceptibility to diet-induced obesity
with age. Aging Cell, 2005. 4(3): p. 147-55.

133.

Enerbäck, S., et al., Mice lacking mitochondrial uncoupling protein are cold-sensitive
but not obese. Nature, 1997. 387(6628): p. 90-4.

134.

Liu, X., et al., Paradoxical resistance to diet-induced obesity in UCP1-deficient mice.
J Clin Invest, 2003. 111(3): p. 399-407.

135.

Cummings, D.E., et al., Genetically lean mice result from targeted disruption of the
RII beta subunit of protein kinase A. Nature, 1996. 382(6592): p. 622-6.

68

136.

Czyzyk, T.A., et al., Disruption of the RIIbeta subunit of PKA reverses the obesity
syndrome of Agouti lethal yellow mice. Proc Natl Acad Sci U S A, 2008. 105(1): p.
276-81.

137.

Zhou, Z., et al., Cidea-deficient mice have lean phenotype and are resistant to obesity.
Nat Genet, 2003. 35(1): p. 49-56.

138.

Blondin, D.P., et al., A critical appraisal of brown adipose tissue metabolism in
humans. Clinical Lipidology, 2015. 10(3): p. 259-280.

139.

Frühbeck, G., et al., BAT: a new target for human obesity? Trends in Pharmacological
Sciences, 2009. 30(8): p. 387-396.

140.

Gesta, S., Y.-H. Tseng, and C.R. Kahn, Developmental Origin of Fat: Tracking
Obesity to Its Source. Cell, 2007. 131(2): p. 242-256.

141.

Carpentier, A.C., et al., Brown Adipose Tissue Energy Metabolism in Humans. Front
Endocrinol (Lausanne), 2018. 9: p. 447.

142.

Hill, J.O., et al., Obesity and the environment: where do we go from here? Science,
2003. 299(5608): p. 853-5.

143.

Hainer, V., H. Toplak, and A. Mitrakou, Treatment modalities of obesity: what fits
whom? Diabetes Care, 2008. 31 Suppl 2: p. S269-77.

144.

Zechner, R., et al., FAT SIGNALS--lipases and lipolysis in lipid metabolism and
signaling. Cell Metab, 2012. 15(3): p. 279-91.

145.

Li, Y., et al., Taking control over intracellular fatty acid levels is essential for the
analysis of thermogenic function in cultured primary brown and brite/beige
adipocytes. EMBO Rep, 2014. 15(10): p. 1069-76.

146.

Osuga, J., et al., Targeted disruption of hormone-sensitive lipase results in male
sterility and adipocyte hypertrophy, but not in obesity. Proc Natl Acad Sci U S A,
2000. 97(2): p. 787-92.

69

147.

Wang, S.P., et al., The adipose tissue phenotype of hormone-sensitive lipase
deficiency in mice. Obes Res, 2001. 9(2): p. 119-28.

148.

Haemmerle, G., et al., Defective lipolysis and altered energy metabolism in mice
lacking adipose triglyceride lipase. Science, 2006. 312(5774): p. 734-7.

149.

Ahmadian, M., et al., Desnutrin/ATGL is regulated by AMPK and is required for a
brown adipose phenotype. Cell Metab, 2011. 13(6): p. 739-48.

150.

Ouellet, V., et al., Brown adipose tissue oxidative metabolism contributes to energy
expenditure during acute cold exposure in humans. J Clin Invest, 2012. 122(2): p.
545-52.

151.

Blondin, D.P., et al., Increased brown adipose tissue oxidative capacity in coldacclimated humans. J Clin Endocrinol Metab, 2014. 99(3): p. E438-46.

152.

Koskensalo, K., et al., Human Brown Adipose Tissue Temperature and Fat Fraction
Are Related to Its Metabolic Activity. J Clin Endocrinol Metab, 2017. 102(4): p. 12001207.

153.

McCallister, A., et al., A pilot study on the correlation between fat fraction values and
glucose uptake values in supraclavicular fat by simultaneous PET/MRI. Magn Reson
Med, 2017. 78(5): p. 1922-1932.

154.

Weir, G., et al., Substantial Metabolic Activity of Human Brown Adipose Tissue
during Warm Conditions and Cold-Induced Lipolysis of Local Triglycerides. Cell
Metab, 2018. 27(6): p. 1348-1355.e4.

155.

Bartelt, A., et al., Brown adipose tissue activity controls triglyceride clearance. Nat
Med, 2011. 17(2): p. 200-5.

156.

Heine, M., et al., Lipolysis Triggers a Systemic Insulin Response Essential for
Efficient Energy Replenishment of Activated Brown Adipose Tissue in Mice. Cell
Metabolism, 2018. 28(4): p. 644-655.e4.

70

157.

Ramasamy, I., Recent advances in physiological lipoprotein metabolism. Clinical
Chemistry and Laboratory Medicine (CCLM), 2014. 52(12): p. 1695-1727.

158.

Goudriaan, J.R., et al., CD36 deficiency in mice impairs lipoprotein lipase-mediated
triglyceride clearance. Journal of Lipid Research, 2005. 46(10): p. 2175-2181.

159.

Khedoe, P.P.S.J., et al., Brown adipose tissue takes up plasma triglycerides mostly
after lipolysis. Journal of Lipid Research, 2015. 56(1): p. 51-59.

160.

Hoeke, G., et al., Role of Brown Fat in Lipoprotein Metabolism and Atherosclerosis.
Circulation Research, 2016. 118(1): p. 173-182.

161.

Dong, M., et al., Cold exposure promotes atherosclerotic plaque growth and
instability via UCP1-dependent lipolysis. Cell Metab, 2013. 18(1): p. 118-29.

162.

Berbée, J.F., et al., Brown fat activation reduces hypercholesterolaemia and protects
from atherosclerosis development. Nat Commun, 2015. 6: p. 6356.

163.

Heeren, J., U. Beisiegel, and T. Grewal, Apolipoprotein E Recycling. Arteriosclerosis,
Thrombosis, and Vascular Biology, 2006. 26(3): p. 442-448.

164.

Nedergaard, J., T. Bengtsson, and B. Cannon, New powers of brown fat: fighting the
metabolic syndrome. Cell Metab, 2011. 13(3): p. 238-40.

165.

M, U.D., et al., Human brown adipose tissue [(15)O]O2 PET imaging in the presence
and absence of cold stimulus. Eur J Nucl Med Mol Imaging, 2016. 43(10): p. 187886.

166.

Chondronikola, M., et al., Brown Adipose Tissue Activation Is Linked to Distinct
Systemic Effects on Lipid Metabolism in Humans. Cell Metab, 2016. 23(6): p. 12001206.

167.

O'Mara, A.E., et al., Chronic mirabegron treatment increases human brown fat, HDL
cholesterol, and insulin sensitivity. J Clin Invest, 2020. 130(5): p. 2209-2219.

71

168.

Huuskonen, J., et al., The impact of phospholipid transfer protein (PLTP) on HDL
metabolism. Atherosclerosis, 2001. 155(2): p. 269-81.

169.

McCormack, J.G. and R.M. Denton, Evidence that fatty acid synthesis in the
interscapular brown adipose tissue of cold-adapted rats is increased in vivo by
insulin by mechanisms involving parallel activation of pyruvate dehydrogenase and
acetyl-coenzyme A carboxylase. Biochem J, 1977. 166(3): p. 627-30.

170.

Trayhurn, P., Fatty acid synthesis in vivo in brown adipose tissue, liver and white
adipose tissue of the cold-acclimated rat. FEBS Lett, 1979. 104(1): p. 13-6.

171.

Trayhurn, P., Fatty acid synthesis in brown adipose tissue in relation to whole body
synthesis in the cold-acclimated golden hamster (Mesocricetus auratus). Biochim
Biophys Acta, 1980. 620(1): p. 10-7.

172.

Kuroshima, A., K. Doi, and T. Ohno, Reduced hyperglycemic action of glucagon in
cold-acclimated rats, especially in venous drainage from brown adipose tissue. Can J
Physiol Pharmacol, 1977. 55(4): p. 951-3.

173.

Doi, K. and A. Kuroshima, Thermogenic response to glucagon in cold-acclimated
mice. Jpn J Physiol, 1982. 32(3): p. 377-85.

174.

Doi, K. and A. Kuroshima, Modified metabolic responsiveness to glucagon in coldacclimated and heat-acclimated rats. Life Sci, 1982. 30(9): p. 785-91.

175.

Greco-Perotto, R., et al., Stimulatory effect of cold adaptation on glucose utilization
by brown adipose tissue. Relationship with changes in the glucose transporter system.
J Biol Chem, 1987. 262(16): p. 7732-6.

176.

Shibata, H., et al., Cold exposure reverses inhibitory effects of fasting on peripheral
glucose uptake in rats. Am J Physiol, 1989. 257(1 Pt 2): p. R96-101.

72

177.

Takahashi, A., T. Shimazu, and Y. Maruyama, Importance of sympathetic nerves for
the stimulatory effect of cold exposure on glucose utilization in brown adipose tissue.
Jpn J Physiol, 1992. 42(4): p. 653-64.

178.

Ferré, P., et al., A method to quantify glucose utilization in vivo in skeletal muscle and
white adipose tissue of the anaesthetized rat. Biochem J, 1985. 228(1): p. 103-10.

179.

Olsen, J.M., et al., Acute β-adrenoceptor mediated glucose clearance in brown
adipose tissue; a distinct pathway independent of functional insulin signaling. Mol
Metab, 2019. 30: p. 240-249.

180.

Olichon-Berthe, C., E. Van Obberghen, and Y. Le Marchand-Brustel, Effect of cold
acclimation on the expression of glucose transporter Glut 4. Mol Cell Endocrinol,
1992. 89(1-2): p. 11-8.

181.

Shimizu, Y., et al., Increased expression of glucose transporter GLUT-4 in brown
adipose tissue of fasted rats after cold exposure. Am J Physiol, 1993. 264(6 Pt 1): p.
E890-5.

182.

Dallner, O.S., et al., Beta3-adrenergic receptors stimulate glucose uptake in brown
adipocytes by two mechanisms independently of glucose transporter 4 translocation.
Endocrinology, 2006. 147(12): p. 5730-9.

183.

Shimizu, Y., et al., Effects of noradrenaline on the cell-surface glucose transporters
in cultured brown adipocytes: novel mechanism for selective activation of GLUT1
glucose transporters. Biochem J, 1998. 330 ( Pt 1)(Pt 1): p. 397-403.

184.

Weir, G., et al., Substantial Metabolic Activity of Human Brown Adipose Tissue
during Warm Conditions and Cold-Induced Lipolysis of Local Triglycerides. Cell
metabolism, 2018. 27(6): p. 1348-1355.e4.

73

185.

Hao, Q., et al., Transcriptome profiling of brown adipose tissue during cold exposure
reveals extensive regulation of glucose metabolism. American Journal of PhysiologyEndocrinology and Metabolism, 2015. 308(5): p. E380-E392.

186.

Ma, S.W. and D.O. Foster, Uptake of glucose and release of fatty acids and glycerol
by rat brown adipose tissue in vivo. Can J Physiol Pharmacol, 1986. 64(5): p. 609-14.

187.

Sanchez-Gurmaches, J., et al., Brown Fat AKT2 Is a Cold-Induced Kinase that
Stimulates ChREBP-Mediated De Novo Lipogenesis to Optimize Fuel Storage and
Thermogenesis. Cell Metab, 2018. 27(1): p. 195-209.e6.

188.

Held, N.M., et al., Pyruvate dehydrogenase complex plays a central role in brown
adipocyte energy expenditure and fuel utilization during short-term beta-adrenergic
activation. Sci Rep, 2018. 8(1): p. 9562.

189.

Irshad, Z., et al., Diacylglycerol acyltransferase 2 links glucose utilization to fatty
acid oxidation in the brown adipocytes. J Lipid Res, 2017. 58(1): p. 15-30.

190.

Bartness, T.J., N.F. Ruby, and G.N. Wade, Dietary obesity in exercising or coldexposed Syrian hamsters. Physiol Behav, 1984. 32(1): p. 85-90.

191.

Vallerand, A.L., J. Lupien, and L.J. Bukowiecki, Cold exposure reverses the
diabetogenic effects of high-fat feeding. Diabetes, 1986. 35(3): p. 329-34.

192.

Ravussin, Y., et al., Effect of intermittent cold exposure on brown fat activation,
obesity, and energy homeostasis in mice. PloS one, 2014. 9(1): p. e85876-e85876.

193.

Zhu, P., et al., Cold exposure promotes obesity and impairs glucose homeostasis in
mice subjected to a high‑fat diet. Mol Med Rep, 2018. 18(4): p. 3923-3931.

194.

van der Lans, A.A., et al., Cold acclimation recruits human brown fat and increases
nonshivering thermogenesis. J Clin Invest, 2013. 123(8): p. 3395-403.

195.

Hanssen, M.J., et al., Short-term Cold Acclimation Recruits Brown Adipose Tissue in
Obese Humans. Diabetes, 2016. 65(5): p. 1179-89.

74

196.

Yoneshiro, T., et al., Recruited brown adipose tissue as an antiobesity agent in
humans. J Clin Invest, 2013. 123(8): p. 3404-8.

197.

Romu, T., et al., A randomized trial of cold-exposure on energy expenditure and
supraclavicular brown adipose tissue volume in humans. Metabolism, 2016. 65(6): p.
926-34.

198.

Arch, J.R. and A.T. Ainsworth, Thermogenic and antiobesity activity of a novel betaadrenoceptor agonist (BRL 26830A) in mice and rats. Am J Clin Nutr, 1983. 38(4): p.
549-58.

199.

Sennitt, M.V., et al., Anti-hyperglycaemic action of BRL 26830, a novel betaadrenoceptor agonist, in mice and rats. Biochem Pharmacol, 1985. 34(8): p. 1279-85.

200.

Carroll, M.J., et al., Improved glycemic control in C57Bl/KsJ (db/db) mice after
treatment with the thermogenic beta-adrenoceptor agonist, BRL 26830. Diabetes,
1985. 34(11): p. 1198-204.

201.

Hashimoto, K., et al., Improvement of metabolic disorders and visceral fat obesity by
the beta 3-adrenoceptor agonist (R*,R*)-(+/-)-methyl-4-[2-[2-hydroxy-2 -(3chlorophenyl)ethylamino]propyl]-phenoxyacetate hydrobromide (BRL35135A) in
genetically obese rodents. Biochem Pharmacol, 1996. 52(10): p. 1529-35.

202.

Yoshida, T., et al., Anti-obesity effect of CL 316,243, a highly specific beta 3adrenoceptor agonist, in mice with monosodium-L-glutamate-induced obesity. Eur J
Endocrinol, 1994. 131(1): p. 97-102.

203.

Ghorbani, M. and J. Himms-Hagen, Appearance of brown adipocytes in white
adipose tissue during CL 316,243-induced reversal of obesity and diabetes in Zucker
fa/fa rats. Int J Obes Relat Metab Disord, 1997. 21(6): p. 465-75.

75

204.

Yoshida, T., et al., Anti-obesity and anti-diabetic effects of CL 316,243, a highly
specific beta 3-adrenoceptor agonist, in yellow KK mice. Life Sci, 1994. 54(7): p.
491-8.

205.

Schiffelers, S.L., et al., In vivo beta3-adrenergic stimulation of human thermogenesis
and lipid use. Clin Pharmacol Ther, 2000. 67(5): p. 558-66.

206.

Vosselman, M.J., et al., Systemic β-adrenergic stimulation of thermogenesis is not
accompanied by brown adipose tissue activity in humans. Diabetes, 2012. 61(12): p.
3106-13.

207.

Weyer, C., et al., Increase in insulin action and fat oxidation after treatment with CL
316,243, a highly selective beta3-adrenoceptor agonist in humans. Diabetes, 1998.
47(10): p. 1555-61.

208.

Buemann, B., S. Toubro, and A. Astrup, Effects of the two beta3-agonists, ZD7114
and ZD2079 on 24 hour energy expenditure and respiratory quotient in obese
subjects. Int J Obes Relat Metab Disord, 2000. 24(12): p. 1553-60.

209.

Larsen, T.M., et al., Effect of a 28-d treatment with L-796568, a novel beta(3)adrenergic receptor agonist, on energy expenditure and body composition in obese
men. Am J Clin Nutr, 2002. 76(4): p. 780-8.

210.

van Baak, M.A., et al., Acute effect of L-796568, a novel β3-adrenergic receptor
agonist, on energy expenditure in obese men. Clinical Pharmacology & Therapeutics,
2002. 71(4): p. 272-279.

211.

Cypess, A.M., et al., Activation of human brown adipose tissue by a β3-adrenergic
receptor agonist. Cell Metab, 2015. 21(1): p. 33-8.

212.

Baskin, A.S., et al., Regulation of Human Adipose Tissue Activation, Gallbladder
Size, and Bile Acid Metabolism by a β3-Adrenergic Receptor Agonist. Diabetes, 2018.
67(10): p. 2113-2125.

76

213.

Loh, R.K.C., et al., Acute metabolic and cardiovascular effects of mirabegron in
healthy individuals. Diabetes Obes Metab, 2019. 21(2): p. 276-284.

214.

Finlin, B.S., et al., The β3-adrenergic receptor agonist mirabegron improves glucose
homeostasis in obese humans. J Clin Invest, 2020. 130(5): p. 2319-2331.

215.

Finlin, B.S., et al., Human adipose beiging in response to cold and mirabegron. JCI
Insight, 2018. 3(15).

216.

Saito, M., T. Yoneshiro, and M. Matsushita, Food Ingredients as Anti-Obesity Agents.
Trends in Endocrinology & Metabolism, 2015. 26(11): p. 585-587.

217.

Yoneshiro, T. and M. Saito, Activation and recruitment of brown adipose tissue as
anti-obesity regimens in humans. Ann Med, 2015. 47(2): p. 133-41.

218.

Burns, J., et al., Plant foods and herbal sources of resveratrol. J Agric Food Chem,
2002. 50(11): p. 3337-40.

219.

Baur, J.A. and D.A. Sinclair, Therapeutic potential of resveratrol: the in vivo
evidence. Nature Reviews Drug Discovery, 2006. 5(6): p. 493-506.

220.

Mele, L., et al., Dietary (Poly)phenols, Brown Adipose Tissue Activation, and Energy
Expenditure: A Narrative Review. Advances in Nutrition, 2017. 8(5): p. 694-704.

221.

Lagouge, M., et al., Resveratrol improves mitochondrial function and protects against
metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 2006. 127(6): p. 110922.

222.

Wang, S., et al., Resveratrol enhances brown adipocyte formation and function by
activating AMP-activated protein kinase (AMPK) α1 in mice fed high-fat diet. Mol
Nutr Food Res, 2017. 61(4).

223.

Andrade, J.M., et al., Resveratrol increases brown adipose tissue thermogenesis
markers by increasing SIRT1 and energy expenditure and decreasing fat

77

accumulation in adipose tissue of mice fed a standard diet. Eur J Nutr, 2014. 53(7): p.
1503-10.
224.

Alberdi, G., et al., Thermogenesis is involved in the body-fat lowering effects of
resveratrol in rats. Food Chem, 2013. 141(2): p. 1530-5.

225.

Ku, C.R., et al., The Effects of High Fat Diet and Resveratrol on Mitochondrial
Activity of Brown Adipocytes. Endocrinol Metab (Seoul), 2016. 31(2): p. 328-35.

226.

Crandall, J.P., et al., Pilot study of resveratrol in older adults with impaired glucose
tolerance. J Gerontol A Biol Sci Med Sci, 2012. 67(12): p. 1307-12.

227.

Movahed, A., et al., Antihyperglycemic effects of short term resveratrol
supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med,
2013. 2013: p. 851267.

228.

Poulsen, M.M., et al., High-dose resveratrol supplementation in obese men: an
investigator-initiated, randomized, placebo-controlled clinical trial of substrate
metabolism, insulin sensitivity, and body composition. Diabetes, 2013. 62(4): p. 118695.

229.

Méndez-del Villar, M., et al., Effect of resveratrol administration on metabolic
syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord, 2014.
12(10): p. 497-501.

230.

Timmers, S., et al., Calorie restriction-like effects of 30 days of resveratrol
supplementation on energy metabolism and metabolic profile in obese humans. Cell
Metab, 2011. 14(5): p. 612-22.

231.

Konings, E., et al., The effects of 30 days resveratrol supplementation on adipose
tissue morphology and gene expression patterns in obese men. Int J Obes (Lond),
2014. 38(3): p. 470-3.

78

232.

Andrade, J.M.O., et al., Effect of resveratrol on expression of genes involved
thermogenesis in mice and humans. Biomed Pharmacother, 2019. 112: p. 108634.

233.

Ludy, M.J., G.E. Moore, and R.D. Mattes, The effects of capsaicin and capsiate on
energy balance: critical review and meta-analyses of studies in humans. Chem
Senses, 2012. 37(2): p. 103-21.

234.

Lv, J., et al., Consumption of spicy foods and total and cause specific mortality:
population based cohort study. BMJ : British Medical Journal, 2015. 351: p. h3942.

235.

Tremblay, A., H. Arguin, and S. Panahi, Capsaicinoids: a spicy solution to the
management of obesity? Int J Obes (Lond), 2016. 40(8): p. 1198-204.

236.

Uchida, K., et al., Involvement of thermosensitive TRP channels in energy
metabolism. J Physiol Sci, 2017. 67(5): p. 549-560.

237.

Kawada, T., et al., Capsaicin-induced beta-adrenergic action on energy metabolism
in rats: influence of capsaicin on oxygen consumption, the respiratory quotient, and
substrate utilization. Proc Soc Exp Biol Med, 1986. 183(2): p. 250-6.

238.

Kawabata, F., et al., Non-Pungent Capsaicin Analogs (Capsinoids) Increase
Metabolic Rate and Enhance Thermogenesis via Gastrointestinal TRPV1 in Mice.
Bioscience, Biotechnology, and Biochemistry, 2009. 73(12): p. 2690-2697.

239.

Ono, K., et al., Intragastric administration of capsiate, a transient receptor potential
channel agonist, triggers thermogenic sympathetic responses. Journal of Applied
Physiology, 2011. 110(3): p. 789-798.

240.

Baskaran, P., et al., Capsaicin induces browning of white adipose tissue and counters
obesity by activating TRPV1 channel-dependent mechanisms. Br J Pharmacol, 2016.
173(15): p. 2369-89.

79

241.

Baskaran, P., et al., TRPV1 activation counters diet-induced obesity through sirtuin-1
activation and PRDM-16 deacetylation in brown adipose tissue. Int J Obes (Lond),
2017. 41(5): p. 739-749.

242.

Okamatsu-Ogura, Y., et al., Capsinoids suppress diet-induced obesity through
uncoupling protein 1-dependent mechanism in mice. Journal of Functional Foods,
2015. 19: p. 1-9.

243.

Yoneshiro, T., et al., Nonpungent capsaicin analogs (capsinoids) increase energy
expenditure through the activation of brown adipose tissue in humans. Am J Clin
Nutr, 2012. 95(4): p. 845-50.

244.

Snitker, S., et al., Effects of novel capsinoid treatment on fatness and energy
metabolism in humans: possible pharmacogenetic implications. Am J Clin Nutr,
2009. 89(1): p. 45-50.

245.

Nirengi, S., et al., Assessment of human brown adipose tissue density during daily
ingestion of thermogenic capsinoids using near-infrared time-resolved spectroscopy.
J Biomed Opt, 2016. 21(9): p. 091305.

246.

Sun, L., et al., Capsinoids activate brown adipose tissue (BAT) with increased energy
expenditure associated with subthreshold 18-fluorine fluorodeoxyglucose uptake in
BAT-positive humans confirmed by positron emission tomography scan. Am J Clin
Nutr, 2018. 107(1): p. 62-70.

247.

Saito, M., T. Yoneshiro, and M. Matsushita, Activation and recruitment of brown
adipose tissue by cold exposure and food ingredients in humans. Best Practice &
Research Clinical Endocrinology & Metabolism, 2016. 30(4): p. 537-547.

248.

Sugita, J., et al., Grains of paradise (Aframomum melegueta) extract activates brown
adipose tissue and increases whole-body energy expenditure in men. Br J Nutr, 2013.
110(4): p. 733-8.

80

249.

Sugita, J., et al., Daily ingestion of grains of paradise (Aframomum melegueta)
extract increases whole-body energy expenditure and decreases visceral fat in
humans. J Nutr Sci Vitaminol (Tokyo), 2014. 60(1): p. 22-7.

250.

Ma, S., et al., Activation of the cold-sensing TRPM8 channel triggers UCP1dependent thermogenesis and prevents obesity. J Mol Cell Biol, 2012. 4(2): p. 88-96.

251.

Rothwell, N.J. and M.J. Stock, A role for brown adipose tissue in diet-induced
thermogenesis. Nature, 1979. 281(5726): p. 31-35.

252.

Vander Tuig, J.G. and D.R. Romsos, Effects of dietary carbohydrate, fat, and protein
on norepinephrine turnover in rats. Metabolism, 1984. 33(1): p. 26-33.

253.

Johnston, J.L. and A.V. Balachandran, Effects of dietary protein, energy and tyrosine
on central and peripheral norepinephrine turnover in mice. J Nutr, 1987. 117(12): p.
2046-53.

254.

Himms-Hagen, J., S. Hogan, and G. Zaror-Behrens, Increased brown adipose tissue
thermogenesis in obese (ob/ob) mice fed a palatable diet. American Journal of
Physiology-Endocrinology and Metabolism, 1986. 250(3): p. E274-E281.

255.

Bukowiecki, L., et al., Brown adipose tissue hyperplasia: a fundamental mechanism
of adaptation to cold and hyperphagia. American Journal of PhysiologyEndocrinology and Metabolism, 1982. 242(6): p. E353-E359.

256.

Schwartz, J.H., J.B. Young, and L. Landsberg, Effect of dietary fat on sympathetic
nervous system activity in the rat. J Clin Invest, 1983. 72(1): p. 361-70.

257.

Fromme, T. and M. Klingenspor, Uncoupling protein 1 expression and high-fat diets.
American Journal of Physiology-Regulatory, Integrative and Comparative
Physiology, 2011. 300(1): p. R1-R8.

81

258.

Sadurskis, A., et al., Polyunsaturated fatty acids recruit brown adipose tissue:
increased UCP content and NST capacity. American Journal of PhysiologyEndocrinology and Metabolism, 1995. 269(2): p. E351-E360.

259.

Takahashi, Y. and T. Ide, Dietary n-3 fatty acids affect mRNA level of brown adipose
tissue uncoupling protein 1, and white adipose tissue leptin and glucose transporter 4
in the rat. Br J Nutr, 2000. 84(2): p. 175-84.

260.

Takahashi, Y., T. Ide, and H. Fujita, Dietary gamma-linolenic acid in the form of
borage oil causes less body fat accumulation accompanying an increase in
uncoupling protein 1 mRNA level in brown adipose tissue. Comp Biochem Physiol B
Biochem Mol Biol, 2000. 127(2): p. 213-22.

261.

Ghandour, R.A., et al., Impact of dietary ω3 polyunsaturated fatty acid
supplementation on brown and brite adipocyte function. Journal of Lipid Research,
2018. 59(3): p. 452-461.

262.

Simopoulos, A.P., The Importance of the Omega-6/Omega-3 Fatty Acid Ratio in
Cardiovascular Disease and Other Chronic Diseases. Experimental Biology and
Medicine, 2008. 233(6): p. 674-688.

263.

Simopoulos, A.P., An Increase in the Omega-6/Omega-3 Fatty Acid Ratio Increases
the Risk for Obesity. Nutrients, 2016. 8(3): p. 128.

264.

Jump, D.B., The Biochemistry of n-3 Polyunsaturated Fatty Acids Journal of
Biological Chemistry, 2002. 277(11): p. 8755-8758.

265.

Jones, P. and S. Kubow, Lipids, Sterols and their Metabolites. 2012.

266.

Simopoulos, A.P., Human Requirement for N-3 Polyunsaturated Fatty Acids. Poultry
Science, 2000. 79(7): p. 961-970.

267.

Williams, C.M. and G. Burdge, Long-chain n−3 PUFA: plant v. marine sources.
Proceedings of the Nutrition Society, 2006. 65(1): p. 42-50.

82

268.

Calder, P.C. and P. Yaqoob, Understanding omega-3 polyunsaturated fatty acids.
Postgrad Med, 2009. 121(6): p. 148-57.

269.

Iqbal, J. and M.M. Hussain, Intestinal lipid absorption. American journal of
physiology. Endocrinology and metabolism, 2009. 296(6): p. E1183-E1194.

270.

Sinclair, A.J., N.M. Attar-Bashi, and D. Li, What is the role of α-linolenic acid for
mammals? Lipids, 2002. 37(12): p. 1113-1123.

271.

Barceló-Coblijn, G. and E.J. Murphy, Alpha-linolenic acid and its conversion to
longer chain n−3 fatty acids: Benefits for human health and a role in maintaining
tissue n−3 fatty acid levels. Progress in Lipid Research, 2009. 48(6): p. 355-374.

272.

Sarah K. Orr, C.T.C., Arthur A. Spector, and Richard P. Bazinet, Lipid Metabolism:
Polyunsaturated Faty Acids. , in Biochemical, Physiological, and Molecular Aspects
of Human Nutrition, M.A.C. Martha H. Stipanuk, Editor. 2013, Elsevier Health
Sciences.

273.

Russo, G.L., Dietary n−6 and n−3 polyunsaturated fatty acids: From biochemistry to
clinical implications in cardiovascular prevention. Biochemical Pharmacology, 2009.
77(6): p. 937-946.

274.

Bazinet, R.P. and S. Layé, Polyunsaturated fatty acids and their metabolites in brain
function and disease. Nature Reviews Neuroscience, 2014. 15(12): p. 771-785.

275.

Das, U.N., Essential fatty acids-a review. Current pharmaceutical biotechnology,
2006. 7(6): p. 467-482.

276.

Konkel, A. and W.-H. Schunck, Role of cytochrome P450 enzymes in the
bioactivation of polyunsaturated fatty acids. Biochimica et Biophysica Acta (BBA)Proteins and Proteomics, 2011. 1814(1): p. 210-222.

277.

Spector, A.A., et al., Epoxyeicosatrienoic acids (EETs): metabolism and biochemical
function. Progress in lipid research, 2004. 43(1): p. 55-90.

83

278.

Fischer, R., et al., Dietary omega-3 fatty acids modulate the eicosanoid profile in man
primarily via the CYP-epoxygenase pathway. Journal of lipid research, 2014. 55(6): p.
1150-1164.

279.

Sampath, H. and J.M. Ntambi, Polyunsaturated Fatty Acid Regulation of Genes of
Lipids Metabolism. Annual Review of Nutrition, 2005. 25(1): p. 317-340.

280.

SanGiovanni, J.P. and E.Y. Chew, The role of omega-3 long-chain polyunsaturated
fatty acids in health and disease of the retina. Prog Retin Eye Res, 2005. 24(1): p. 87138.

281.

Salem, N., et al., Mechanisms of action of docosahexaenoic acid in the nervous
system. Lipids, 2001. 36(9): p. 945-959.

282.

Calder, P.C., Mechanisms of Action of (n-3) Fatty Acids. The Journal of Nutrition,
2012. 142(3): p. 592S-599S.

283.

Innes, J.K. and P.C. Calder, Marine Omega-3 (N-3) Fatty Acids for Cardiovascular
Health: An Update for 2020. International journal of molecular sciences, 2020. 21(4):
p. 1362.

284.

Avallone, R., G. Vitale, and M. Bertolotti, Omega-3 Fatty Acids and
Neurodegenerative Diseases: New Evidence in Clinical Trials. Int J Mol Sci, 2019.
20(17).

285.

Scorletti, E. and C.D. Byrne, Omega-3 fatty acids and non-alcoholic fatty liver
disease: Evidence of efficacy and mechanism of action. Mol Aspects Med, 2018. 64:
p. 135-146.

286.

Calder, P.C., Omega-3 fatty acids and inflammatory processes: from molecules to
man. Biochem Soc Trans, 2017. 45(5): p. 1105-1115.

84

287.

Huang, C.-W., et al., Role of n-3 Polyunsaturated Fatty Acids in Ameliorating the
Obesity-Induced Metabolic Syndrome in Animal Models and Humans. International
Journal of Molecular Sciences, 2016. 17(10): p. 1689.

288.

Buckley, J.D. and P.R.C. Howe, Anti-obesity effects of long-chain omega-3
polyunsaturated fatty acids. Obesity Reviews, 2009. 10(6): p. 648-659.

289.

Buckley, J.D. and P.R. Howe, Long-chain omega-3 polyunsaturated fatty acids may
be beneficial for reducing obesity—a review. Nutrients, 2010. 2(12): p. 1212-1230.

290.

de Mello, A.H., et al., n-3 PUFA and obesity: from peripheral tissues to the central
nervous system. Br J Nutr, 2018. 119(11): p. 1312-1323.

291.

Kalupahana, N.S., B.L. Goonapienuwala, and N. Moustaid-Moussa, Omega-3 Fatty
Acids and Adipose Tissue: Inflammation and Browning. Annual Review of Nutrition,
2020. 40(1): p. 25-49.

292.

Oudart, H., et al., Brown fat thermogenesis in rats fed high-fat diets enriched with n-3
polyunsaturated fatty acids. International Journal of Obesity, 1997. 21(11): p. 955962.

293.

Kawada, T., et al., Fish (Bonito) Oil Supplementation Enhances the Expression of
Uncoupling Protein in Brown Adipose Tissue of Rat. Journal of Agricultural and Food
Chemistry, 1998. 46(4): p. 1225-1227.

294.

Kim, M., et al., Fish oil intake induces UCP1 upregulation in brown and white
adipose tissue via the sympathetic nervous system. Sci Rep, 2015. 5: p. 18013.

295.

Kim, J., et al., Eicosapentaenoic Acid Potentiates Brown Thermogenesis through
FFAR4-dependent Up-regulation of miR-30b and miR-378. J Biol Chem, 2016.
291(39): p. 20551-62.

296.

Bargut, T.C., et al., Mice fed fish oil diet and upregulation of brown adipose tissue
thermogenic markers. Eur J Nutr, 2016. 55(1): p. 159-69.

85

297.

Oliveira, T.E., et al., Fish Oil Protects Wild Type and Uncoupling Protein 1-Deficient
Mice from Obesity and Glucose Intolerance by Increasing Energy Expenditure. Mol
Nutr Food Res, 2019. 63(7): p. e1800813.

298.

Pahlavani, M., et al., Eicosapentaenoic Acid Reduces Adiposity, Glucose Intolerance
and Increases Oxygen Consumption Independently of Uncoupling Protein 1. Mol
Nutr Food Res, 2019. 63(7): p. e1800821.

299.

Villarroya, J., et al., Fibroblast growth factor-21 and the beneficial effects of longchain n-3 polyunsaturated fatty acids. Lipids, 2014. 49(11): p. 1081-9.

300.

Pahlavani, M., et al., Eicosapentaenoic acid regulates brown adipose tissue
metabolism in high-fat-fed mice and in clonal brown adipocytes. J Nutr Biochem,
2017. 39: p. 101-109.

301.

Worsch, S., et al., Dietary n-3 long-chain polyunsaturated fatty acids upregulate
energy dissipating metabolic pathways conveying anti-obesogenic effects in mice.
Nutr Metab (Lond), 2018. 15: p. 65.

302.

Pahlavani, M., et al., Transcriptomic and microRNA analyses of gene networks
regulated by eicosapentaenoic acid in brown adipose tissue of diet-induced obese
mice. Biochim Biophys Acta Mol Cell Biol Lipids, 2018. 1863(12): p. 1523-1531.

303.

Zhuang, P., et al., Differential Anti-Adipogenic Effects of Eicosapentaenoic and
Docosahexaenoic Acids in Obesity. Mol Nutr Food Res, 2019. 63(14): p. e1801135.

304.

Quesada-López, T., et al., The lipid sensor GPR120 promotes brown fat activation
and FGF21 release from adipocytes. Nat Commun, 2016. 7: p. 13479.

305.

Chartoumpekis, D.V., et al., Brown adipose tissue responds to cold and adrenergic
stimulation by induction of FGF21. Molecular medicine, 2011. 17(7): p. 736-740.

86

306.

Hondares, E., et al., Thermogenic activation induces FGF21 expression and release
in brown adipose tissue. Journal of Biological Chemistry, 2011. 286(15): p. 1298312990.

307.

Chau, M.D., et al., Fibroblast growth factor 21 regulates energy metabolism by
activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci U S A, 2010.
107(28): p. 12553-8.

308.

Bjursell, M., et al., The beneficial effects of n-3 polyunsaturated fatty acids on diet
induced obesity and impaired glucose control do not require Gpr120. PLoS One,
2014. 9(12): p. e114942.

309.

Hondares, E., et al., Peroxisome proliferator-activated receptor α (PPARα) induces
PPARγ coactivator 1α (PGC-1α) gene expression and contributes to thermogenic
activation of brown fat: involvement of PRDM16. Journal of Biological Chemistry,
2011. 286(50): p. 43112-43122.

310.

Stanley, W.C., R.J. Khairallah, and E.R. Dabkowski, Update on lipids and
mitochondrial function: impact of dietary n-3 polyunsaturated fatty acids. Current
opinion in clinical nutrition and metabolic care, 2012. 15(2): p. 122-126.

311.

Houtkooper, R.H. and F.M. Vaz, Cardiolipin, the heart of mitochondrial metabolism.
Cell Mol Life Sci, 2008. 65(16): p. 2493-506.

312.

Paradies, G., et al., Functional role of cardiolipin in mitochondrial bioenergetics.
Biochim Biophys Acta, 2014. 1837(4): p. 408-17.

313.

Sustarsic, E.G., et al., Cardiolipin Synthesis in Brown and Beige Fat Mitochondria Is
Essential for Systemic Energy Homeostasis. Cell Metab, 2018. 28(1): p. 159-174.e11.

314.

Lynes, M.D., et al., Cold-Activated Lipid Dynamics in Adipose Tissue Highlights a
Role for Cardiolipin in Thermogenic Metabolism. Cell Rep, 2018. 24(3): p. 781-790.

87

315.

Hoang, T., M.D. Smith, and M. Jelokhani-Niaraki, Expression, folding, and proton
transport activity of human uncoupling protein-1 (UCP1) in lipid membranes:
evidence for associated functional forms. J Biol Chem, 2013. 288(51): p. 36244-58.

316.

Lee, Y., et al., Uncoupling protein 1 binds one nucleotide per monomer and is
stabilized by tightly bound cardiolipin. Proc Natl Acad Sci U S A, 2015. 112(22): p.
6973-8.

317.

Silva, J.E., Thermogenic mechanisms and their hormonal regulation. Physiol Rev,
2006. 86(2): p. 435-64.

318.

Bargut, T.C.L., et al., Administration of eicosapentaenoic and docosahexaenoic acids
may improve the remodeling and browning in subcutaneous white adipose tissue and
thermogenic markers in brown adipose tissue in mice. Mol Cell Endocrinol, 2019.
482: p. 18-27.

319.

Zhao, M. and X. Chen, Eicosapentaenoic acid promotes thermogenic and fatty acid
storage capacity in mouse subcutaneous adipocytes. Biochemical and Biophysical
Research Communications, 2014. 450(4): p. 1446-1451.

320.

Ohinata, H., et al., Effect of dietary docosahexaenoic acid on in vitro thermogenesis
and fatty acid compositions of brown adipose tissue. Jpn J Physiol, 1998. 48(3): p.
189-96.

321.

Félix-Soriano, E., et al., Changes in brown adipose tissue lipid mediator signatures
with aging, obesity, and DHA supplementation in female mice. Faseb j, 2021. 35(6):
p. e21592.

322.

Wei, W., et al., Anti-obesity effects of DHA and EPA in high fat-induced insulin
resistant mice. Food Funct, 2021. 12(4): p. 1614-1625.

323.

Pinel, A., et al., EPA prevents fat mass expansion and metabolic disturbances in mice
fed with a Western diet. J Lipid Res, 2016. 57(8): p. 1382-97.

88

324.

Zhang, G., S. Kodani, and B.D. Hammock, Stabilized epoxygenated fatty acids
regulate inflammation, pain, angiogenesis and cancer. Progress in lipid research,
2014. 53: p. 108-123.

325.

Westphal, C., A. Konkel, and W.-H. Schunck, Cytochrome P450 Enzymes in the
Bioactivation of Polyunsaturated Fatty Acids and Their Role in Cardiovascular
Disease, in Monooxygenase, Peroxidase and Peroxygenase Properties and
Mechanisms of Cytochrome P450, E.G. Hrycay and S.M. Bandiera, Editors. 2015,
Springer International Publishing: Cham. p. 151-187.

326.

Spector, A.A. and H.-Y. Kim, Cytochrome P450 epoxygenase pathway of
polyunsaturated fatty acid metabolism. Biochimica et biophysica acta, 2015. 1851(4):
p. 356-365.

327.

Inceoglu, B., et al., Modulation of mitochondrial dysfunction and endoplasmic
reticulum stress are key mechanisms for the wide-ranging actions of epoxy fatty acids
and soluble epoxide hydrolase inhibitors. Prostaglandins & other lipid mediators,
2017. 133: p. 68-78.

328.

McReynolds, C., et al., Epoxy Fatty Acids Are Promising Targets for Treatment of
Pain, Cardiovascular Disease and Other Indications Characterized by Mitochondrial
Dysfunction, Endoplasmic Stress and Inflammation, in Druggable Lipid Signaling
Pathways. 2020, Springer. p. 71-99.

329.

Calder, P.C. and P. Yaqoob, Omega-3 polyunsaturated fatty acids and human health
outcomes. Biofactors, 2009. 35(3): p. 266-72.

330.

Xu, X., et al., The Role of Cytochrome P450 Epoxygenases, Soluble Epoxide
Hydrolase, and Epoxyeicosatrienoic Acids in Metabolic Diseases. Adv Nutr, 2016.
7(6): p. 1122-1128.

89

331.

Khadir, A., et al., Soluble Epoxide Hydrolase 2 Expression Is Elevated in Obese
Humans and Decreased by Physical Activity. Int J Mol Sci, 2020. 21(6).

332.

Wang, Y., et al., Soluble epoxide hydrolase is an endogenous regulator of obesityinduced intestinal barrier dysfunction and bacterial translocation. Proc Natl Acad Sci
U S A, 2020. 117(15): p. 8431-8436.

333.

Luria, A., et al., Soluble epoxide hydrolase deficiency alters pancreatic islet size and
improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci U
S A, 2011. 108(22): p. 9038-43.

334.

Zha, W., et al., Functional characterization of cytochrome P450-derived
epoxyeicosatrienoic acids in adipogenesis and obesity. Journal of lipid research,
2014. 55(10): p. 2124-2136.

335.

Roche, C., et al., Impact of soluble epoxide hydrolase inhibition on early kidney
damage in hyperglycemic overweight mice. Prostaglandins Other Lipid Mediat, 2015.
120: p. 148-54.

336.

Roche, C., et al., Soluble epoxide hydrolase inhibition improves coronary endothelial
function and prevents the development of cardiac alterations in obese insulinresistant mice. Am J Physiol Heart Circ Physiol, 2015. 308(9): p. H1020-9.

337.

López-Vicario, C., et al., Inhibition of soluble epoxide hydrolase modulates
inflammation and autophagy in obese adipose tissue and liver: role for omega-3
epoxides. Proc Natl Acad Sci U S A, 2015. 112(2): p. 536-41.

338.

Iyer, A., et al., Pharmacological inhibition of soluble epoxide hydrolase ameliorates
diet-induced metabolic syndrome in rats. Exp Diabetes Res, 2012. 2012: p. 758614.

339.

Liu, L., et al., Ablation of soluble epoxide hydrolase reprogram white fat to beige-like
fat through an increase in mitochondrial integrity, HO-1-adiponectin in vitro and in
vivo. Prostaglandins Other Lipid Mediat, 2018. 138: p. 1-8.

90

340.

do Carmo, J.M., et al., Inhibition of soluble epoxide hydrolase reduces food intake
and increases metabolic rate in obese mice. Nutr Metab Cardiovasc Dis, 2012. 22(7):
p. 598-604.

341.

Ikeda, K., P. Maretich, and S. Kajimura, The Common and Distinct Features of
Brown and Beige Adipocytes. Trends Endocrinol Metab, 2018. 29(3): p. 191-200.

342.

Shinde, A.B., A. Song, and Q.A. Wang, Brown Adipose Tissue Heterogeneity, Energy
Metabolism, and Beyond. Front Endocrinol (Lausanne), 2021. 12: p. 651763.

343.

Brondani, L.A., et al., The role of the uncoupling protein 1 (UCP1) on the
development of obesity and type 2 diabetes mellitus. Arq Bras Endocrinol Metabol,
2012. 56(4): p. 215-25.

91

Appendix

Figure 2.1. Major anatomic Locations of brown adipose tissue in mice and humans.
Brown adipose tissue (BAT) reside in the interscapular, axillary, deep anterior cervical,
periaortic and perirenal area of mice. In infants, BAT major presents in interscapular and
perirenal areas. In adult humans, it resides in the cervical, supraclavicular, axillary, and
paravertebral regions. (Adapted from Kenji Ikeda and Pema Maretich et al. 2018 [341],
additional reference [24-27, 34, 35])
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Figure 2.2. Schematic representation of three types of adipocytes. White, beige, and brown
adipocytes are three types of adipocytes. Their major characters and markers are indicated
below. (Adapted from Abhijit Babaji Shinde and Anying Song et al. 2021 [342]; additional
reference[38-42].)
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Figure 2.3. Developmental origins of brown adipocytes and the molecular regulators. EN1,
MYF5, and PAX7 positive precursors, derived from the dermomyotome, are committed to
brown preadipocytes. EBF2 or BMP7 regulates the commitment process from somatic
precursors to brown preadipocytes. BMP7 is transcriptionally regulated by EWS/YBX1.
PRDM16 complex (PRDM16/C/EBPβ/EHMT1) facilitates the brown adipose commitment
while suppresses the myogenic process. Committed brown preadipocytes, marked by EBF2,
differentiated to mature brown adipocytes regulated by multiple regulators including PPARγ,
EBF2, PGC-1α, and PRDM16. EN1, engrailed 1; PAX7, paired box 7; MYF5, myogenic factor
5; EBF2, early B-cell factor 2; BMP7, bone morphogenetic protein 7; EWS, ewing sarcoma
breakpoint region 1; YBX1, Y-box-binding protein 1; PRDM16, PR domain zinc finger protein
16; C/EBPβ CCAAT/enhancer-binding protein-beta; EHMT1, euchromatic histone-lysine Nmethyltransferase 1; PPARγ, peroxisome proliferator activated receptor gamma; PGC-1α,
PPARγ coactivator 1 alpha; PIC, preinitiation complex; MED1, mediator of RNA polymerase
II transcription subunit 1. (Adapted from Wenshan Wang and Patrick Seale 2016[29])
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Figure 2.4. Uncoupling protein 1-mediated thermogenesis. Uncoupling protein 1(UCP1)
presents in the inner membrane of mitochondria. It uncouples the proton gradient from ATP
synthase to generate heat. (Adapted from Leticia de Almeida Brondani and Tais Silveira
Assmann et al. 2012 [343])

95

Chapter III Soluble Epoxide Hydrolase Inhibition by
t-TUCB Reduces Serum Triglycerides in Diet-Induced
Obese Mice
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Abstract
BAT is an important target for obesity treatment and prevention. sEH converts bioactive
EpFAs into less active diols. sEH inhibitors are beneficial in many chronic diseases by
stabilizing EpFAs. Our lab previously found that sEH expression was increased in brown
adipogenesis and in the BAT of diet-induced obese mice. In addition, sEH inhibitor t-TUCB
promoted brown adipogenesis in vitro. However, the effects of sEH inhibitor in BAT activity
in treating diet-induced obesity have not been reported. In this chapter, the effects of the sEH
inhibitor t-TUCB were studied in obese mice via mini osmotic pump delivery. Although tTCUB (3mg/kg/day) did not change body weight, fat pad weight, or glucose and insulin
tolerance in the obese mice, it significantly decreased serum triglycerides level. In addition, the
protein expression of PLIN, a lipid coating protein important for lipid metabolism, was
significantly increased by t-TCUB treatment in the iBAT. Our results suggest that sEH
inhibitor may be beneficial in improving BAT protein expression involved in lipid metabolism
in high-fat diet-induced obese mice. Further studies using the sEH inhibitor combined with n3 EpFAs substrates for obesity treatment and prevention are warranted.
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3.1 Introduction
BAT has recently emerged as a novel target for obesity treatment/prevention [1-3]. In
contrast to WAT, BAT is responsible for non-shivering thermogenesis through uncoupling
ATP synthesis from respiration via UCP1, leading to dissipation of energy as heat [1]. It was
long believed that BAT was transient within the first months of life and then drastically reduced
in adulthood. Using PET/CT imaging technique, it was recently discovered that adult humans
do have a significant amount of functional BAT [4-7]. These depots are either classical brown
or beige fat [8-10]. Beige fat or brown-like fat is a type of fat that is formed in the WAT depot
by a "browning" process in response to various stimuli [11, 12]. Current strategies to enhance
functional BAT mass/activity include cold exposure and β-adrenergic stimulation; however,
these strategies have issues of compliance and side effects. Novel effective strategies are
needed for obesity treatment and prevention.
sEH (encoded by the Ephx2 gene) is a predominant cytosolic enzyme that converts epoxy
EpFAs into less active diols by adding a water molecule [13]. EpFAs are produced by CYP450
epoxygenase from n-6 PUFA, such as ARA, and n-3 PUFA, such as DHA and EPA. Many
EpFAs are autocrine/paracrine lipid signaling molecules that play essential roles in pain,
inflammation, vascular dilation, and cell growth/differentiation [13]; therefore, sEH, expressed
in various tissues, including in white adipocytes and WAT [14], has become a pharmacological
target. Potent small molecule sEH inhibitors have been developed to stabilize endogenous
EpFAs and enhance their beneficial effects.
sEH inhibition and/or sEH deficiency have been shown to decrease ER stress [15] and
inflammation [16] in the WAT and liver in diet-induced obesity and associated liver steatosis
[16], cardiac remodeling [17], and endothelial dysfunction [18]. Interestingly, one study
reported that sEH inhibitor-induced weight loss in high fat-high fructose-fed obese mice was
associated with increased heat production and UCP1 protein expression in the iBAT [19]. In
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another study, a different sEH inhibitor significantly increased the iBAT mass in the fat-1 mice
[20], which had the transgenic expression of the n-3 desaturase, leading to enriched
endogenous n-3 PUFA levels and higher n-3 EpFAs production [20]. However, whether an
sEH inhibitor enhances iBAT activity and improves metabolic dysfunction in diet-induced
obesity has not been investigated.
In the current chapter, the effects of sEH inhibition by t-TUCB were studied in obese
C57BL/6J mice via osmotic pump delivery.
3.2 Materials and methods
3.2.1 Animal studies
All mice studies were approved by the Institutional Animal Care and Use Committee at
the University of Tennessee, Knoxville. Mice were singly caged at 22-23 0C with 12 hr
light/dark shifts. Male C57BL/6J mice (n=10 per group) (The Jackson Laboratory) were
purchased at 3 weeks old and were fed a high fat-diet diet (60% kcal from fat, D12492)
(Research Diets) for 8 weeks to establish the obese condition. The mice were then surgically
implanted with Alzet osmotic minipumps (model 2006) (DURECT Corporation, Cupertino,
CA) filled t-TUCB into the subcutaneous compartment from an interscapular incision nearby
the iBAT. t-TUCB was dissolved in a mixed solvent (25% DMSO in polyethylene glycol 400
(PEG400) as described (7) and delivered at 3 mg/kg/day for 6 weeks. Insulin and glucose
tolerance tests and indirect calorimetry were performed. Upon termination, four mice per group
were randomly selected and subjected to cold tolerance tests. Immediately after the tests, whole
blood was collected by cardiac puncture under anesthesia. After the mice were euthanized,
various fat tissues, liver, and gastrocnemius muscle were collected and weighed. Some tissue
was sampled for histological examination, and the rest was snap-frozen in liquid nitrogen then
stored at -80 °C until analysis. The rest of the mice from each group were terminated the next
day at room temperature (RT) following the same procedures.
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3.2.2 Insulin and glucose tolerance test
For insulin tolerance tests, the mice were fasted for 6 hr before they were given insulin
(Humulin) (Eli Lilly, Indianapolis, Indiana) at 0.5 U/kg of body weight through intraperitoneal
injection. For glucose tolerance tests, the mice were fasted overnight (12-15 hr) before oral
gavage with dextrose solution at 2 mg/g of body weight. Blood glucose levels were monitored
and recorded at time 0, 15, 30, 60, 90, and 120 minutes after the administration of insulin or
glucose with a handheld glucometer. These two tests were performed on all animals and one
week apart.
3.2.3 Cold tolerance test
Mice were randomly selected (n=4 per group) and singly housed in their home cage
without the filter top and bedding at 4 ℃. Water and food were provided ad libitum. The mice
body core temperatures were taken at time 0, 30, 60, 90, 120, 150, and 180 min, 4 hr, 5 hr, and
6 hr using RET 3 ISO rectal probe for mice and a portable temperature monitor (Physitemp
Instruments, Clifton, NJ).
3.2.4 Lipid accumulation in the iBAT slides
Freshly isolated iBAT per mouse were sliced and fixed in 10% neutral buffered formalin
before they were processed for Haematoxylin and Eosin staining at the University of Tennessee
College of Veterinary Medicine Diagnostic Laboratory Service. 2-3 fields were taken per slide
per mouse with a Nikon Eclipse E-600 microscopy. The pictures were analyzed by the Image
J software.
3.2.5 Blood biochemical analysis
Plasma glucose was measured by Mouse Glucose Assay (Crystal Chem, Downers Grove,
IL). Serum insulin was measured using an Ultra Sensitive Mouse Insulin ELISA kit (Crystal
Chem). Serum triglycerides, NEFA, and cholesterol were measured using respective tests from
Wako Diagnostics (FUJIFILM Wako Diagnostics, Mountain View, CA). Serum adiponectin
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and leptin were measured using the Mouse Quantikine ELISA kit for the respective analyte
(R&D Systems, Minneapolis, MN). All samples were analyzed according to the manufacturers'
instructions.
3.2.6 Western blot analysis
Total cell lysates were prepared using 1X lysis buffer (Cell Signaling, Danvers, MA), and
protein concentrations were determined using the BCA assay kit (Thermo Scientific, Waltham,
MA). Proteins were separated on a 10% SDS-PAGE and then transferred to polyvinylidene
difluoride membranes (Bio-Rad, Hercules, CA). The membranes were blocked in TBST buffer
(20 mM Tris Base, 137 mM NaCl, and 0.1% Tween 20 (pH 7.4)) containing 5% nonfat milk.
Membranes were then immunoblotted with the indicated primary antibodies against proteins
of interest at 4 °C overnight, followed by 1 hr incubation with secondary antibodies conjugated
with horseradish peroxidase. Bands of the protein of interest were visualized using SuperSignal
West Pico Chemiluminescent Substrate (Thermo Scientific, Pittsburgh, PA). Densitometry of
bands was quantified using Image Studio software (LI-COR Biosciences, Lincoln, NE) or
ChemiDoc XRS+ system with Image Lab software (Bio-Rad, Hercules, CA).
3.2.7 Statistical analysis
The number of experiments and replicates are indicated in figure legends. Statistical
analysis was performed using SigmaPlot 14.0 (Systat Software, San Jose, CA) or Prism 8
(GraphPad Software, San Diego, CA). Student's t-test was performed to determine the
differences between treatment groups in body weight, food intake, tissue pad weight, core body
temperature, cold tolerance test, oral glucose tolerance test (OGTT), and insulin tolerance test
(ITT), respectively. Two-way ANOVA followed by the same multi group-wise comparison
was performed to determine the differences between treatment groups and between the room
temperature and cold condition. The level of significance was set at p<0.05.
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3.3 Results
3.3.1 t-TUCB delivered via mini osmotic pump did not decrease the body weight in
diet-induced obese mice
To confirm whether the effects of sEH inhibition by t-TUCB on brown adipogenesis and
function can be beneficial in diet-induced obesity in a mouse model, osmotic minipumps filled
with t-TUCB to provide 3 mg/kg/day were implanted into the subcutaneous area on top of the
iBAT of the diet-induced obese C57BL/6J male mice. The purpose of such delivery was to
maximize the effects of t-TUCB on the iBAT while minimizing its systemic effects. After 6
weeks of treatment, t-TUCB did not change the body weight, food intake, fasting glucose level,
or individual fat pad mass, including iBAT (Fig. 3.1). All figures are shown in the Appendix.
3.3.2 t-TUCB delivered via mini osmotic pump did not improve the cold tolerance in dietinduced obese mice
Since the important role of BAT in thermogenesis, we further investigated whether local
delivery of t-TUCB can improve the cold tolerance in diet-induced obese mice. There was no
difference in core body temperature at the baseline between two groups. In addition, t-TUCB
did not improve the cold tolerance during 6 hr cold exposure at 4 ℃ compared to the controls
(Fig. 3.2).
3.3.3 t-TUCB delivered via mini osmotic pump decreased serum triglycerides in dietinduced obese mice
To examine whether local delivery of t-TUCB can improve body metabolism, we
performed an oral glucose tolerance test and insulin tolerance test (Fig. 3.3A-B). In addition,
blood biochemical analysis was performed to analyze metabolic parameters (Fig. 3.3C-I).
There were no improvements in glucose tolerance and insulin sensitivity by t-TUCB treatment
compared to the groups (Fig. 3.3A-B). Although t-TUCB did not change blood levels of insulin,
glucose, total cholesterol, NEFA, adiponectin, or leptin levels, serum TG levels at room
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temperature (RT) were significantly decreased by t-TUCB compared to the controls (p<0.05
in RT) (Fig. 3.3C-I).
3.3.4 t-TUCB delivered via mini osmotic pump increased protein expression of genes
involved in lipid metabolism in the iBAT of diet-induced obese mice
Histological analysis of the iBAT slides showed that t-TUCB treated mice tended to have
less lipid accumulation caused by high-fat feeding than the control mice; however, the changes
were not significant (Fig. 3.4A-B). Analysis of thermogenic protein expression in the iBAT
revealed that t-TUCB treated mice had no significant increases in UCP1 and PGC1α protein
expression in the iBAT compared with the controls both in RT and the cold condition (Fig.
3.4C).
Since t-TUCB treated mice had significantly lower TG levels, we examined the protein
expression of genes involved in fatty acid uptake from the circulation, including LPL and CD36,
in the iBAT. t-TUCB treated mice had a higher LPL protein expression; however, the changes
did not reach significance. There were no significant changes in CD36 expression in the iBAT
in the t-TUCB treated mice compared to the controls (Fig. 3.5A-B).
We further analyzed the expression and phosphorylation of the proteins in the iBAT
involved in lipolysis. The cold exposure significantly increased HSL protein abundance and
phosphorylation of HSL at S565 and S660 (p<0.05) but did not affect the phosphorylation of
HSL at S563. t-TUCB treated mice had a higher HSL protein abundance and higher
phosphorylation of HSL at S563 and S660 at RT (Fig. 3.5C-D); however, the changes did not
reach significance. Moreover, cold exposure decreased ATGL protein abundance (p<0.01);
however, t-TUCB treatment did not affect ATGL protein expression (Fig. 3.5C-D). On the
other hand, the cold exposure significantly decreased PLIN protein abundance (p<0.01) but
increased phosphorylation of PLIN at S517 (p<0.05) (Fig. 3.5C-D). t-TUCB treated mice had
significantly higher PLIN expression in the iBAT both in RT and the cold condition (p<0.05),
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but no change in the phosphorylation of PLIN at S517 compared to the controls in either RT
or the cold conditions (Fig. 3.5C-D).
3.4 Discussion
Although questions remain on the composition and origin of BAT in adult humans [21,
22], it is generally believed that BAT is a novel target to combat human obesity and associated
metabolic disorders.
Our lab previously found that sEH expression was increased during both murine and
human brown adipocyte differentiation [23], which are in line with sEH expression patterns in
3T3-L1 white adipocyte differentiation [14]. In addition, some diol/epoxide ratios were
significantly higher in the media from differentiated brown adipocytes than that from the
preadipocytes, which indicates higher sEH activities in the differentiated brown adipocytes[23].
Moreover, the sEH inhibitor t-TUCB dose-dependently promoted brown adipogenesis and
mitochondrial uncoupling in vitro [23].
Based on these brown cell culture results, we have focused on the effects of sEH inhibition
on the iBAT in the animal studies in this chapter. To explore the mechanisms by which t-TUCB
improved serum TG levels in diet-induced obese mice, we analyzed protein expression
involved in TG uptake and breakdown in the iBAT. It has been reported that LPL and CD36,
two genes primarily responsible for the hydrolysis of circulating TRLs and taking up fatty acids,
respectively, were both upregulated in the BAT and required for increased TG clearance in
response to the cold [24]. In addition, LPL expression was also increased by cold-induced
lipokine 12,13-dihydroxy-9Z-octadecenoic acid (12,13-DiHOME) in the BAT [25]. Injection
of 12,13-DiHOME into obese B6 mice was shown to decrease serum TG without affecting
body weight and glucose tolerance by increasing fatty acid uptake into the BAT [25]. Increased
fatty acid uptake was attributed to increased translocation of fatty acid transporters, such as
CD36, in brown adipocytes by the lipokine [25]. Due to limited tissue samples, we could not
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investigate the effects of t-TUCB on CD36 translocation. Future studies are needed to
investigate the effects of t-TUCB on fatty acid uptake in brown adipocytes. It is worth noting
that we previously found that t-TUCB dose-dependently increased both mRNA and protein
expression of CD36 and protein (but not mRNA) expression of LPL in vitro [23]. Therefore,
decreased serum TG levels by t-TUCB local delivery seems to be consistent with the published
reports on BAT activation by the cold and the lipokine [24, 25] and suggests that t-TUCB may
enhance BAT activity, which in turn can promote TG clearance from circulation by increasing
hydrolysis of TG and possibly fatty acid uptake into the brown adipocytes.
In adaptive thermogenesis, BAT responds to the β-adrenergic stimulation by increasing
lipolysis to provide fatty acids as substrates for heat production via uncoupling. As the most
abundant lipid-coating protein on mature lipid droplets (LD), Plin1 is critical for NE-induced
lipolysis in the BAT and thermal response to NE in vivo [26]. Moreover, transgenic mice with
adipose-specific aP2 promoter/enhancer-driven murine Plin1 overexpression led to significant
increases of mRNA expression of fatty acid oxidative genes in the BAT, but not in the WAT
[27, 28]. Furthermore, phosphorylation of murine PLIN sequence on serine 517 (equivalent to
human PLIN serine 522) by activated PKA in response to cold exposure is essential for the
ATGL activity [29]. ATGL catalyzes the removal of sn-1 fatty acid from the stored TGs to
produce diacylglycerol DAG [30]. DAG can be further hydrolyzed by HSL producing
monoacylglycerol, which is further hydrolyzed by the monoacylglycerol lipase [31].
Phosphorylation of HSL on Ser 563, Ser 565, and Ser 660 have been shown to affect HSLmediated lipolysis [32-34]. It is worth noting that our lab previously found that t-TUCB dosedependently increased mRNA and protein expression of Plin1 and mRNA expression of Atgl
and Hsl in murine brown adipocytes in vitro [23]. Increases in lipolytic gene expression,
together with increases in thermogenic UCP1 and PGC-1a expression, are consistent with
increases in ISO-stimulated oxygen consumption and mitochondrial uncoupling in t-TUCB
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treated brown adipocytes in vitro [23]. In this study, we demonstrated that t-TUCB increased
the PLIN protein expression in iBAT of obese mice. Combined with previous in vitro data,
results from the current animal study suggest that t-TUCB may promote BAT activity by
increasing protein expression involved in lipolysis, leading to less lipid accumulation in the
BAT and significantly lower serum TG levels in diet-induced obesity.
It should be noted that our studies cannot rule out the effects of t-TUCB on other tissues,
such as subcutaneous white fat and liver, to improve lipid metabolism. Previous studies have
shown sEH inhibition reduced inflammation [16], reduced ER stress [15], and restored
autophagy [20] in the white adipose and liver, and improved the overall metabolic health in
DIO of mice. In addition, it is worth noting that the BAT is partially activated at 22-23 °C (RT)
and further activated at 4 °C (Cold) in our studies; however, there was minimal browning of
iWAT and eWAT in the mice either at RT or at 4 °C for only 6 hr (data not shown). Therefore,
the observed decreases in TG levels in t-TUCB treated mice at RT are more likely due to the
enhanced BAT activities rather than enhanced browning of white fat. Previous studies by others
have also investigated this topic. It was reported that sEH genetic deficiency led to the
reprogramming of white fat with increases in mitochondrial and thermogenic Ucp1 mRNA
expression [35]. Similarly, an EET analog was shown to induce UCP1 protein expression in
3T3-L1 adipocytes [36]. Therefore, it is possible that sEH inhibition could affect browning;
however, our current study designs do not support the study of browning of the WAT. Future
studies are needed to study the effects of t-TUCB on the browning of WAT.
In a preventive study, t-TUCB was systemically administered at ~1.67 mg/kg/day for 16
weeks starting at the same time with a high-fat diet; it increased BAT volume of fat-1 mice,
but not the WT controls [20]. Due to overexpression of an n-3 desaturase, fat-1 mice had
increased endogenous levels of n-3 PUFA and n-3 PUFA-derived EpFAs. The t-TUCB
administration further increased n-3 PUFA derived EpFAs in the fat-1-mice. In contrast, t-
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TUCB did not seem to affect the weight gain or total (white) fat volume in either fat-1 or WT
mice on the high-fat diet [20]. Our studies further add to the current understanding by
demonstrating the effects of t-TUCB on improving TG levels in high fat diet-induced obese
mice. The t-TUCB dose at 3 mg/kg/day we used has been demonstrated by other studies to
achieve beneficial effects with minimal toxicity in mice [20, 37]. On the other hand, our
findings that t-TUCB at this dose for 6-weeks improved TG levels but did not alter body weight
in the obese mice seem to support the notion that enhanced BAT mass/activity may improve
metabolisms in a relatively short period but may require a longer duration of intervention to
decrease body weights. For example, BAT transplantation improved high fat-induced glucose
intolerance after 8 weeks of transplantation and only partially attenuated the body weight after
12 weeks of transplantation [38]. Together, these results suggest that sEH inhibition by t-TUCB
may be a novel strategy for diet-induced obesity by promoting BAT activities; however, a long
duration of treatment or combination with EpFAs-generating diets may be necessary to reduce
the body weight gain and other aspects of metabolism in obesity.
The mechanisms by which the sEH inhibitors improved BAT protein expression in obese
mice remain to be determined. Our lab previously found that t-TUCB activated both PPARg
and PPARα in brown preadipocytes at the tested concentrations in vitro [23]. PPARa and
PPARg are known to be expressed in the BAT [39, 40]. Both PPARs modulate gene expression
by binding to the PPAR response element(s) present in the target genes' promoter in
heterodimers with the RXR. PPARs target genes include Ucp1 [12, 39], Lpl [39], and Plin1
[40], which were found to be induced by t-TUCB in the current in vivo study and our previous
in vitro studies[23]. Herein, t-TUCB most likely functions either through the stabilization of
EpFAs or by acting as a PPAR agonist. EETs, among the main EpFAs generated by CYPs from
AA, were shown to bind and activate PPARs and induce target gene transcription [41]. Some
of the biological effects of EETs and sEH inhibitors have been shown to be mediated through
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PPARg in various disease models [41-45]. However, it is also possible that t-TUCB may mimic
the effects of EpFAs by binding to PPARs directly as an agonist, as the structural component
of urea present in t-TUCB has been used to mimic epoxides [46]. Future studies are needed to
explore the mechanisms by which t-TUCB activates PPARs to modulate gene expression in
brown adipocytes and BAT.
3.5 Conclusion
In conclusion, although the exact molecular mechanisms are yet to be determined, the
results presented herein show that sEH inhibition may be beneficial in improving BAT protein
expression involved in lipid metabolism in diet-induced obesity. Further studies using the sEH
inhibitors combined with EpFAs substrates for obesity treatment and prevention are warranted.
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Appendix

Figure 3.1. t-TUCB delivered via mini osmotic pump did not decrease the body weight in
diet-induced obese mice. C57BL/6J mice were fed a high-fat diet for 8 weeks, followed by tTUCB (3 mg/kg/day) (open bar or circle) or the vehicle (solid bar or circle) containing osmotic
minipump implantation for 6 weeks. Body weight, food intakes, fasting glucose, and various
tissue pad weights were recorded (A) Changes in body weight after the mini pump implantation;
(B) Average food intake per day after the mini pump implantation; (C) Fasting glucose levels
after 6 weeks of mini pump implantation; (D) Fat pad weights at termination. No significant
differences were detected between the treated and the control group (Student's t-test).
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Figure 3.2. t-TUCB delivered via mini osmotic pump did not improve the cold tolerance
in diet-induced obese mice. C57BL/6J mice were fed a high-fat diet for 8 weeks, followed by
t-TUCB (3 mg/kg/day) (open bar or circle) or the vehicle (solid bar or circle) containing
osmotic minipump implantation for 6 weeks. Core body temperature (A) and cold tolerance
tests (B) were performed as described. No significant differences were detected between the
treated and the control group (Student's t-test).
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Figure 3.3. t-TUCB delivered via mini osmotic pump decreased serum triglycerides in
diet-induced obese mice. C57BL/6J mice were fed a high-fat diet for 8 weeks, followed by tTUCB (3 mg/kg/day) or the vehicle containing osmotic minipump implantation for 6 weeks as
described. Oral glucose test (A) and insulin tolerance test (B) were performed as described.
Serum insulin (C), plasma glucose (D), serum total cholesterol (E), NEFA (F), adiponectin (G),
leptin (H), and TG (I) levels in the control and t-TUCB treated mice in the RT and cold
condition. Data=Mean+SEM (n=4-5). *, **, ***, p<0.05, p<0.01, and p<0.001 compared to
the controls, respectively. No significant differences were detected between the treated and the
control group in the glucose tolerance test and insulin tolerance test (Student's t-test).
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Figure 3.4. The effects of t-TUCB minipump delivery on lipid accumulation and UCP1
and PGC1a protein expression in the iBAT of obese C57BL/6J mice. After termination,
the iBAT tissue slides from mice were stained with Hematoxylin and Eosin (H&E) (A), and %
area occupied by lipid from 2-3 fields per slide per mouse (n=9-10) were measured using Image
J software as described and graphed in (B). (C) Protein expression of UCP1 and PGC1α in the
BAT of t-TUCB treated or the control mice. Bar graphs show normalized densitometry for
UCP1/ERK and PGC1α/ERK. Data=Mean+SEM (n=3). No significant differences were
detected between the groups.
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Figure 3.5. t-TUCB delivered via mini osmotic pump increased protein expression of
genes involved in lipid metabolism in the iBAT of diet-induced obese mice. (A-B) Protein
expression of LPL, CD36, and the loading control ERK in the iBAT of t-TUCB treated and the
control mice, and their densitometry. (C-D) Protein expression of HSL, ATGL, PLIN, the
phosphorylation of HSL and PLIN, and the loading control ERK in the iBAT of t-TUCB treated
or the control mice and their densitometry. Bar graphs show normalized densitometry for
LPL/ERK1/2 and CD36/ERK1/2 in (B) HSL/ERK1/2, ATGL/ERK1/2, PLIN/ERK1/2, and pHSL(S563)/HSL, p-HSL(S565)/HSL, p-HSL(S660)/HSL and p-PLIN(S517)/PLIN in (D).
Data=Mean+SEM (n=3). *, **, ***, p<0.05, p<0.01, and p<0.001 compared to the controls,
respectively.

119

Chapter IV Effects of 19,20-EDP Combined with
Soluble Epoxide Hydrolase Inhibition by t-TUCB in
Diet-Induced Obese Mice
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Abstract
Obesity is a worldwide epidemic associated with various comorbidities. BAT becomes a
promising target for obesity treatment and prevention due to its role in energy homeostasis.
19,20-EDP is a bioactive EpFAs derived from an n-3 PUFA DHA by CYP450 epoxygenase.
19,20-EDP has been reported to be anti-inflammatory and cardioprotective recently. However,
endogenous EpFAs are not stable and are metabolized into less active diols in vivo by a
cytosolic enzyme, sEH. sEH inhibitors are, therefore, beneficial in many chronic diseases by
stabilizing endogenous EpFAs, including 19,20-EDP. We have found that t-TUCB, a potent
sEH inhibitor, promoted brown adipogenesis in vitro. In addition, minipump delivery of tTCUB (3mg/kg/day) to the iBAT decreased serum triglycerides and increased protein
expression of genes important for lipid metabolism in the BAT of diet-induced obese mice
(Chapter III). However, whether the addition of 19,20-EDP can enhance the beneficial effects
of t-TUCB is unknown. Therefore, in this chapter, we investigate the potential beneficial
effects of 19,20-EDP alone or combined with t-TUCB via osmotic minipump in diet-induced
obese mice. We found that 19,20-EDP alone or combined with t-TUCB improved the cold
tolerance test in the obese mice. However, body weight, fat pad mass, glucose tolerance, insulin
tolerance, or blood metabolic parameters were not changed by 19,20-EDP alone or combined
with t-TUCB. Future studies on the mechanisms by which 19,20-EDP combined t-TUCB
improves cold tolerance and on the effective treatment time and dose are warranted.
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4.1 Introduction
BAT has become a novel target for obesity treatment or prevention due to its thermogenic
function [1-3]. Current strategies to enhance functional BAT mass/activity to combat obesity,
such as cold exposure and β-adrenergic agonists, have been challenged by incompliance and
side effects [4]. Novel effective strategies targeting BAT to fight against obesity and associated
metabolic disorders are needed.
Dietary ingredients, such as fish oil with enriched DHA and EPA, have been reported to
promote BAT activity [5, 6]. It has been reported that fish oil, commonly enriched with EPA
and DHA, increased the UCP1 mRNA expression and protein expression in the iBAT of rats
fed with a high-fat diet, which was accompanied by decreased WAT pad weight [7, 8].
Similarly, fish oil intake increased the core body temperature and heat production by
upregulating UCP1 and β3-AR of the iBAT in mice fed a chow diet [9]. Moreover, fish oil
prevented the high-fat diet-induced body weight gain and hypertriglyceridemia and improved
the glucose tolerance in part by enhanced BAT thermogenesis, as evidenced by upregulated
expression of UCP1, PGC1a, and β3-AR in the iBAT [10]. The mechanisms by which n-3
PUFA promotes BAT activity to combat obesity may partially be attributed to the production
of n-3 PUFA-derived metabolites, but the specific metabolites are not fully determined [11].
N-3 EpFAs are bioactive metabolites generated by CYP450 epoxygenases from n-3
PUFAs [12, 13]. These EpFAs are known to modulate angiogenesis, vascular dilation,
inflammation, and cell growth and differentiation and are implicated in tumor growth and
metastasis, cardiovascular disease, type 2 diabetes, metabolic syndromes, and pain [14-16].
However, these EpFAs are not stable and are metabolized into less active diols quickly in vivo
by soluble sEH, encoded by the Ephx2 gene [17]. Therefore, many of the beneficial effects of
these EpFAs were potentiated by co-administration of an sEH inhibitor [13, 15, 16].
Interestingly, it has been reported that an sEH inhibitor significantly increased the iBAT mass
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in the fat-1 mice [18], which had the transgenic expression of the n-3 desaturase, leading to the
accumulation of endogenous n-3 PUFA and its derived EpFA [18]. Moreover, sEH inhibitor
alone did not show strong beneficial effects in some disease models unless it was combined
with an EpFAs [19] or enriched tissue levels of n-3 PUFAs [18]. These results led us to
hypothesize that n-3 EpFAs may be responsible for the anti-obesity effects of n-3 PUFAs by
regulating BAT activity.
We have previously demonstrated that t-TUCB promoted brown adipogenesis in vitro [20],
decreased serum TG levels, and increased protein expression of lipid metabolic genes in the
iBAT of diet-induced obese mice (Chapter III). However, the effects of n-3 EpFAs in obesity
are unknown. 19,20-EDP is the predominant EpFA derived from DHA, which is enriched in
fish oil. Therefore, here we investigate the effects of 19,20-EDP alone or combined with tTUCB on BAT activation in obese C57BL/6J mice via osmotic pump delivery.
4.2 Materials and methods
4.2.1 Animal studies
All mice studies were approved by the Institutional Animal Care and Use Committee at
the University of Tennessee, Knoxville. Male C57BL/6J mice (n=15 per group) (The Jackson
Laboratory) were purchased at 3 weeks old and were singly housed at 22-23℃ with 12 hr
light/dark shifts. After one week of acclimation, the mice were fed a high fat-diet diet (60%
kcal from fat, D12492) (Research Diets) for 8 weeks to establish diet-induced obesity. The
mice were then surgically implanted with Alzet osmotic minipumps (model 2006) (DURECT
Corporation, Cupertino, CA) filled with the following: mixed solvent (Control), 19,20-EDP
alone (0.05 mg/kg/d) (EDP) or 19,20-EDP (0.05 mg/kg/d) combined with t-TUCB (3 mg/kg/d)
(E+T). All pumps were implanted into the subcutaneous compartment from an interscapular
incision nearby the iBAT. t-TUCB, 19,20-EDP were dissolved in a mixed solvent (25% DMSO
in polyethylene glycol 400 (PEG 400) as previously described [21]. Insulin and glucose
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tolerance tests and indirect calorimetry were performed. Upon termination, seven to eight mice
per group were randomly selected and subjected to cold tolerance tests (6 hours cold exposure
from 10 am to 4 pm) and remained in the cold environment until 24 hr. After 24hr-cold
exposure, whole blood was collected by cardiac puncture under anesthesia. After the mice were
euthanized, various fat tissue, liver, and gastrocnemius muscle were collected and weighed.
Some tissues were sampled for histological examination, and the rest was snap-frozen in liquid
nitrogen then stored at -80°C until analysis. The rest of the mice from each group were
terminated the next day at room temperature following the same procedures.
4.2.2 Insulin and glucose tolerance test
For insulin tolerance tests, mice were randomly selected (n=7 per group) and were fasted
for 6 hr before giving the insulin (Humulin) (Eli Lilly, Indianapolis, Indiana) at 0.5 U/kg of
body weight through intraperitoneal injection. For glucose tolerance tests, 9-10 mice per group
were randomly selected and were fasted overnight (12-15 hr) before oral gavage with dextrose
solution at 1.5 g/kg of body weight. Blood glucose levels were monitored and recorded at time
0, 15, 30, 60, 90, and 120 min after the administration of insulin or glucose with a handheld
glucometer. These two tests were performed 5 days apart.
4.2.3 Cold tolerance test
Mice were randomly selected (n=7-8 per group) and subjected to three-day cold
acclimation before the cold tolerance test. Briefly, from day one to day three, mice were singly
housed in their home cage without the filter top and bedding at 4°C for 6 hours from 10 am-4
pm, and then moved back to the single cage with filter top and bedding at room temperature
22-23°C for the rest of time. Water and food were provided ad libitum. On day 4, the mice
were housed at 4 °C, and body core temperatures were taken at time 0, 15, 30, 60, 90, 120, 150,
and 180 min, 4 hr, 5 hr, and 6 hr using RET 3 ISO rectal probe for mice connected with a
portable temperature monitor (Physitemp Instruments, Clifton, NJ).
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4.2.4 Blood biochemical analysis
The Mouse Glucose Assay kit (Crystal Chem, Downers Grove, IL) is used to measure
plasma glucose. The Ultra Sensitive Mouse Insulin ELISA kit (Crystal Chem) was used to
quantify the serum insulin level. Wako Diagnostics (FUJIFILM Wako Diagnostics, Mountain
View, CA) was utilized to analyze serum triglycerides, NEFA, and cholesterol levels. All
samples were analyzed according to the manufacturers’ instructions.
4.2.5 Statistical analysis
The number of experiments and replicates are indicated in figure legends. Prism 8
(GraphPad Software, San Diego, CA) was used in statistical analysis. The differences between
treatment groups (in body weight, food intake, tissue pad weight, core body temperature, cold
tolerance test, OGTT, and ITT, respectively) were determined by Student’s t-tests. The
differences between treatment groups and between the room temperature and cold condition
were analyzed by Two-way ANOVA followed by a multi-group-wise comparison. The level
of significance was set at p<0.05.
4.3 Results
4.3.1 19,20-EDP alone or combined with t-TUCB delivered via mini osmotic pump did
not decrease the body weight, food intakes, and fasting glucose in diet-induced obese mice
To investigate whether the effects of 19,20-EDP alone or combined with sEH inhibitor tTUCB on BAT function in the diet-induced obese mouse model, osmotic minipumps filled
with 19.20-EDP or 19,20-EDP combined with t-TUCB were implanted into the subcutaneous
area on top of the iBAT of the diet-induced obese C57BL/6J male mice, which had been fed
with a high-fat diet for 8 weeks. After 6 weeks of treatment, 19,20-EDP alone or combined
with t-TUCB did not change the body weight, food intake, fasting glucose level, or individual
fat pad mass, including iBAT (Fig. 4.1). All figures are shown in the Appendix.
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4.3.2 19,20-EDP alone or combined with t-TUCB via mini osmotic pump improved the
cold tolerance in diet-induced obese mice
Due to the important role of BAT in thermogenesis, we further investigated whether local
delivery of 19,20-EDP alone or combined with t-TUCB can improve the cold tolerance in dietinduced obese mice. Although there was no difference in core body temperature at the baseline
in the two treated groups (the EDP and E+T group) compared to the controls, both 19,20-EDP
alone or combined with t-TUCB significantly improved the cold tolerance during 6 hr cold
exposure at 4℃ compared to the controls (p<0.01 for the EDP group and p<0.001 for E+T
group) (Fig. 4.2).
4.3.3 19,20-EDP or combined with t-TUCB via mini osmotic pump did not improve
systemic metabolism in diet-induced obese mice
To examine whether local delivery of 19,20-EDP or 19,20-EDP combined with t-TUCB
can improve metabolism, we performed the oral glucose tolerance test and insulin tolerance
test (Fig.4.3 A-B). In addition, blood biochemical analysis was performed to analyze metabolic
parameters (Fig.4.3 C-G). There were no improvements in glucose tolerance and insulin
sensitivity by either 19,20-EDP alone or 19,20-EDP combined with t-TUCB treatment
compared to the controls (Fig. 4.3 A-B). Cold exposure significantly decreased the serum
insulin and TG levels while significantly increased the serum NEFA levels in all three groups
(Fig. 4.3D-F). However, 19,20-EDP alone or combined with t-TUCB did not change plasma
glucose, serum insulin, TG, NEFA, or total cholesterol (TC) levels compared to the controls
(Fig. 4.3 C-G).
4.4 Discussion
In the current study, we tested the effects of 19,20-EDP, a prominent epoxy metabolite of
DHA, alone or combined with t-TUCB in reducing the body weight and improving metabolic
health in diet-induced obese mice. Under the experimental conditions (e.g., with doses and
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treatment time), 19,20-EDP alone or combined with t-TUCB did not decrease the body weight
nor improved the metabolic health in the obese mice. However, both 19,20-EDP alone and
19,20-EDP combined with t-TUCB significantly improved cold tolerance in the obese mice.
A few studies have tested whether enhanced BAT mass or activities can be of therapeutic
value for obesity. For example, when small pieces of BAT were transplanted into high-fat dietinduced obese mice, high-fat diet-induced glucose intolerance was improved after 8 weeks’
transplantation, and the body weight gains were only partially attenuated after 12 weeks of
transplantation [22]. However, in another study, the body weights of diet-induced obese mice
were significantly decreased as early as 4 weeks after BAT transplantation [23]. This
discrepancy may be due to the different study designs between these two studies. In the first
study [22], the brown fat pads (0.1 g per mouse) were taken from 12-weeks old donors and
were transplanted into the visceral cavity of the recipient mice. In contrast, the BAT (0.15 g),
taken from 6-weeks old donors, was transplanted into the subcutaneous interscapular area in
the second study [23]. It is worth noting, the initial average body weight of mice before BAT
transplantation was around 32-35 grams after 6-8 weeks of high-fat diet feeding (60% kcal
from fat) in these two studies [22, 23]. The average body weight of non-transplanted mice
reached to 45-50 grams with additional 10-12 weeks of high-fat feeding at the end of the study
[22, 23]. However, the initial average body weight of mice before osmotic pump implantation,
was already reached 42 grams in our study. Therefore, the unchanged body weight and
systemic metabolisms by 19,20-EDP alone or combined with t-TUCB in our study may be
partially due to the severe obese condition and the relatively short treatment duration (6 weeks).
The current dose of 19,20-EDP (0.05 mg/kg/day) used in our study was based on the serum
levels achieved in mice fed an n-3 PUFAs enriched diet [24], which were reported to show
beneficial effects in several disease models [21, 24, 25]. However, it may not be sufficient to
reverse existing severe obesity in our current study. A higher dose of 19,20-EDP have been
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used in other studies. 19,20-EDP treatment by osmotic pump delivery at the dose of 1
mg/kg/day for 10-14 days was shown to protect kidney function in renal fibrosis and
hypertensive mouse models [26, 27]. Therefore, further studies are needed to determine the
optimal dose of 19,20-EDP, possibly a range from 0.05 mg/kg/day to 1 mg/kg/day, to improve
BAT activity to treat obesity.
Interestingly, although the core body temperature was not affected by 19,20-EDP alone or
combined with t-TUCB at room temperature, mice treated with 19,20-EDP alone or combined
with t-TUCB maintained higher core body temperature under 6-hours cold exposure at 4 ℃.
These results indicate that 19,20-EDP may facilitate BAT thermogenic function under certain
stress conditions, such as cold exposure. The molecular mechanisms by which 19,20-EDP
improves BAT thermogenesis after stimulation need further investigation. For example, we
could investigate whether the beneficial effects of 19,20-EDP in cold tolerance observed here
are associated with improved brown adipogenesis and enhanced thermogenic capacity at cell
level using in vitro cell models. Brown adipogenesis can be studied by oil red O staining and
brown marker gene expression, whereas the thermogenic capacity can be investigated by the
mitochondrial stress test, which provides multiple parameters to analyze mitochondrial
function, including basal and maximal respiration, ATP-production, and proton leak (i.e.,
uncoupling) [20]. In addition, stimulation with b-AR agonist, such as isoproterenol (ISO), can
be used to mimic the cold exposure in mice [28]. Therefore, we can further investigate whether
19,20-EDP treatment can enhance the thermogenic capacity of murine brown cells with or
without the ISO stimulation.
In addition, the EPA, another major n-3 PUFA enriched in fish oil, has been reported to
improve BAT activity to combat obesity in mice [29], which may have targeted BAT and
contributed to anti-obesity effects observed with fish oil. Moreover, in fat-1 mice with a
transgenic expression of the n-3 desaturase that increases endogenous n-3 PUFAs in tissues,
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both 17,18-EEQ and 19,20-EDP were enriched in insulin-sensitive tissues, including liver and
adipose tissue [18]. 17,18-EEQ is the major n-3 EpFA derived from EPA [30]. Furthermore,
differential effects of DHA and EPA were reported in various disease models [31]. Therefore,
the effects of 17,18-EEQ on BAT activation in reversing obesity and whether the effects of
17,18-EEQ are different from 19,20-EDP warrant further investigation in the future.
4.5 Conclusion
We report that 19,20-EDP alone or combined with t-TUCB improved cold tolerance but
did not affect body weight and metabolic health in diet-induced obese mice under our study
conditions. Future studies on the mechanisms by which 19,20-EDP combined with t-TUCB
improve cold tolerance and on determining the effective treatment time and dose are warranted.
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Appendix

Figure 4.1. 19,20-EDP along or combined with t-TUCB delivered via mini osmotic pump
did not decrease the body weight, food intake, and fasting glucose in diet-induced obese
mice. C57BL/6J mice were fed the high-fat diet for 8 weeks, followed by implantation of
osmotic minipumps filled with 19,20-EDP (0.05 mg/kg/d) (magenta color) or 19,20-EDP
combined with t-TUCB (3 mg/kg/day) (turquoise color) or the vehicle control (black color) for
6 weeks. Body weight, food intakes, fasting glucose, and various tissue pad weights were
recorded. (A) Changes in body weight after the mini pump implantation; (B) Fat pad weights
at termination; (C) Average food intake per day after the mini pump implantation; (D) Fasting
glucose levels after 6 weeks of mini pump implantation; Data=Mean±SEM. No significant
differences were detected between the treated and the control group (Student’s t-test).
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Figure 4.2. 19,20-EDP alone or combined with t-TUCB delivered via mini osmotic pump
improved cold tolerance in diet-induced obese mice. C57BL/6J mice were fed the high-fat
diet for 8 weeks, followed by implantation of osmotic minipumps filled with 19,20-EDP (0.05
mg/kg/day) (magenta color) or 19,20-EDP combined with t-TUCB (3 mg/kg/day) (turquoise
color) or the vehicle control (black color) for 6 weeks. Core body temperature (n=14-15) (A)
and cold tolerance tests (n=7-8) (B) were performed as described. The area under the curve
(AUC) was calculated (C). Data=Mean±SEM. *, **, ***, p<0.05, p<0.01, and p<0.001
compared to the controls, respectively (Student’s t-test).
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Figure 4.3. 19,20-EDP alone or combined with t-TUCB delivered via mini osmotic pump
did not improve body metabolism in diet-induced obese mice. C57BL/6J mice were fed a
high-fat diet for 8 weeks, followed by t-TUCB (3 mg/kg/day) or the vehicle containing osmotic
minipump implantation for 6 weeks as described. Oral glucose test (A) and insulin tolerance
test (B) were performed as described. Plasma glucose (C), Serum insulin (D), serum TG (E),
NEFA (F), and TC (G) levels in the control, EDP, or E+T group in the RT and cold condition
are shown. Data=Mean±SEM (n=7-8). *, **, ***, p<0.05, p<0.01, and p<0.001 compared to
the room temperature, respectively. No significant differences were detected between the
treated and the control groups in the glucose tolerance test and insulin tolerance test (Student’s
t-test).
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Chapter V Differential Effects of 17,18-EEQ and
19,20-EDP Combined with Soluble Epoxide
Hydrolase Inhibitor t-TUCB on Diet-induced Obesity
in Mice
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Abstract
17,18-EEQ and 19,20-EDP are bioactive epoxides produced from EPA and DHA,
respectively, which are quickly metabolized to less active diols by cytosolic enzyme, sEH. We
have previously demonstrated that an sEH inhibitor t-TUCB decreased serum TG and increased
lipid metabolic protein expression in the iBAT of diet-induced obese mice. This study
investigated the preventive effects of t-TUCB (T) alone or combined with 19,20-EDP (T+EDP)
or 17,18-EEQ (T+EEQ) on BAT activation in the development of diet-induced obesity and
metabolic disorders via osmotic minipump delivery in mice. Both T+EDP and T+EEQ groups
showed significant improvement in fasting glucose, serum triglycerides, and higher core body
temperature, whereas heat production was only significantly increased in the T+EEQ group.
Moreover, both T+EDP and T+EEQ groups showed less lipid accumulation in the BAT.
Although UCP1 expression was not changed, PGC1α expression was increased in all three
treated groups. In contrast, the expression of CPT1A and CPT1B, which are responsible for
the rate-limiting step for fatty acid oxidation, was only increased in the T+EDP and T+EEQ
groups. Interestingly, as a fatty acid transporter, CD36 expression was only increased in the
T+EEQ group. Furthermore, both T+EDP and T+EEQ groups showed decreased inflammatory
NFκB signaling in the BAT. Our results suggest that 17,18-EEQ or 19,20-EDP combined with
t-TUCB may prevent high-fat diet-induced metabolic disorders, in part through increasing
thermogenesis, upregulating lipid metabolic protein expression, and decreasing inflammation
in the iBAT.
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5.1 Introduction
Obesity remains one of the biggest public health issues worldwide [1], which is associated
with various diseases, including dyslipidemia, cardiovascular diseases, and certain types of
cancers, leading to a shorter lifespan and higher medical costs [2, 3]. Recent studies have
indicated that obesity is also associated with the high prevalence and severity of COVID-19,
an infectious disease caused by coronavirus SARS-CoV-2 [4, 5]. A surge of studies targeting
BAT to treat or prevent obesity due to its ability to increase energy expenditure through nonshivering thermogenesis [6-9]. Strategies that enhance BAT metabolic activity and improve
BAT thermogenic function may confer beneficial diet-induced obesity and associated
metabolic comorbidities.
17,18-EEQ and 19,20-EDP are the major EpFAs derived from EPA and DHA, respectively
[10, 11]. These EpFAs modulate angiogenesis, vascular dilation, inflammation, and cell growth
and differentiation and are implicated in tumor growth and metastasis, cardiovascular disease,
diabetes, metabolic syndromes, and pain [12-14]. Because these epoxides are unstable and
quickly metabolized to less active diols by a cytosolic enzyme, sEH (encoded by the Ephx2
gene) [11], many of the beneficial effects of these EpFAs were enhanced by simultaneously
providing an sEH inhibitor [11, 13, 14].
We have previously demonstrated that t-TUCB promoted brown adipogenesis in vitro [15],
decreased serum TG levels, and increased protein expression of lipid metabolic genes in the
BAT of diet-induced obese mice (Chapter III). In addition, 19,20-EDP alone or combined with
t-TUCB significantly improved the cold tolerance in diet-induced obese mice (Chapter IV). In
this study, we further investigated the effects of t-TUCB (T) alone or combined with 19,20EDP (T+EDP) or 17,18-EEQ (T+EEQ) on BAT activation in preventing the development of
diet-induced obesity and associated metabolic disorders in mice by mini pump delivery.
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5.2 Materials and methods
5.2.1 Reagents
Antibodies used in the study are shown in Table 5.1. All tables and figures are shown in
the Appendix.
5.2.2 Animal study
All animal procedures were approved by the Institutional Animal Care and Use Committee
at the University of Tennessee, Knoxville. Mice were housed individually at 22-23 ℃ with a
12-hour light/dark cycle.
3 weeks old male C57BL/6J mice were purchased from the Jackson Laboratory and were
fed a regular chow diet (14% kcal from fat, 8604) (Teklad Rodent Diet, ENVIGO) for 5 weeks.
At 8 weeks old, 10 mice were randomly selected as the non-transplanted controls. They were
fed a low-fat diet (10% kcal from fat, D12450H) or a high-fat diet (45% kcal from fat, D12451)
(Research Diets) for 6 weeks. At the same time, the rest mice were randomly divided into 4
groups (n=5-6 per group) and were fed the same high-fat diet (45% kcal from fat, D12451)
(Research Diets). In addition, these 4 groups of mice were surgically implanted with Alzet
osmotic minipumps (model 2006) (DURECT Corporation, Cupertino, CA) filled with the
following: mixed solvent (the vehicle control), t-TUCB alone (T), or t-TUCB combined with
19,20-EDP (T+EDP) or 17,18-EEQ (T+EEQ). All pumps were implanted into the
subcutaneous compartment from an interscapular incision nearby the iBAT. t-TUCB, 19,20EDP, and 17,18-EEQ were dissolved in a mixed solvent (25% DMSO in polyethylene glycol
400 (PEG 400)) as previously described [16]. The deliver rate was 3 mg/kg/day for t-TUCB,
and 0.05 mg/kg/day for 19,20-EDP and 17,18-EEQ, respectively. The maximal delivery
duration was 6 weeks by design for the model. Body weight and food intake were measured
every week. Insulin and glucose tolerance tests, indirect calorimetry, and cold tolerance tests
were performed as previously described [15]. The animals were then terminated at room

141

temperature. Whole blood was collected by cardiac puncture under anesthesia. Subcutaneous
WAT, epididymal WAT, interscapular BAT, liver, and gastrocnemius muscle were collected
and weighed. A small piece of tissue samples was fixed for histopathological analysis, and the
rest of tissue samples were snap-frozen in liquid nitrogen and then stored at -80 °C until
analysis.
5.2.3 Blood biochemical analysis
The Mouse Glucose Assay kit (Crystal Chem, Downers Grove, IL) is used to measure
plasma glucose. The Ultra Sensitive Mouse Insulin ELISA kit (Crystal Chem) was used to
quantify the serum insulin level. Wako Diagnostics (FUJIFILM Wako Diagnostics, Mountain
View, CA) was utilized to analyze serum triglycerides, NEFA, and cholesterol levels. All
samples were analyzed according to the manufacturers’ instructions.
5.2.4. Western blot analysis
Tissue samples were homogenized by an electric homogenizer in 1xRIPA lysis buffer
(Cell Signaling, Danvers, MA) and then centrifuge for 15 minutes at 12000 rpm at 4 °C to
obtain protein samples. BCA assay kit (Thermo Scientific, Waltham, MA) was used to
determine protein concentrations. Protein samples (1-45 µg per lane) were separated on 10%
or 12% SDS-PAGE and then transferred to polyvinylidene difluoride (PVDF) membranes
purchased from Bio-Rad (Hercules, CA) in the transfer buffer (25 mM Tris base, 190mM
glycine, 20% methanol) at 25 volts for 20 hours. Then the membranes were blocked in TBST
buffer (20 mM Tris Base, 137 mM NaCl, and 0.1% Tween 20 (pH 7.4)) with 5% nonfat milk
for 1 hour at room temperature. Next, membranes were immunoblotted with the indicated
primary antibodies (Table 1) against proteins of interest at 4 °C overnight at 1:1000 dilution
(at 1:2000 dilution for UCP1 antibody, 1:500 dilution for CD36 and HSL antibodies). After 10
minutes of wash by TBST buffer 3 times, membranes were incubated with secondary
antibodies (horseradish peroxidase conjugated) at 1:4000 dilution for 1 hour. Bands of the
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protein of interest were visualized by Pierce ECL Western Blotting Substrate or SuperSignal
West Pico Chemiluminescent Substrate (Thermo Scientific, Pittsburgh, PA). To facilitate the
detection of some proteins of interest, two gels were run and detected at the same time to
accommodate all samples and/or large sample volumes. Densitometry of bands was quantified
using ChemiDoc XRS+ system with Image Lab software (Bio-Rad, Hercules, CA) or Image J
software (an open source from NIH).
5.2.5 BAT lipid accumulation and sWAT adipocyte area determination
The iBAT and sWAT from each mouse were isolated. A small piece was fixed in 10%
neutral buffered formalin and then processed for hematoxylin and eosin staining at the
University of Tennessee College of Veterinary Medicine Diagnostic Laboratory Service.
Nikon Eclipse E-600 microscopy was used to take pictures from 2-3 fields of each slide of
iBAT or sWAT from each mouse. The % area occupied by lipid or adipocyte areas from 2-3
fields per slide per mouse was then quantified by the Image J software.
5.2.6. Statistical analysis
Prism 8 (GraphPad Software, San Diego, CA) was used to conduct statistical analysis. The
two-tailed Student's t-test was used to analyze the differences in group means among the
treatment groups and the control group. For the OGTT, ITT, cold tolerance tests, and heat
production, areas under the curve were calculated using Prism 8, and a two-tailed Student's ttest was used to compare differences between the treatment and the control group. The level of
significance was set at p<0.05.
5.3 Results
5.3.1 17,18-EEQ or 19,20-EDP combined with t-TUCB differentially affected body weight
in diet-induced obesity
To investigate whether treatments of t-TUCB alone or combined either with 17,18-EEQ
or 19,20-EDP are beneficial in preventing the development of diet-induced obesity, osmotic
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minipumps filled with vehicle control, t-TUCB (T) alone or combined with 19,20-EDP
(T+EDP) or 17,18-EEQ (T+EEQ) were implanted into the subcutaneous compartment on top
of the interscapular BAT (iBAT) of C57BL/6J male mice fed a high-fat diet (45% kcal from
fat). In addition, we set up another two groups (n=5 per group) of mice fed either a low-fat diet
(10% kcal from fat) or a high-fat diet (45% kcal from fat) for 6 weeks without osmotic
minipumps implantation as controls.
6-weeks administration of the high-fat diet did not affect the food intake, body weight,
brown fat weight but induced a significant increase in subcutaneous and epididymal WAT mass
(Fig. 4.1A-E). Although the fasting glucose level was not affected, the glucose tolerance was
impaired in mice fed the high-fat diet (Fig. 5.1F-G). In addition, the high-fat diet induced a
significant increase in serum TG level without affecting serum NEFA and TC levels (Fig. 5.1HJ). Moreover, core body temperature and heat production were not different between low-fat
diet-fed mice and high-fat diet-fed mice (Fig. 5.1K-L).
After 6 weeks of treatment, t-TUCB alone or combined with either 19,20-EDP or 17,18EEQ did not change the food intakes and individual fat pad mass, including sWAT, epididymal
WAT (eWAT), and iBAT (Fig. 5.2A, C-E). However, there were small but significant
increases in body weight in both T and T+EDP groups compared with the vehicle control group
(Fig. 5.2B). Although not significantly different from the control group, the T+EEQ group had
a lower body weight than the T and T+EDP groups (p<0.01 and p<0.001, respectively) (Fig.
5.2B).
5.3.2 17,18-EEQ or 19,20-EDP combined with t-TUCB improved fasting glucose and
serum TG levels in diet-induced obesity
To investigate the effects of sEH inhibition combined with 17,18-EEQ or 19,20-EDP on
glucose metabolism, we performed ITT and OGTT. Although there were no differences in ITT
among groups (Fig. 5.3A-B), the T+EEQ group showed a trend of improvement in glucose
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tolerance tests (p=0.079) (Fig. 5.3C-D). Additionally, while there were no significant
differences in serum insulin levels among groups (Fig. 5.3F), both T+EEQ and T+EDP groups
showed significant improvement in fasting glucose compared to the controls (208.8 ± 36.4
mg/d vs. 214 ± 10.8 mg/dL vs. 262.8 ± 8.9 mg/dL) (p<0.05 and p<0.01, respectively) (Fig.
5.3E).
We have previously shown that t-TUCB decreased the serum TG levels in diet-induced
obese mice (Chapter III). To determine whether t-TUCB combined with 17,18-EEQ or 19,20EDP can improve lipid metabolism in diet-induced obesity, we investigated blood lipid
parameters (Fig. 5.3G-I). While the serum TC and NEFA levels were unchanged in response
to treatment with t-TUCB alone or combined with 17,18-EEQ or 19,20-EDP (Fig. 5.3G-H),
serum TG levels were significantly decreased in the T+EDP (45.8 ± 2.2 mg/dL; p<0.01) and
T+EEQ (38.3 ± 6.7 mg/dL; p<0.05) groups compared to the controls (69.7 ± 7.2 mg/dL) (Fig.
5.3I).
5.3.3 17,18-EEQ or 19,20-EDP combined with t-TUCB increased thermogenesis in dietinduced obesity
In Chapter IV, we found that 19,20-EDP alone or combined with t-TUCB improved the
cold tolerance in diet-induced obese mice. Here, to investigate whether the beneficial effects
of 17,18-EEQ or 19,20-EDP combined with t-TUCB on metabolism are correlated with
improved thermogenesis, we measured the core body temperature and performed cold
tolerance test and indirect calorimetry (Fig. 5.4). These tests were performed at room
temperature. Core body temperature was not changed by t-TUCB (37.3 ± 0.08 °C) but was
significantly increased in the T+EDP (37.9 ± 0.06 °C; p<0.01) and T+EEQ (38.1 ± 0.09 °C;
p<0.001) groups compared to the controls (37.3 ± 0.14 °C) (Fig.5.4A). In addition, both
T+EDP and T+EEQ groups showed significantly higher core body temperature than the T
group (p<0.01 and p<0.001, respectively). Consistently, both T+EDP and T+EEQ groups
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showed significantly improved cold tolerance compared to the control (p<0.05 and p<0.001,
respectively) (Fig. 5.4B-C). Also, the T+EEQ group showed better cold tolerance than the T
group (p<0.05). Furthermore, heat production, measured by indirect calorimetry, was
significantly higher in the T+EEQ group (p<0.001) but not in the T and T+EDP groups
compared to the control group (Fig. 5.4D-E).
5.3.4 17,18-EEQ or 19,20-EDP combined with t-TUCB decreased lipid accumulation and
regulated protein expression of thermogenic genes in the iBAT of diet-induced obesity
Since 17,18-EEQ or 19,20-EDP combined with t-TUCB alleviated some of the obesityinduced metabolic dysregulations and increased thermogenesis, we further investigated
whether 17,18-EEQ or 19,20-EDP combined with t-TUCB modulated BAT activation, leading
to the beneficial effects.
First, we examined changes in lipid accumulation in the iBAT by measuring the % area
occupied by lipid from hematoxylin-eosin (H&E) stained iBAT slides of each mouse (Fig.
5.5A-B). t-TUCB alone did not change the lipid accumulation compared to the controls, but
the lipid accumulation in the iBAT of the T+EDP and T+EEQ groups was significantly lower
than the controls (p<0.05 and p<0.01, respectively).
Next, we analyzed the protein expression of thermogenic genes in the iBAT (Fig. 5.5C-D).
We found that UCP1 protein expression in the iBAT was not changed in the T and T+EDP
groups, but the T+EEQ group showed a trend of increase in UCP1 protein expression compared
to the controls (p=0.07). On the other hand, PGC1a protein expression in the T, T+EDP, and
T+EEQ groups was significantly increased compared to the control group (p<0.05, p<0.001,
and p<0.05, respectively).
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5.3.5 17,18-EEQ or 19,20-EDP combined with t-TUCB regulated protein expression of
genes involved in lipid metabolism in the iBAT of diet-induced obesity
We have previously demonstrated that t-TUCB decreased serum TG levels accompanied
by increased protein expression of PLIN, a gene involved in lipid lipolysis, in the iBAT of dietinduced obese mice (Chapter III). Consistently, we show that the T+EDP and T+EEQ groups
had significantly lower serum TG levels in this study. Moreover, the lipid accumulation in the
iBAT was significantly decreased by 19,20-EDP or 17,18-EEQ combined with t-TUCB.
Therefore, we further investigated the protein expression of genes involved in lipid
metabolisms in the iBAT of diet-induced obesity (Fig. 5.6-5.7).
First, protein expression of LPL, CD36, FABP4, CPT1A, and CPT1B, which are involved
in fatty acids uptake, transport, binding, and oxidation in the iBAT, were analyzed by western
blot analysis (Fig. 5.6). There were no significant changes in LPL expression in the iBAT
among groups. In contrast, CD36 expression was not changed in both T and T+EDP groups
but was significantly increased in the T+EEQ group compared to the control, T, or T+EDP
group (p<0.01) (Fig. 5.6). Moreover, CPT1A and CPT1B protein expression were significantly
increased in both T+EDP (p<0.05 for CPT1A and p<0.01 for CPT1B) and T+EEQ groups
(p<0.01 for CPT1A and p<0.001 for CPT1B), but not in the T group (Fig. 5.6). In addition,
FABP4 protein expression was significantly higher in both T and T+EDP groups (p<0.01 and
p<0.001, respectively) (Fig. 5.6), consistent with their increased body weights.
Next, we examined the protein expression and phosphorylation of genes involved in
lipolysis (Fig. 5.7). Consistent with previous results, PLIN expression was significantly
increased in the iBAT of mice treated with t-TUCB (p<0.05) alone or combined with 19,20EDP (p<0.001) or 17,18-EEQ (p<0.05). In addition, phosphorylation of PLIN at S517 was
significantly higher in the T, T+EDP, and T+EEQ groups compared to the controls (p<0.05,
p<0.05, and p<0.01, respectively). Moreover, HSL protein expression and phosphorylation
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were differentially regulated in the T+EEQ group compared to the other groups (Fig. 5.7).
There were no significant changes in ATGL protein expression in the iBAT among all groups
(Fig. 5.7).
5.3.6. 17,18-EEQ or 19,20-EDP combined with t-TUCB decreased inflammatory response
in the iBAT of diet-induced obesity
It has been reported that BAT content and activity declined in the obese animals partly
because of the inflammatory microenvironment of BAT caused by low-grade inflammation in
obesity [17, 18]. Targeting systematic and local inflammation could be a possible way to
restore BAT function, thereby improving metabolic health [19]. As the parental PUFAs of
17,18-EEQ and 19,20-EDP, EPA and DHA have long been reported to regulate inflammatory
processes in both rodents and humans [20, 21]. Moreover, the anti-inflammatory roles of 17,18EEQ or 19,20-EDP have been revealed in multiple disease models [22]. Therefore, we analyzed
whether 17,18-EEQ or 19,20-EDP combined with t-TUCB can suppress inflammatory
pathways in the iBAT of diet-induced obese mice, thereby improving the iBAT activity (Fig.
5.8).
As the hallmarks of NFkB activation, the phosphorylation of NFkB inhibitor alpha (IkBa)
at S32 was significantly lower, and the IkBa abundance was significantly higher in both
T+EDP and T+EEQ groups than in the control group (p<0.05) (Fig. 4.9). However, the
phosphorylation of c-Jun NH2-terminal kinase (JNK) and extracellular signal-regulated kinase
(ERK), the hallmarks of activation of inflammatory MAPK pathways, were only decreased in
the T+EDP group compared to the control group (p<0.05) (Fig. 5.8).
5.4 Discussion
BAT has emerged as a promising target to combat obesity and its associated metabolic
disorders due to its role in non-shivering thermogenesis [23-25]. In the current study, we have
demonstrated that fatty acid epoxide 17,18-EEQ or 19,20-EDP combined with t-TUCB via
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mini osmotic pump delivery significantly decreased fasting glucose and serum TG levels while
increased the core body temperature, improved cold tolerance, and thermogenesis in dietinduced obesity. In addition, 17,18-EEQ or 19,20-EDP combined with t-TUCB reduced the
lipid accumulation in the iBAT, which was accompanied by enhanced protein expression of
genes involved in thermogenesis and lipid metabolism and reduced inflammatory response in
the iBAT.
5.4.1 17,18-EEQ and 19,20-EDP contribute to the beneficial effects of EPA and fish oil
As the precursors of EEQs and EDPs, EPA and fish oil (known to be enriched with both
DHA and EPA) have long been reported to improve obesity and its associated metabolic
disorders at least in part by regulating energy expenditure and/or thermogenesis in rodents [2629]. Many of the animal studies with fish oil [30-32] showed increased energy expenditure
and/or thermogenesis and improvement in glucose and lipid metabolism with concurrent
increases of thermogenic Ucp1 and/or Pgc1a expression in the BAT. However, increased
energy expenditure and improvement in metabolism without significant increases in Ucp1
and/or Pgc-1a expression have also been reported [33], possibly due to the differences in study
designs, fish oil source and composition, and the dose and duration of the treatments. Mice
studies with pure EPA showed dose-dependent increases in energy expenditure [34] and
increased UCP1 protein expression at the highest dose tested [35]. However, whether the
downstream epoxidized metabolites of EPA and DHA are at least partially responsible for the
beneficial effects remains elusive. Our study has shed new light on the mechanisms underlying
the anti-obesity effects of n-3 PUFAs by demonstrating that their downstream epoxide
metabolites 17,18-EEQ and 19,20-EDP, when combined with t-TUCB, had similar regulatory
effects on energy expenditure, thermogenesis, and glucose and lipid metabolism accompanied
by changes in gene expression of Pgc-1a and Ucp1. Our results suggest that 17,18-EEQ and

149

19,20-EDP may at least in part contribute to the beneficial effects reported for EPA and fish
oil.
5.4.2 17,18-EEQ is more potent in increasing thermogenesis and improving metabolism
in diet-induced obesity
Interestingly, differential effects among three treatment groups are noted in our study.
Even though both T+EEQ and T+EDP groups showed beneficial effects in thermogenesis and
metabolic biomarkers (i.e., increased core body temperature and cold tolerance and improved
fasting glucose and serum TG levels, and less lipid accumulation in the BAT), these beneficial
effects were not observed in the T group. Moreover, significant increases in heat production
were only found in the T+EEQ group, suggesting that T+EEQ has more potent effects than
T+EDP. Limited studies comparing the effects of EPA and DHA have suggested that EPA
seemed to be more potent than DHA as a thermogenic stimulus [26]. To explore the molecular
mechanisms by which the 17,18-EEQ or 19,20-EDP combined with sEH inhibitor showed
differential effects, we further analyzed the protein expression of genes involved in lipid
metabolism and inflammatory pathways in the BAT.
Upon cold stimulation, BAT consumes free fatty acids primarily derived from the lipolysis
of intracellular lipid droplets [36, 37], which need to be replenished by the uptake of circulating
TG-enriched lipoproteins [9, 38]. In addition, fatty acid oxidation (FAO) in mitochondria is
enhanced to meet the high energetic demands [39, 40]. Therefore, activated BAT shows
increases in FAO and enhances TG clearance from circulation [9]. We found that serum TG
levels and lipid accumulation in the iBAT were decreased by 17,18-EEQ or 19,20-EDP
combined with t-TUCB. Therefore, we further investigated the protein expression of genes
responsible for lipolysis, FAO, and fatty acids uptake in the BAT.
In adaptive thermogenesis, lipolysis in brown adipocytes was mediated by PLIN, a lipidcoating protein whose phosphorylation promotes lipase activity in response to β-adrenergic
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stimulation [41]. We found that in all three treatment groups, PLIN protein abundance and
phosphorylation of PLIN at S517 were significantly increased, indicating that enhanced
intracellular lipolysis for all three treatment groups, consistent with previous results (Chapter
III). In addition, we observed that HSL protein expression and phosphorylation were
differentially regulated in the T+EEQ group compared to the other groups. HSL hydrolyzes
diacylglycerol and produces monoacylglycerol, which is further hydrolyzed by the
monoacylglycerol lipase [42]. Phosphorylation of HSL has been shown to affect HSL-mediated
lipolysis [43-45]. The effects of 17,18-EEQ on lipolysis need to be determined in future studies.
As the rate-limiting enzyme in FAO, the CPT1 family has three isoforms, including
CPT1A, B, and C, distributed differently among tissues [46-48]. Although both CPT1A and
CPT1B are expressed in the BAT of mice and rats, CPT1B has a much higher expression than
CPT1A [46, 48]. Specific CPT1 inhibition by 2-tetradecylglycidic acid (McN-3802) decreased
palmitic acid-induced mitochondrial respiration in murine primary brown adipocytes [49].
While Cpt1b-/- mice were embryonically lethal, more than half of the Cpt1+/- mice developed
fatal hypothermia after a prolonged cold exposure compared to 21% of Cpt1b+/+ mice [50].
Moreover, overexpressing an active mutant form of CPT1A (insensitive to malonyl-CoA
inhibition) in fully matured rat brown adipocytes significantly enhanced FAO, lipolysis, and
mitochondria activity, which in turn inhibited the palmitate-induced triglyceride accumulation
[51]. Our results show that both T+EEQ and T+EDP groups had significantly increased CPT1A
and CPT1B protein expression in the BAT, suggesting that these epoxides combined with tTUCB, but not the t-TUCB alone, may enhance FAO, thereby promoting BAT activity in dietinduced obesity.
LPL is a critical lipase that is involved in TG-enriched lipoprotein hydrolysis for the uptake
of free fatty acids into the cells [52]. Short-term cold exposure [53] and cold-induced lipokine
[54] increase free fatty acids uptake in the BAT by regulating the LPL activity and expression.
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However, we did not find changes in LPL protein expression among the different treatment
groups, which were housed under room temperature. CD36 is a cell surface protein responsible
for fatty acid uptake from circulation and was also upregulated in the BAT by the cold
temperature and contributed to cold-induced TG clearance [53]. Cd36-/- mice showed
decreases in fatty acid uptake and thermogenic gene expression in the BAT after cold exposure,
leading to impaired cold tolerance [55]. In addition, CD36 is indispensable for the BAT
thermogenic function by mediating coenzyme Q uptake from circulation for mitochondria
respiration [56]. Interestingly, we found that CD36 protein expression was only upregulated in
the T+EEQ group compared to other treated groups, consistent with the increased heat
production in the T+EEQ group. Our results suggest that CD36 may be specifically regulated
by 17,18-EEQ but not by 19,20-EDP, which partially contributes to more potent thermogenic
effects observed in the T+EEQ group. The molecular mechanisms by which 17,18-EEQ
upregulates CD36 need further investigation.
5.4.3 Both 17,18-EEQ and 19,20-EDP suppress NFkB activation in the BAT of dietinduced obesity
Obesity is associated with low-grade chronic inflammation, leading to impaired BAT
activity, which contributes to the development of insulin resistance and type 2 diabetes [17,
18]. Therefore, targeting the inflammatory pathways may reverse the BAT dysfunction and
prevent the development of metabolic disorders [19]. We found that the fasting glucose levels
were significantly decreased by both 17,18-EEQ and 19,20-EDP combined with t-TUCB, and
there was a trend of improvement in glucose tolerance in the T+EEQ group. Therefore, we
further investigated the hallmarks of activation for inflammatory pathways in brown adipocytes
[57]. We found that while activation of JNK and EKR pathways were suppressed by T+EDP,
NFkB activation was significantly suppressed by both epoxides combined with t-TUCB. In
contrast, t-TUCB alone did not suppress any of these inflammatory pathways under our study
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conditions. These results suggest anti-inflammatory effects of 17,18-EEQ and 19,20-EDP,
which may contribute to the improvement of glucose metabolism and thermogenesis in dietinduced obesity.
Limited studies have been reported on the anti-inflammatory effects of 17,18-EEQ and
19,20-EDP on adipose tissue in diet-induced obesity [58] [59]. In fat-1 mice with enriched
endogenous n-3 PUFA by transgenic expression of n-3 desaturase, 17,18-EEQ and 19,20-EDP
were significantly increased in the liver and eWAT, accompanied by deceased macrophage
infiltration and reduced pro-inflammatory markers in the eWAT compared to the wild type
controls [58]. Moreover, injection of 17,18-EEQ combined with two metabolites of EPA from
lipoxygenase (5-HEPE and 9-HEPE) for 4 days significantly reduced the inflammatory
response in the adipose tissue of high-fat induced obese mice [59]. Our results further suggest
anti-inflammatory effects of 17,18-EEQ and 19,20-EDP on the BAT in diet-induced obesity.
However, due to the limited amount of tissue samples, we were not able to analyze further the
downstream mechanisms involved in glucose metabolisms, such as GLUT4 translocation, in
the BAT. Future studies on how 17,18-EEQ and 19,20-EDP improve glucose metabolism
through suppression of BAT inflammation are warranted.
5.4.4 Limitations and future directions
There are a few limitations in our studies. We only studied male C57BL/6J mice. Female
of the C57BL/6J mice are not sensitive to a high-fat diet in our hands (our unpublished results)
and may respond differently to 17,18-EEQ and 19,20-EDP. Future studies are needed to
examine the effects of these epoxides on obesity and metabolic biomarkers in female mice.
In addition, sEH ablation and an n-6 epoxide analog have been reported to induce
browning in the WAT [60] and 3T3-L1 adipocytes [61]. However, consistent with our previous
study [15], we did not find browning of sWAT by n-3 epoxides combined with t-TUCB in the
mice housed at 22-23℃ (preliminary results, data not shown). Although we delivered 17,18-
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EEQ, 19,20-EDP, and t-TUCB locally to the iBAT, we found the average area of adipocytes
of the sWAT was significantly decreased in the T+EEQ group (preliminary results, data not
shown), suggesting systemic effects of T+EEQ. Therefore, it is possible that these epoxides
may improve systemic metabolism through modulating activities of other metabolic active
tissues, such as WAT and muscle. Further studies are needed to examine the effects of 17,18EEQ or 19,20-EDP combined with sEH inhibitor on WAT and muscle.
Lastly, the specific effects of 17,18-EEQ and 19,20-EDP on the BAT were extrapolated
by comparing their biological effects when combined with t-TUCB with the effects by t-TUCB
alone due to the quick metabolism of epoxides by the sEH. Future studies are needed to confirm
the effects of 17,18-EEQ and 19,20-EDP on the BAT, using either sEH knockout mice or stable
epoxide analogs [62].
5.5 Conclusion
Overall, the results demonstrate that local delivery of 17,18-EEQ or 19,20-EDP combined
with t-TUCB by osmotic pump to iBAT may promote BAT activity by regulating the protein
expression of genes involved in mitochondrial biogenesis, lipolysis, fatty acid oxidation, and
inflammatory pathways, leading to increased thermogenesis and improvement of glucose and
lipid metabolism in diet-induced obesity. 17,18-EEQ may be more potent than 19,20-EDP in
enhancing thermogenesis by upregulating a more comprehensive set of genes involved in lipid
metabolism, including CD36, in the BAT. Future studies are needed to confirm the beneficial
effects of these epoxides on the BAT using either sEH knockout mice or stable epoxide analogs.
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Appendix
Table 5.1. Antibodies used in the western blot
Antibodies
Anti-ATGL
Anti-CD36
Anti-CPT1A
Anti-CPT1B
Anti-ERK1/2
Anti-FABP4
Anti-IκBα
Anti-JNK
Anti-LPL
Anti-PGC1α
Anti-phosphoERK(T202/Y204)
Anti-phospho-IκBα
Anti-phosphoJNK(T183/Y185)
Anti-phospho-PLIN (S517)
Anti-UCP1
Lipolysis Activation Antibody
Sampler Kit (Antibodies for
phospho-HSL (Ser 563, Ser
565, and Ser 660), HSL, and
PLIN)

Catalog
Number

Company
Cell Signaling Technology
(Danvers, MA, USA)
Novus Biologicals
(Centennial, CO, USA)
Cell Signaling Technology
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Figure 5.1. The effects of high-fat diet on food intake, body weights, fat pad weights,
glucose tolerance, fasting glucose, serum TG and NEFA, core body temperature, and heat
production in C57BL/6J mice. Male C57BL/6J mice were fed either a low-fat or a high-fat
diet for 6 weeks. Body weight, food intake, fasting glucose were recorded, and glucose
tolerance test, cold tolerance test, and indirect calorimetry were performed as described. (A)
Changes in average food intake. (B) body weight at termination; (C), (D), (E) Fat pad weights
at termination; (F) Fasting glucose; (G) Oral glucose tolerance test and areas under the curve;
(H), (I), (J) Serum TG, NEFA, and TC levels at termination; (K) Core body temperature at
termination; (L) Heat production and area under the curve; Data=Mean±SEM (n=5). *, **, ***,
p<0.05, p<0.01, and p<0.001 compared to the low-fat group, respectively (Student’s t-test).
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Figure 5.1 (continued)
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Figure 5.2. 17,18-EEQ or 19,20-EDP combined with t-TUCB delivered via mini osmotic
pump affected body weight differentially in diet-induced obesity. Male C57BL/6J mice fed
with a high-fat diet (45% kcal from fat) were treated with t-TUCB (3 mg/kg/day) alone or
combined with 19,20-EDP (0.05 mg/kg/day) (T+EDP) or 17,18-EEQ (0.05 mg/kg/day)
(T+EEQ) by osmotic minipump implantation for 6 weeks as described in the methods section.
Average daily food intake after implantation (A), body weight (B), subcutaneous WAT (C),
epididymal WAT (D), and interscapular BAT weight (E) at the end of 6 weeks were shown.
Data=Mean±SEM (n=5-6). *, **, ***, p<0.05, p<0.01, and p<0.001 compared to the controls,
respectively. a, aa, aaa, p<0.05, p<0.01, and p<0.001 compared to the T group, respectively. b,
bb, bbb, p<0.05, p<0.01, and p<0.001 compared to the T+EDP group, respectively.
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Figure 5.3. 17,18-EEQ or 19,20-EDP combined with t-TUCB delivered via mini osmotic
pump decreased fasting glucose and serum TG levels in diet-induced obesity. 17,18-EEQ
or 19,20-EDP combined with t-TUCB delivered via mini osmotic pump decreased fasting
glucose and serum TG levels in diet-induced obesity. Male C57BL/6J mice fed with a high fat
diet (45% kcal from fat) were treated with t-TUCB (3 mg/kg/day) or combined with 19,20EDP (0.05 mg/kg/day) (T+EDP) or 17,18-EEQ (0.05 mg/kg/day) (T+EEQ) by osmotic
minipump implantation for 6 weeks as described. Insulin tolerance test and the area under the
curve (A-B), oral glucose tolerance test and the area under the curve (C-D), fasting glucose
levels (E), serum insulin (F), serum TC (G), NEFA (H), and TG levels (I) after 6 weeks of
implantation are shown; Data=Mean±SEM (n=5-6). *, **, ***, p<0.05, p<0.01, and p<0.001
compared to the controls, respectively.
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Figure 5.3 (continued)
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Figure 5.4. 17,18-EEQ or 19,20-EDP combined with t-TUCB delivered via mini osmotic
pump increased thermogenesis in diet-induced obesity. Male C57BL/6J mice fed with a
high fat diet (45% kcal from fat) were treated with t-TUCB alone (3 mg/kg/day) or combined
with 19,20-EDP (0.05 mg/kg/day) (T+EDP) or 17,18-EEQ (0.05 mg/kg/day) (T+EEQ) by
osmotic minipump implantation for 6 weeks as described. Core body temperature (A); cold
tolerance test and the area under the curve (B-C); heat production and the area under the curve
(D-E) after 6 weeks of minipump implantation were shown; Data=Mean±SEM (n=5-6) (A-C
and E) or Data=Mean (n=5-6) (D). *, **, ***, p<0.05, p<0.01, and p<0.001 compared to the
controls, respectively. a, aa, aaa, p<0.05, p<0.01, and p<0.001 compared to the T group,
respectively. b, bb, bbb, p<0.05, p<0.01, and p<0.001 compared to the T+EDP group,
respectively.
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Figure 5.5. 17,18-EEQ or 19,20-EDP combined with t-TUCB delivered via mini osmotic
pump decreased lipid accumulation and regulated thermogenic gene expression in the
iBAT of diet-induced obesity. After termination, the iBAT tissue slides from mice were
stained with hematoxylin and eosin (H&E; A), and the % area occupied by lipid from 2-3 fields
per slide per mouse (n=5) were analyzed using Image J software (B). Scale bars = 100 µm.
Protein expression of PGC1α, UCP1, and the loading control ERK in the iBAT of mice in the
control, T, T+EDP, and T+EEQ group (C), and their densitometry (D) are shown; Bar graphs
show normalized densitometry for PGC1a/ERK1/2 and UCP1/ERK1/2. Data=Mean±SEM
(n=5-6). *, **, ***, p<0.05, p<0.01, and p<0.001 compared to the controls, respectively.
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Figure 5.6. 17,18-EEQ or 19,20-EDP combined with t-TUCB delivered via mini osmotic
pump regulated protein expression of lipid metabolic genes in the iBAT of diet-induced
obesity. Protein expression of LPL, CD36, CPT1A, CPT1B, FABP4, and the loading control
ERK in the iBAT of mice in control, T, T+EDP, and T+EEQ groups (A), and their densitometry
(B) are shown; Bar graphs show normalized densitometry for LPL/ERK1/2, CD36/ERK1/2,
CPT1A/ERK1/2, CPT1B/ERK1/2, and FABP4/ERK1/2. Data=Mean±SEM (n=5-6). *, **, ***,
p<0.05, p<0.01, and p<0.001 compared to the control, respectively. a, aa, aaa, p<0.05, p<0.01,
and p<0.001 compared to the T group, respectively. b, bb, bbb, p<0.05, p<0.01, and p<0.001
compared to the T+EDP group, respectively.
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Figure 5.7. 17,18-EEQ or 19,20-EDP combined with t-TUCB delivered via mini osmotic
pump regulated protein expression of genes involved in lipolysis in diet-induced obesity.
Protein expression of PLIN, HSL and ATGL, the phosphorylation of PLIN and HSL, and the
loading control ERK in the iBAT of mice in control, T, T+EDP, and T+EEQ groups (A), and
their densitometry (B) are shown; Bar graphs show normalized densitometry for pPLIN(S517)/PLIN,

PLIN/ERK1/2,

p-HSL(S563)/HSL,

p-HSL(S565)/HSL,

p-

HSL(S660)/HSL, HSL/ERK1/2, and ATGL/ERK1/2. Data=Mean±SEM (n=5-6). *, **, ***,
p<0.05, p<0.01, and p<0.001 compared to the control, respectively. a, aa, aaa, p<0.05, p<0.01,
and p<0.001 compared to the T group, respectively. b, bb, bbb, p<0.05, p<0.01, and p<0.001
compared to the T+EDP group, respectively.
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Figure 5.8. 17,18-EEQ or 19,20-EDP combined with t-TUCB delivered via mini osmotic
pump regulated activation of inflammatory pathways in the iBAT of diet-induced obesity.
Protein expression of p-IkBα(S32), IkBα, p-JNK(T183/Y185), JNK, p-ERK1/2(T202/Y204),
and ERK1/2 in the iBAT of mice in control, T, T+EDP, and T+EEQ groups (A), and their
densitometry (B) are shown; Bar graphs show normalized densitometry for p-IkBa(S32)/IkBa,
IkBa, p-JNK(T183/Y185)/JNK, and p-ERK(T202/Y204)/ERK. Data=Mean±SEM (n=5-6). *,
**, ***, p<0.05, p<0.01, and p<0.001 compared to the control, respectively.
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Chapter VI 17,18-EEQ and 19,20-EDP Combined
with t-TUCB Promote Murine Brown Adipogenesis
and Mitochondrial Respiration and Uncoupling in
vitro
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Abstract
N-3 EpFAs, such as 17,18-EEQ and 19,20-EDP, are bioactive metabolites produced from
EPA and DHA by CYP 450 epoxygenase, respectively. Cytosolic enzymes metabolized these
EpFAs to less active diols very quickly by adding a water molecule. Previously, we have
demonstrated that an sEH inhibitor t-TUCB decreased serum TG and increased lipid metabolic
protein expression in the iBAT of diet-induced obese mice (Chapter III). In addition, 19,20EDP or 17,18-EEQ combined with t-TUCB prevented the high-fat diet-induced increase of
fasting glucose and triglyceride levels, in part through differentially regulating protein
expression involved in thermogenesis, lipid metabolism, and inflammatory pathways in the
iBAT (Chapter V). Therefore, here we investigated whether n-3 epoxides combined with tTUCB have direct effects on brown adipocyte differentiation and thermogenic capacity using
a brown adipocyte cell model. We reported that 19,20-EDP or 17,18-EEQ combined with tTUCB promote murine brown adipogenesis and mitochondrial respiration and uncoupling in
vitro, possibly associated with PPARg activation. Moreover, when combined with t-TUCB,
both 19,20-EDP and 17,18 EEQ improved mitochondrial respiration of mature brown
adipocytes; however, only 17,18-EEQ combined with t-TUCB increased the proton leak in
mature brown adipocytes. These findings are in line with the result (Chapter V) that when
combined with t-TUCB, 17,18-EEQ had more potent effects than 19,20-EDP in increasing core
body temperature and improving cold tolerance, and only 17,18-EEQ combined with t-TUCB
significantly increased heat production in mice. Our results suggest that 17,18-EEQ may be
more potent than 19,20-EDP in promoting BAT activity for obesity prevention.
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6.1 Introduction
EDPs and EEQs are epoxy fatty acids produced from DHA and EPA by CYP450
epoxygenases, respectively [1]. EDPs and EEQs consist of several regioisomers, depending on
which double bonds are converted to the monoepoxide ring [1]. CYP2C and 2J subfamilies are
two major families of CYP epoxygenases that metabolize DHA to 19,20-EDP and EPA to
17,18-EEQ in both rodents and humans [1]. These epoxides are bioactive metabolites involved
in vasodilation, angiogenesis, and inflammation; however, they are not stable and quickly
metabolized into less active diols by sEH, a cytosolic enzyme expressed in various tissues, and
is encoded by the EPHX2 gene in both rodents and humans [2]. Therefore, potent
pharmacological sEH inhibitors are developed and widely used to study the functional effects
of EpFAs, and many of the beneficial effects of EpFAs were potentiated by co-administration
of an sEH inhibitor [2-4].
Recent studies indicate that higher sEH activity was associated with obesity and metabolic
diseases in rodents [5]. In addition, sEH expression in subcutaneous adipose tissue of obese
adults was significantly higher than that of lean subjects [6]. Moreover, sEH inhibitor
significantly increased the iBAT mass in the fat-1 mice [7], which had a transgenic expression
of the n-3 desaturase, leading to enriched endogenous n-3 PUFAs content and a higher n-3
EpFAs level [7]. On the other hand, dietary n-3 PUFAs supplementation has shown to increase
energy expenditure and thermogenesis in animals, and n-3 PUFAs, EPA in particular, have
been reported to promote brown adipogenesis and browning in vitro [8, 9]. These results lead
us to hypothesize that n-3 EpFAs may promote BAT development or thermogenic function to
combat obesity and may partially contribute to the anti-obesity effects of n-3 PUFAs. In the
previous chapter (chapter IV), we demonstrated that 19,20-EDP or 17,18-EEQ combined with
sEH inhibitor t-TUCB prevented the high-fat diet-induced increase of fasting glucose and
serum triglyceride levels, in part through differentially regulating protein expression
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responsible for thermogenesis, lipid metabolism, and inflammatory pathways in the BAT. In
the current study, we use murine brown adipocytes to explore whether n-3 epoxides combined
with t-TUCB have direct effects on brown adipocyte differentiation and thermogenic capacity.
6.2 Materials and methods
6.2.1 Reagents
sEH inhibitors t-TUCB and n-3 epoxides (17,18-EEQ and 19,20-EDP) were synthesized
as described [10, 11]. Antibodies used for western blot analysis were listed as following: AntiUCP1 antibody (Catalog# U6382) was purchased from Sigma Aldrich (St. Louis, MO); AntiPGC-1α antibody (Catalog# AB3242) was purchased from Millipore (Temecula, CA); AntiCD36 (NB400-144) was purchased from Novus Biologicals (Centennial, CO).
6.2.2 Cell culture and treatment
The interscapular brown fat of newborn C57BL/6J mice was used to generate murine
brown preadipocyte cell line as described [12], which was a generous gift from Dr. Johannes
Klein (University of Lubeck, Lubeck, Germany). The cells were maintained in growth media
containing 20% fetal bovine serum (FBS) (Atlanta Biologicals, Flowery Branch, GA) in
Dulbecco's Modified Eagle's medium (DMEM) in a humidified incubator (maintained with
37 °C and 5 % CO2) until they reached 100% confluence. The cells were then induced to
differentiate in differentiation media (Day 0) (DMEM supplemented with 20% FBS, 1 nM T3,
and 20 nM insulin). The media was changed every 2 days for 6 days (Day6).
For experiments that investigate the effects on brown preadipocytes differentiation
(During differentiation), cells were treated with the DMSO (Control), t-TUCB (TUCB) alone
or combined with 17,18-EEQ (T+EEQ) or 19,20-EDP (T+EDP) at the indicated concentrations
on day 0 (D0) of the differentiation program and replaced with each change of media until day
6 (D6). For experiments that examined the effects on mature brown adipocytes (Post
differentiation), cells were induced to differentiate in differentiation media described above
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and then maintained in growth media in the presence of the DMSO (Control), t-TUCB (TUCB)
alone or combined with 17,18-EEQ (T+EEQ) or 19,20-EDP (T+EDP) at the indicated
concentrations for 3 days.
6.2.3 Oil red O staining
Lipid accumulation in the differentiated brown adipocytes was assessed by oil red O (ORO)
staining and ORO absorbance, as described [13].
6.2.4 Western blot analysis
1xRIPA lysis buffer (Cell Signaling, Danvers, MA) was used to collect total cell lysates.
Protein concentrations were determined by the BCA assay kit (Thermo Scientific, Waltham,
MA). 10% SDS-PAGE gels were used to separate protein samples (35 μg per lane). Proteins
within the gels were then transferred to polyvinylidene difluoride membranes (Bio-Rad,
Hercules, CA) at 25 volts for 20 hr. A blocking buffer (TBST buffer, 20 mM Tris Base, 137
mM NaCl, and 0.1% Tween 20 (pH 7.4)) supplemented with 5% nonfat milk were used to
block the membranes for 1 hr. After 3 washes by TBST buffer for 10 minutes each, membranes
were then immunoblotted with the indicated primary antibodies against proteins of interest at
4 °C overnight at 1:1000 dilution. Next, membranes were washed by TBST buffer 5 times (5
minutes each) and then incubated in secondary antibodies conjugated with horseradish
peroxidase at 1:4000 dilution for 1 hr. After 3 washes by TBST buffer for 15 minutes each,
bands of the protein of interest on the membranes were detected with SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific, Pittsburgh, PA), and visualized and
quantified by ChemiDoc XRS+ system with Image Lab software (Bio-Rad, Hercules, CA).
6.2.5 Analysis of mitochondrial respiration
For experiments that investigate the effects of n-3 epoxides on mitochondrial respiration
during differentiation, murine brown preadipocytes were differentiated in the presence or
absence of the following treatments DMSO (Control), 1 μM of t-TUCB alone (TUCB) or
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combined with 1 μM of 17,18-EEQ (T+EEQ 1) or 19,20-EDP (T+EDP 1) or 10 μM of 17,18EEQ (T+EEQ 10) or 19,20-EDP (T+EDP 10) for 4 days.
For experiments that examined the effects on mature murine brown adipocytes, cells were
induced to differentiate and then maintained in growth media with the treatment of DMSO
(Control), 1 μM of t-TUCB (TUCB) alone or combined with 10 μM of 17,18-EEQ (T+EEQ
10) or 19,20-EDP (T+EDP 10) for 3 days.
Then the cells were reseeded onto a 24-well XFe assay plates at 2.0x104 cells per well.
On the next day, cells in 24-well XFe assay plate were washed by XF assay media (XF assay
base medium supplemented with 1 μM sodium pyruvate, 10 μM glucose, 2 μM glutamax, and
2% BSA) twice with a volume of 400 μl each. Then the assay plate was added with 525 μL
XF assay media into each well and incubated in a non-CO2 incubator (maintained at 37 °C)
for 1 hr. Cell’s real-time oxygen consumption rate (OCR) and extracellular acidification rate
(ECAR) were measured at the basal level and then in response to the injections of oligomycin
(1.5 µM), carbonyl cyanide-ptrifluoromethoxyphenylhydrazone (FCCP; 6 µM), and antimycin
A/rotenone (1 µM each) by an XFe24 Extracellular Flux Analyzer (Seahorse Biosciences,
North Billerica, MA). OCR and ECAR were automatically recorded by XFe24 software v1.8
provided by the manufacturer. Basal OCR, ATP production coupled OCR, proton leak coupled
OCR, coupling efficiency, and maximal respiration capacity were calculated based on the
manufacturer's instructions.
6.2.6 Reporter gene assays
Brown preadipocytes seeded in 24-well plates were transiently transfected with murine
PPARg or NFκB activation reporters and β-galactosidase control plasmid with Lipofectamine
2000 transfection reagent and Plus reagent (Thermo Fisher Scientific, Carlsbad, CA) for 24 hr.
PPARg transactivation reporters consist of two separate systems described as following:
murine PPARg ligand-binding domain ligated to the Gal4 DNA binding domain (DBD)
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(mPPARg-Gal4) and a reporter construct containing an upstream activating sequence (UAS)–
linked luciferase, 4xUAS-TK-Luc (TK: thymidine kinase) [13]. NFκB activation reporter
consists of an upstream NFκB-response element-linked luciferase, NFκB-Luc [14]. For PPARg
activation, the cells were treated with the following treatments: DMSO (Control), 17,18-EEQ
at 1 or 10 μM (EEQ 1 or EEQ10;) or 19,20-EDP at 1 or 10 μM (EDP 1 or EDP 10) alone, or
combined with t-TUCB (1 μM) for 24 hr. For NFκB activation, the cells were pretreated with
DMSO, 17,18-EEQ or 19,20-EDP alone (10 µM) or combined with t-TUCB (1 μM) for 1hr
and then were treated with above treatments in the presence of LPS (100 ng/ml) for 18 hr. Cell
lysates were prepared for the measurement of reporter luciferase and β-galactosidase activities
by GloMax Luminometer (Promega, Madison, WI). Relative luciferase activity was
normalized to β-galactosidase activity and indicated as fold compared to the DMSO group.
6.2.7 Statistical analysis
Data are presented as Mean+SEM (n=3) for oil red O staining and absorbance, western
blot analysis, and reporter assay; n=3-4 for mitochondria respiration assay due to the design of
XFe 24 assay plate. Statistical analysis was performed using Prism 8 (GraphPad Software, San
Diego, CA). Student’s t-Test was performed to determine the differences in group mean
between the treatment groups and the control group. The level of significance was set at p<0.05.
6.3 Results
6.3.1 17,18 EEQ and 19,20-EDP combined with t-TUCB differentially promoted murine
brown adipogenesis, upregulated protein expression of thermogenic genes and lipid
metabolic genes, and enhanced the mitochondrial respiration and uncoupling
Firstly, we investigate the effects of 17,18-EEQ and 19,20-EDP on brown adipocyte
differentiation. Murine brown preadipocytes were differentiated in the presence of the
following treatments: the DMSO (Control), t-TUCB alone (TUCB), or combined with 17,18EEQ (T+EEQ) or 19,20-EDP (T+EDP) for 6 days as indicated in the method section. We
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analyze lipid accumulation as a measure of adipocyte differentiation. Both 17,18-EEQ and
19,20-EDP significantly increased ORO absorbance at the dose of 10 μM when combined with
1 μM of t-TUCB compared to the t-TUCB alone (p<0.01 for 19,20-EDP; p<0.001 for 17,18EEQ) or the controls (p<0.01 for 19,20-EDP; p<0.001 for 17,18-EEQ), indicating an enhanced
differentiation (i.e., adipogenesis) in murine brown adipocytes (Fig. 6.1). All figures are shown
in the Appendix.
Since 17,18-EDP and 19,20-EEQ combined with t-TUCB regulated the protein expression
of thermogenic genes and lipid metabolic genes in the iBAT in in vivo studies, we further
analyzed the protein expression of thermogenic genes and lipid metabolic genes in vitro (Fig.
6.2). Both T+EEQ and T+EDP groups but not the TUCB group showed significantly increased
protein expression of PGC1α compared to the controls (p<0.05) (Fig. 6.2A-B). Only T+EEQ
group presented significantly increased CD36 protein expression compared to the t-TUCB
alone or the controls (p<0.05), consistent with previous results of mice study (Fig. 6.2A-B).
Similarly, UCP1 protein expression was only significantly increased in the T+EEQ group
compared to the controls and the TUCB group (p<0.05) (Fig. 6.2A-B).
To confirm whether 17,18-EDP or 19,20-EEQ combined with t-TUCB induced brown
adipogenic differentiation and upregulation of thermogenic genes lead to increased
thermogenic function, we performed the mitochondrial stress test to measure cellular energetics
using an XFe24 Extracellular Flux Analyzer. The effects of 17,18-EEQ and 19,20-EDP on
mitochondrial respiration during murine brown preadipocytes differentiation were analyzed
(Fig. 6.3). Combined with t-TUCB, 17,18-EEQ treated brown adipocytes presented significant
higher basal oxygen consumption rate (OCR) (p<0.01 and p<0.001 for 17,18-EEQ at 1 μM and
10 μM), ATP production coupled OCR (p<0.05 and p<0.001 for 17,18-EEQ at 1 μM and 10
μM) and maximal OCR (p<0.05 and p<0.01 for 17,18-EEQ at 1 μM and 10 μM) than the
controls (Fig. 6.3A-B). In addition, basal OCR (p<0.01 for 17,18-EEQ at 10 μM), ATP
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production coupled OCR (p<0.01 for 17,18-EEQ at 10 μM), and maximal OCR (p<0.05 for
17,18-EEQ at 10 μM) were significantly higher in the T+EEQ (with 10 µM of 17,18-EEQ)
group than the TUCB group (Fig. 6.3A-B). Proton leak coupled OCR was only increased by
10 μM of 17,18-EEQ combined with t-TUCB compared to the control group (p<0.01) and the
TUCB group (p<0.05) (Fig. 6.3A-B). Consistently, coupling efficiency was only decreased by
10 μM of 17,18-EEQ combined with t-TUCB compared to the controls (p<0.05) (Fig. 6.3AB).
Differentiating brown adipocytes treated with 19,20-EDP combined with t-TUCB
presented the significant higher basal oxygen consumption rate (OCR) (p<0.001), ATP
production coupled OCR (p<0.001), and maximal OCR (p<0.01) than the controls only at the
dose of 10 μM (Fig. 6.3C-D). Similar to that of 17,18-EEQ, brown adipocytes treated by 10
μM of 19,20-EDP combined with t-TUCB showed significantly higher basal OCR (p<0.001),
ATP production coupled OCR (p<0.001), and maximal OCR (p<0.01) than the cells treated by
t-TUCB alone (Fig. 6.3C-D). Also, proton leak coupled OCR was only increased by 10 μM of
19,20-EDP combined with t-TUCB compared to the control group (p<0.001) and the TUCB
group (p<0.001) (Fig. 6.3C-D). However, 10 μM of 19,20-EDP plus t-TUCB did not decrease
the coupling efficiency compared to the controls (Fig. 6.3C-D). Moreover, brown adipocytes
showed higher basal respiration (p<0.05), ATP production, maximal respiration (p<0.05), and
proton leak (p<0.05) when treated by 10 μM of 17,18-EEQ than by 10 μM of 19,20-EDP (Fig.
6.3C-D) combined with t-TUCB.
6.3.2 17,18-EEQ combined with t-TUCB upregulated thermogenic and lipid metabolic
genes and promoted mitochondrial respiration and uncoupling in mature murine brown
adipocytes
We found that 17,18-EEQ and 19,20-EDP combined with t-TUCB both increased
thermogenesis without affecting the iBAT mass or UCP1 protein expression in the mice study
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(Chapter V), suggesting the effects of 17,18-EEQ and 19,20-EDP may be independent of
brown adipogenic differentiation. To investigate the effects of 17,18-EEQ and 19,20-EDP
combined with t-TUCB on mature brown adipocyte function, we treated differentiated mature
murine brown adipocytes with the DMSO (Control), t-TUCB alone (TUCB) or combined with
17,18-EEQ (T+EEQ) or19,20-EDP (T+EDP) for 3 days as described in the methods section.
Protein expression of thermogenic genes and lipid metabolic genes were analyzed by western
blot (Fig. 6.2C-D). Similarly, PGC-1a protein expression was significantly increased in both
T+EEQ and T+EDP groups but not in the TUCB group compared to the controls (p<0.05) (Fig.
6.2 C-D). Although CD36 protein expression was significantly increased in all treated groups
compared to the controls (p<0.05, p<0.05, and p<0.001 for the TUCB, T+EDP, and T+EEQ
groups, respectively), T+EEQ presented the significantly higher CD36 protein expression than
the TUCB and T+EDP groups (p<0.001) (Fig. 6.2C-D). However, all three treated groups did
not increase the protein expression of UCP1 compared to the controls, similar to the results in
the previous mice study (Chapter V) (Fig. 6.2C-D).
Next, the effects of 17,18-EEQ and 19,20-EDP combined with t-TUCB on mitochondrial
respiration of mature murine brown adipocytes were analyzed (Fig. 6.4). Among all treated
groups, murine brown adipocytes treated with 10 μM of 17,18-EEQ plus t-TUCB had the
significantly higher basal OCR, ATP production coupled OCR, and proton leak coupled OCR
than the control group (p<0.001, p<0.001, and p<0.01, respectively), TUCB group (p<0.001),
and T+EDP 10 group (p<0.05, p<0.05, and p<0.01, respectively) (Fig. 6.4). However, coupling
efficiency and maximal respiration were not significantly changed by 17,18-EEQ or 19,20EDP plus t-TUCB compared to the controls (Fig. 6.4).
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6.3.3 17,18-EDP and 19,20-EEQ activated PPAR gamma and inhibited LPS-induced
activation of NFκB
To investigate the molecular mechanisms by which 17,18-EEQ or 19,20-EDP promote
murine brown differentiation, the abilities of 17,18-EEQ and 19,20-EDP to activate PPAR
gamma (PPARg) were measured using the transactivation reporter assays since PPARg is one
of the master regulators of brown adipogenic differentiation [15]. Either 17,18-EEQ or 19,20EDP alone at 10 µM or combined with t-TUCB significantly activated PPARg (Fig. 6.5A),
suggesting that 17,18-EEQ and 19,20-EDP may promote brown adipocytes differentiation
through, at least in part, PPARg activation.
In the mice study (Chapter V), we found that 17,18-EEQ or 19,20-EDP combined with tTUCB increased the total amount of IκBa (i.e., prevented the degradation of IκBα) and
inhibited its phosphorylation in the iBAT, suggesting a decreased NFκB-induced inflammatory
response. IκBa is a protein that binds and inactivates the NFκB, which is a key transcription
activator for genes that eccode pro-inflammatory cytokines such as TNFa and IL-6 [16]. Upon
phosphorylation and subsequent degradation of IκBa, NFκB is released and activated, leading
to increased gene expression of pro-inflammatory cytokines and inflammatory response [16].
Therefore, we investigate the molecular mechanisms of the anti-inflammatory effects of 17,18EEQ and 19,20-EDP by NFκB reporter assays (Fig. 5.5B). We found that either 17,18-EEQ or
19,20-EDP alone (at 10 μM) or combined with t-TUCB significantly suppressed the NFκB
activation (p<0.01 and p<0.001 for EDP and EDP+t-TUCB respectively; p<0.05 for EEQ and
EEQ+t-TUCB) (Fig. 6.5B). Our results, in line with suppressed NFkB signaling in the BAT in
vivo, suggest that 17,18-EEQ and 19,20-EDP may improve the inflammatory response by
suppressing NFκB pathways.
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6.4 Discussion
In the current chapter, we demonstrate that 19,20-EDP or 17,18-EEQ, when stabilized by
sEH inhibitor t-TUCB, significantly promote murine brown adipocyte differentiation and
mitochondrial respiration and uncoupling. Moreover, 17,18-EEQ combined with t-TUCB also
significantly promote mitochondrial respiration and uncoupling of mature brown adipocytes,
which is accompanied by enhanced fatty acid transporter CD36 protein expression.
Furthermore, we demonstrate that 17,18-EEQ and 19,20-EDP activate PPARg and suppress
NFkB activation in murine brown preadipocytes.
6.4.1 Significance
To our knowledge, this is the first report demonstrating the promoting effects of 17,18-EEQ
and 19,20-EDP combined with t-TUCB on murine brown adipocyte differentiation and
mitochondrial respiration and uncoupling in differentiating brown adipocytes. 17,18-EEQ and
19,20-EDP are major epoxy metabolites from EPA and DHA, respectively. EPA and DHA are
n-3 PUFAs mainly derived from fatty fish or fish oil. Dietary n-3 PUFAs supplementation,
usually provided as fish oil with the different formulations, has been reported to increased
thermogenesis and heat production in rodents to protect against diet-induced obesity and
associated metabolic disorders [8, 9]. In addition, n-3 PUFAs, especially EPA, are shown to
promote brown adipogenesis [17, 18]and browning [19, 20] in vitro. However, the active
metabolites that are responsible for EPA or DHA’s effects are not known. Our results may add
new insights to this knowledge gap by demonstrating that 17,18-EEQ and 19,20-EDP are
effective metabolites that may be responsible for EPA or fish oil-induced increases in energy
expenditure and thermogenesis.
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6.4.2 17,18-EEQ may be more potent than 19,20-EDP in promoting brown adipocyte
thermogenesis
As a mixture of EPA and DHA, fish oil has been reported to promote energy expenditure
and thermogenesis in animals [8, 9]. However, whether the beneficial effects of fish oil come
from EPA, DHA, or both are largely uncharacterized. In addition, few studies directly
compared the effects between EPA and DHA. One study reported that EPA increased
thermogenic gene expression, mitochondria function, and β-oxidation in murine brown
adipocytes and promoted the browning process in inguinal white adipocytes, whereas no
effects on thermogenic gene expression were observed in DHA-treated murine brown and
inguinal white adipocytes [20]. In the current study, we found that when combined with tTUCB, both 19,20-EDP and 17,18-EEQ promoted brown adipocyte differentiation and
improved mitochondria respiration and uncoupling of brown adipocytes; however, only 17,18EEQ combined with t-TUCB increased mitochondrial respiration and uncoupling in mature
brown adipocytes. These findings are in line with the results (Chapter V) that when combined
with t-TUCB, only 17,18-EEQ significantly increased heat production in mice and had more
potent effects than 19,20-EDP in increasing core body temperature and improving cold
tolerance. Taken together, these results suggest that 17,18-EEQ may be more potent than
19,20-EDP in promoting brown adipogenesis and brown adipocyte function for obesity
prevention.
6.4.3 The role of PPARg and NFκB pathways
How n-3 EpFAs activate brown adipogenesis and increase thermogenesis remains
unknown. PPARg is one of the master regulators of brown adipogenesis and thermogenesis
[15]. Several studies have reported that n-3 PUFA supplementation in mice regulated BAT
thermogenesis at least in part through PPARg activation [8, 21]. Moreover, some of the
biological effects of n-3 EpFAs have been shown to be mediated through PPARg in various
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disease models [22, 23]. For example, 17,18-EEQ was reported to suppress inflammation in
bronchi to protect lung function in a PPARg-dependent manner [24]. However, to date, no
studies have reported the effects of n-3 EpFAs on PPARg activation in brown preadipocytes.
Our results showed that both 17,18-EEQ and 19,20-EDP significantly activated PPARg in
brown preadipocytes in reporter assays, suggesting that 17,18-EEQ and 19,20-EDP may
promote brown adipocytes differentiation through, at least in part, PPARg activation. Future
studies demonstrating that epoxides physically bind and activate PPARg are needed.
Pro-inflammatory cytokines, such as TNFa, are reported to impair the brown adipocyte
thermogenic properties [25]. NFκB is one of the major transcriptional activators for proinflammatory cytokines to induce inflammatory response [16]. Using reporter assays, we
demonstrated that 17,18-EEQ or 19,20-EDP significantly suppressed the NFκB activation in
brown preadipocytes, suggesting that the anti-inflammatory effects of 17,18-EEQ or 19,20EDP may contribute to their beneficial effects on thermogenesis in brown adipocytes. However,
the direct changes of downstream pro-inflammatory cytokines regulated by n-3 EpFAs in
brown adipocytes need further investigation.
6.4.4 Limitations and future directions
In the current study and previous in vivo study (Chapter V), the effects of 17,18-EEQ or
19,20-EDP on the cells or the mice were demonstrated when stabilized with the sEH inhibitor
t-TUCB, as these epoxides are quickly metabolized by sEH [2]. In addition, these epoxides are
also known to be metabolized by autoxidation, β-oxidation, esterification, and by other
enzymes, such as cyclooxygenases and lipoxygenases [26]. Future confirmation of the effects
of 17,18-EEQ and 19,20-EDP are needed, possibly by testing them in sEH knockout cells or
using structural and metabolic stable analogs [27].
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6.5 Conclusion
In conclusion, the current study suggests that when combined with sEH inhibitor t-TUCB,
17,18-EEQ or 19,20-EDP promote brown adipogenesis and thermogenic function in vitro,
which may be associated with their abilities to activate PPARg and suppressing NFκB
activation. Moreover, 17,18-EEQ may be more potent than 19,20-EDP in promoting brown
adipogenesis and brown adipocyte function for obesity treatment and prevention.
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Appendix

Figure 6.1. 17,18-EEQ and 19,20-EDP combined with t-TUCB promoted murine brown
adipogenesis in vitro. Murine brown preadipocytes were differentiated in the presence of the
following treatments: the DMSO (0.5%, Control), t-TUCB alone (TUCB) or combined with
17,18-EEQ (T+EEQ) or 19,20-EDP (T+EDP), as indicated for 6 days. Oil red O-stained cell
morphology (A) and ORO absorbance (B) were shown. Data=Mean±SEM (n=3). *, **, ***,
p<0.05, p<0.01, and p<0.001 compared to the controls, respectively.
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Figure 6.2. 17,18-EEQ or 19,20-EDP combined with t-TUCB differentially regulated
protein expression of thermogenic genes and lipid metabolic genes in vitro. Murine brown
preadipocytes were differentiated in the presence of the following treatments: the DMSO
(Control), t-TUCB alone (TUCB) or combined with 17,18-EEQ (T+EEQ) or 19,20-EDP
(T+EDP), as indicated for 6 days (During differentiation) (A-B). Mature murine brown
adipocytes were maintained in growth media in the presence of the same treatments for 3 days
(Post differentiation) (C-D). Protein expression of UCP1, PGC-1a, CD36, and the loading
control ERK1/2 and the densitometry are shown. Bar graphs showed the normalized
densitometry for UCP1/ERK1/2, PGC1a/ERK1/2, and CD36/ERK1/2. Data=Mean±SEM
(n=3). *, **, ***, p<0.05, p<0.01, and p<0.001 compared to the controls, respectively. #, ##,
###, p<0.05, p<0.01, and p<0.001 compared to the T group, respectively. a, aa, aaa, p<0.05,
p<0.01, and p<0.001 compared to the T+EDP 10 group, respectively.
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Figure 6.3. 17,18-EEQ and 19,20-EDP combined with t-TUCB increased mitochondrial
respiration and proton leak in differentiating murine brown adipocytes. Murine brown
preadipocytes were differentiated in the presence of the following treatments: the DMSO
(Control), t-TUCB alone (TUCB) or combined with 17,18-EEQ (T+EEQ) or19,20-EDP
(T+EDP), as indicated for 4 days. Then differentiating brown adipocytes were reseeded onto a
24-well XFe assay plate at 2.0x104 cells per well. After 24 hr, the cells were then subjected to
real-time measurements of OCR using an XFe24 Extracellular Flux Analyzer. OCR overtime
during mitochondrial stress tests (A, C) and bar graphs (B, D) of the basal respiration, ATP
production, proton leak, coupling efficiency (%), and maximal respiration are shown.
Data=Mean±SEM (n=3-4). *, **, ***, p<0.05, p<0.01, and p<0.001 compared to Controls,
respectively. #, ##, ###, p<0.05, p<0.01, and p<0.001 compared to the T group, respectively.
a, aa, aaa, p<0.05, p<0.01, and p<0.001 compared to the T+EEQ 1 group, respectively.
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Figure 6.3 (continued)
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Figure 6.4. 17,18-EEQ combined with t-TUCB increased mitochondrial respiration and
proton leak in mature murine brown adipocytes. Murine brown preadipocytes were
differentiated for 6 days and then maintained in the growth condition in the presence of the
following treatments: the DMSO (Control), t-TUCB alone (TUCB) or combined with 10 μM
of 17,18-EEQ (T+EEQ 10) or 19,20-EDP (T+EDP 10), as indicated for another 3 days. Then
brown adipocytes were reseeded onto a 24-well XFe assay plate at 2.0x104 cells per well. After
24 hr, the cells were then subjected to real-time measurements of OCR using an XFe24
Extracellular Flux Analyzer. OCR overtime during mitochondrial stress tests (A) and the bar
graphs (B) of the basal respiration, ATP production, proton leak, coupling efficiency (%), and
maximal respiration are shown. Data=Mean±SEM (n=3-4). *, **, ***, p<0.05, p<0.01, and
p<0.001 compared to Controls, respectively. #, ##, ###, p<0.05, p<0.01, and p<0.001
compared to the T group, respectively. a, aa, aaa, p<0.05, p<0.01, and p<0.001 compared to
the T+EDP 10 group, respectively.
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Figure 6.5. 17,18-EDP and 19,20-EEQ activated PPAR gamma and inhibited LPSinduced activation of NFκB in murine brown preadipocytes. Murine brown preadipocytes
were seeded onto 24-well plates at 1.5.0x104 cells per well. On the next day, cells were
transiently transfected with murine PPARg (A) or NFκB (B) transactivation reporters and βgal plasmid for 24 hr. For PPARg activation, the cells were treated with the following
treatments: DMSO (Control), 17,18-EEQ (1 or 10 μM) or 19,20-EDP (1or 10 μM) in the
presence or absence of t-TUCB (1 μM) for 24 hr. For NFκB activation, the cells were pretreated
with DMSO (Control), 10 μM of 17,18-EEQ or 19,20-EDP, t-TUCB (1 μM) alone or combined
with 10 μM of 17,18-EEQ or 19,20-EDP in the presence or absence of t-TUCB (1 μM) for 1
hr then were co-treated with LPS overnight. Reporter gene assays were performed and
normalized to β-gal activity. Relative luciferase activities were expressed as fold of the controls
(set as 1). Data=Mean±SEM (n=3). *, **, ***, p<0.05, p<0.01, and p<0.001 compared to the
controls, respectively.
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Chapter VII Conclusion and Future Direction
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7.1 Conclusions
There are four main studies included in this dissertation (i.e., Chapter III, IV, V, and VI).
In Chapter III, the effects of the sEH inhibitor t-TUCB were studied in the obese mice via
mini osmotic pump delivery. Although t-TCUB (3 mg/kg/day) did not change body weight, fat
pad weight, or glucose and insulin tolerance, it decreased serum triglycerides level and
increased protein expression of PLIN in the iBAT of diet-induced obese mice. Our results
suggest that sEH inhibition may be beneficial in obesity-related hypertriglyceridemia through
improving metabolic activity of BAT by regulating protein expression involved in lipid
metabolism.
In Chapter IV, we further investigated whether 19,20-EDP, a prominent epoxy metabolite
of DHA, has similar beneficial effects as those of sEH inhibitor t-TUCB (chapter III). We
found that 19,20-EDP alone or combined with t-TUCB did not improve body weight and
metabolic health; however, both treatments significantly improved cold tolerance in the dietinduced obese mice.

Our results suggest that 19,20-EDP may improve cold-induced

thermogenesis of BAT in obese mice. Future studies on the effective treatment time and dose
of 19,20-EDP alone or combined with t-TUCB for obesity treatment are needed.
In Chapter V, the effects of sEH inhibitor t-TUCB alone or combined with 19,20-EDP or
17,18-EEQ on BAT activation in preventing diet-induced obesity were investigated through
mini osmotic pump delivery. When combined with t-TUCB, both 19,20-EDP and 17,18-EEQ
significantly improved fasting glucose and serum triglycerides levels, core body temperature,
and lipids accumulation in BAT, whereas heat production was only significantly increased by
19,20-EEQ treatment. Protein expression of PGC1a was significantly increased in all three
treated groups, whereas UCP1 protein expression was unchanged. In contrast, protein
expressions of CPT1A and CPT1B (rate-limiting enzymes for fatty acid b-oxidation) were only
increased in the T+EDP and T+EEQ groups. Interestingly, protein expression of CD36, a
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membrane transporter responsible for fatty acids uptake, was only increased in the T+EEQ
group. Furthermore, inflammatory NFkB signaling in the iBAT was decreased by the treatment
of 19,20-EDP or 17,18-EEQ combined with t-TUCB. These results indicate that 17,18-EEQ or
19,20-EDP combined with t-TUCB may be beneficial in preventing high-fat diet-induced
metabolic disorders, at least in part, through increasing thermogenesis, upregulating protein
expression of genes involved in lipid metabolism, and suppressing inflammatory signaling in
the BAT. In addition, we found that when combined with t-TUCB, 17,18-EEQ is more potent
than 19,20-EDP in promoting thermogenesis and upregulating lipid metabolic genes in the
BAT.
Finally, in Chapter VI, we investigated whether the beneficial effects of n-3 epoxides
combined with t-TUCB in animal models are associated with improved brown adipogenic
differentiation and enhanced thermogenic capacity in murine brown adipocytes. We found that
19,20-EDP or 17,18-EEQ combined with t-TUCB promote murine brown adipogenesis and
mitochondrial respiration in vitro, which were accompanied by activation of PPARγ and
suppression of NFkB. However, only 17,18-EEQ combined with t-TUCB increased
mitochondrial respiration, including basal respiration and ATP-linked and proton-linked
oxygen consumption, in mature brown adipocytes. Combined with the results of core body
temperature, cold tolerance, and heat production from the mice studies (Chapter V), our results
suggest that 17,18-EEQ may be more potent than 19,20-EDP in enhancing mitochondrial
respiration and upregulating lipid metabolic genes in brown adipocytes, thereby increasing
thermogenesis and improving obesity-associated metabolic disorders.
In summary, sEH inhibition by t-TUCB alone or combined with n-3 EpFAs is beneficial
in obesity-associated metabolic disorders through improving BAT activity by modulating gene
expression in thermogenesis and lipid metabolism. Combined with t-TUCB, 17,18-EEQ and
19,20-EDP differentially regulate thermogenic and lipid metabolic gene expression in the BAT
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and brown adipocytes, and 17,18-EEQ is more potent than 19,20-EDP, in increasing
thermogenesis and improving metabolism in mice and increasing mitochondrial respiration and
upregulating thermogenic and lipid metabolic genes in brown adipocytes.
7.2 Significance of the study
Obesity is a worldwide pandemic with increased risks of multiple diseases, including type
2 diabetes, cardiovascular diseases, and cancers. In recent years, BAT has become a potential
target to fight against obesity and associated metabolic diseases.
N-3 PUFAs are promising dietary factors that have been shown to be beneficial for obesity,
at least in part, through targeting BAT. However, the mechanisms by which n-3 PUFAs
improve BAT activity to protect against obesity remain unclear. As the downstream epoxy
metabolites of n-3 PUFAs, n-3 EpFAs are thought to contribute to the beneficial effects of n-3
PUFAs in cardiovascular diseases and inflammatory diseases. In addition, sEH inhibitors are
also shown to be beneficial in multiple disorders, possibly through stabilizing endogenous n-3
EpFAs. But it is undetermined whether n-3 EpFAs are responsible for the effects of n-3 PUFAs
on BAT activity in obesity prevention/treatment. Results presented in the current dissertation
have provided new insights on the mechanism by which n-3 PUFAs improved diet-induced
obesity. The downstream epoxides derived from n-3 PUFAs, 17,18-EEQ and 19,20-EDP, when
combined with t-TUCB modulated thermogenesis, energy expenditure, and glucose and lipid
metabolism concurrent with changes in thermogenic and lipid metabolic gene expression.
These results indicated that 17,18-EEQ and 19,20-EDP may be, at least in part, responsible for
the anti-obesity effects reported for n-3 PUFAs, such as EPA and fish oil.
To our knowledge, there have been no studies directly comparing the effects of DHA and
EPA on BAT in diet-induced obesity. We demonstrate that as EPA and DHA epoxy
metabolites, 17,18-EEQ and 19,20-EDP differentially regulate lipid metabolic gene expression
in the BAT and brown adipocytes, and 17,18-EEQ is more potent than 19,20-EDP in promoting
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thermogenesis in the BAT and brown adipogenesis and mitochondrial respiration in brown
adipocytes.
With the increasing prevalence of obesity during past decades, it is important to establish
effective strategies to prevent and manage obesity. It is not always feasible to lose or maintain
body weight by simply changing lifestyles (e.g., physical exercise or caloric restriction) or
surgical treatments. Therefore, pharmacological agents or dietary factors are promising
alternative or adjunctive strategies to lifestyle changes in preventing and treating obesity. Our
studies suggest that pharmacological sEH inhibitors, such as t-TUCB, alone or combined with
17,18-EEQ or 19,20-EDP may be novel pharmaceutical/nutritional strategies to improve
obesity-associated metabolic disorders in mice, which may be beneficial for human obesity.
7.3 Limitations and future directions
There are several limitations in the current dissertation. Only male C57BL/6J mice were
studied in in vivo studies (Chapter III-V). Female C57BL/6J mice are not sensitive to a highfat diet in our hands (our unpublished results) and may respond differently to 17,18-EEQ and
19,20-EDP. Effects of these epoxides on obesity and metabolic parameters in female mice need
to be investigated in the future.
The duration of our in vivo studies was 6 weeks, which was based on the osmotic mini
pump’s maximal delivery capacity. However, some studies may need a longer time, for
example, 8-12 weeks, to achieve optimal anti-obesity effects by improving BAT mass/activity
in obese mice. Therefore, future studies are needed to determine the optimal duration of the
treatment of t-TUCB alone or combined with n-3 epoxides in reversing obesity in mice.
In addition, it has been reported that sEH ablation and an n-6 epoxide analog induced
browning in the WAT [1] and 3T3-L1 adipocytes [2]. However, we did not find browning of
sWAT by t-TUCB alone or combined with n-3 epoxides in the mice housed at 22-23℃
(maintained room temperature of the animal facility) (data not shown). We did find the average
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area of adipocytes of sWAT was significantly decreased by the treatment of t-TUCB combined
with 17,18-EEQ in the mice of diet-induced obesity in Chapter V (data not shown). These
results suggest that although we delivered 17,18-EEQ, 19,20-EDP, and t-TUCB locally to the
iBAT, the local treatment had systemic metabolic effects. Therefore, we could not fully rule
out the possibility that sEH inhibition combined with epoxides can benefit systemic
metabolism by regulating activities of other metabolic active tissues, such as WAT, liver, and
muscle, in addition to the BAT. Investigating the effects of 17,18-EEQ or 19,20-EDP combined
with sEH inhibitor on WAT, liver, or muscle in fighting against obesity is needed in future
studies.
Moreover, we speculated the specific effects of 17,18-EEQ and 19,20-EDP on the BAT
by comparing biological effects of these epoxides when combined with t-TUCB with the
effects of t-TUCB alone since the epoxides are quickly metabolized by the sEH. Effects of
17,18-EEQ and 19,20-EDP on the BAT need to be confirmed by using either sEH knockout
mice or stable epoxide analogs [3] in future studies.
In addition, there are other major epoxy regioisomers produced from n-3 PUFAs,
particularly from DHA, such as 7,8-EDP and 13,14-EDP. Also, major epoxy metabolites are
produced from n-6 PUFA, such as arachidonic acid. The effects of other epoxy regioisomers
from DHA and from arachidonic acid on BAT and brown adipocytes warrant future
investigation.
Finally, to translate our findings into novel and effective strategies for human obesity
treatment and prevention, future studies on the effects of t-TUCB alone or combined with
17,18-EEQ or 19,20-EDP on human brown adipocyte differentiation and mitochondrial
respiration are warranted.
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